-- 2025 Semi-annual Report

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Company code: 603658 Company abbreviation: Antu Bio Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

1/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Important tips

1. The company’s board of directors, board of supervisors and directors, supervisors and senior managers guarantee the authenticity, accuracy and completeness of the contents of the semi-annual report and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.

2. All directors of the company shall attend the board meeting.

3. This semi-annual report has not been audited.

4. The person in charge of the company, Yang Zengli, the person in charge of accounting work, Feng Chaojie, and the person in charge of the accounting department (accounting supervisor) Yang Yuhong declare that they guarantee the authenticity, accuracy and completeness of the financial report in the semi-annual report.

5. There is no profit distribution plan for the reporting period or a plan for converting public reserve funds into share capital passed by the board of directors.

6. Risk Statement for Forward-Looking Statements

√Applicable □Not applicable

The forward-looking statements such as future plans and development strategies involved in this report do not constitute the company's substantive commitment to investors. Investors are advised to pay attention to investment risks.

7. Whether there is any non-operational occupation of funds by controlling shareholders and other related parties

No

8. Whether there is any violation of the prescribed decision-making procedures in providing external guarantees

No

9. Whether more than half of the directors cannot guarantee the authenticity, accuracy and completeness of the semi-annual report disclosed by the company

10. Major Risk Warning

The company has elaborated in this report the various risks and countermeasures that the company may face in the production and operation process. Please refer to "Possible Risks" in "Section 3 Management Discussion and Analysis". Investors are advised to pay attention to investment risks.

11. Others

□Applicable √Not applicable

2/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Directory

Section 1 Interpretation......................................................................................................................................4

Section 2 Company Profile and Main Financial Indicators......................................................................................5

Section 3 Management Discussion and Analysis................................................................................................................8

Section 4 Corporate Governance, Environment and Society......................................................................................33

Section 5 Important Matters................................................................................................................................35

Section 6 Changes in Shares and Shareholders...................................................................................49

Section 7 Bond-related situations................................................................................................................53

Section 8 Financial Report................................................................................................................................54

Financial statements signed and stamped by the person in charge of the company, the person in charge of accounting work, and the person in charge of the accounting department.

List of documents available for inspection: The text of the semi-annual report signed by the chairman and stamped by the company.

The original texts of all company documents and announcements publicly disclosed on the "Shanghai Securities News", "Securities Times" and the Shanghai Stock Exchange website during the reporting period.

3/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Section 1 Interpretation

In this report, unless the context otherwise requires, the following words have the following meanings:

Commonly used word definitions

Our company/company/joint-stock company/Antu Biotechnology refers to Zhengzhou Antu Bioengineering Co., Ltd.

Antu Industrial refers to Zhengzhou Antu Industrial Group Co., Ltd.

Z&F refers to Z&F International Trading Limited

Advan Bio refers to the company's wholly-owned subsidiary, Zhengzhou Imeno Biotechnology Co., Ltd. Antu Technology refers to the company's wholly-owned subsidiary, Zhengzhou Antu Technology Development Co., Ltd. Antu Instruments refers to the company's wholly-owned subsidiary, Antu Experimental Instruments (Zhengzhou) Co., Ltd. Sikun Bio refers to the company's wholly-owned subsidiary, Zhengzhou Sikun Bioengineering Co., Ltd. Shanghai Antu refers to the company's wholly-owned subsidiary, Shanghai Antu Biotechnology Co., Ltd. Advan Bio/AdvanBio, Inc. refers to The company's wholly-owned subsidiary, Edelman Biomedical Co., Ltd. Shenzhen Antu refers to the company's wholly-owned subsidiary, Shenzhen Antu Bioengineering Co., Ltd.

The company's wholly-owned subsidiary, Beijing Antu Bioengineering Co., Ltd., formerly Beijing Antu refers to

Beijing Biotaikang Biotechnology Co., Ltd.

Antu Bio (Hong Kong) refers to the company's wholly-owned subsidiary, Antu Bio (Hong Kong) Co., Ltd. Shanghai Biaoyuan refers to the company's holding subsidiary, Shanghai Biaoyuan Biotechnology Co., Ltd. Hebei Antu Jiuhe refers to the company's holding subsidiary, Hebei Antu Jiuhe Medical Technology Co., Ltd. Yunnan Antuino refers to the company's holding subsidiary, Yunnan Antuino Technology Co., Ltd. Matris Bio refers to the company's secondary subsidiary, Zhengzhou Matris Biotechnology Co., Ltd. Sanhe Baian refers to The company's secondary subsidiary, Sanhe Baian Biotechnology Co., Ltd. Antu Biotechnology refers to the company's secondary subsidiary, Zhengzhou Antu Biotechnology Co., Ltd. Autobio Trading (Hong Kong) refers to the company's secondary subsidiary, Antu Trading (Hong Kong) Co., Ltd. Hungary subsidiary refers to the company's secondary subsidiary, AutobioDiagnostics (Hungary) Kft.

The company's secondary subsidiary, PTAUTOBIODIAGNOSTICS Indonesian subsidiary refers to

INDONESIA

Zhengzhou Biaoyuan refers to the company’s secondary subsidiary, Zhengzhou Biaoyuan Biotechnology Co., Ltd. Yunnan Antu Jiuhe refers to the company’s secondary subsidiary, Yunnan Antu Jiuhe Technology Development Co., Ltd.

The company's secondary subsidiary, Qiqihar Antu Medical Laboratory Co., Ltd., Qiqihar Antu refers to

Former Qiqihar Jiuhe Medical Laboratory Co., Ltd.

Chengdu Kerui refers to the company's joint-stock company, Chengdu Kerui Technology Co., Ltd.

Meili Technology refers to the company's joint-stock company, Shenzhen Meili Nanopore Technology Co., Ltd. Huayinkang Medical refers to the company's joint-stock company, Guangzhou Huayinkang Medical Group Co., Ltd.

The company's joint-stock company, Renke (Shenzhen) Biotechnology Co., Ltd., Renke (Shenzhen) Biotechnology refers to

Zeng Yongmingke (Beijing) Biotechnology Co., Ltd.

Zhengzhou Gongdong refers to the company's joint-stock company, Zhengzhou Gongdong Medical Equipment Co., Ltd.

The company's indirect shareholding company, Zhengzhou Jiuhe Medical Laboratory Laboratory Co., Ltd. Zhengzhou Jiuhe refers to

company

The company participates in the subscription fund, Suzhou Jinhe Phase III Equity Investment Partnership Suzhou Jinhe Fund refers to

Business (limited partnership)

Zhengzhou Antumobi Molecular Diagnostic Technology Antumobi, formerly a holding subsidiary of the company, refers to

Ltd.

Hiken Medical refers to Hiken Medical Technology (Suzhou) Co., Ltd.

Hiken Biotechnology refers to Hiken Biotechnology (Suzhou) Co., Ltd.

A-shares refer to RMB ordinary shares with a par value of RMB 1.00 per share.

China Securities Regulatory Commission, China Securities Regulatory Commission refers to China Securities Regulatory Commission

Shanghai Stock Exchange refers to Shanghai Stock Exchange

Ministry of Finance refers to the Ministry of Finance of the People's Republic of China

4/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Sponsor, sponsor institution and lead underwriter refer to China Merchants Securities Co., Ltd.

Accountant, Zhongqin Wanxin refers to Zhongqin Wanxin Accounting Firm (Special General Partnership)

"Company Law" means "Company Law of the People's Republic of China"

“Securities Law” refers to the “Securities Law of the People’s Republic of China”

The company's current effective "Articles of Association of Zhengzhou Antu Bioengineering Co., Ltd." refers to

Articles of Association

Reporting period refers to January 1, 2025 to June 30, 2025

It can stimulate the body to produce (specific) immune responses, and can combine with immune response product antibodies and sensitized lymphocytes in vivo and in vitro to generate antigens.

It is a substance that produces immune effects (specific reactions) and is one of the core raw materials of in vitro diagnostic reagents.

When the body's immune system is stimulated by antigens, B lymphocytes or memory cells proliferate and differentiate into plasma cells that can react with corresponding anti-antibodies.

Immunoglobulin that specifically binds to the original protein is one of the core raw materials of in vitro diagnostic reagents.

The compounds that enzymes act on and catalyze can be chemical elements, molecules or substrates. Compounds can form products through the action of enzymes. The products can form measurable signals such as color, photons, fluorescence, etc.

Materials with biological activity or reactivity, such as antigens, antibodies, bovine active materials/bioactive materials refer to

Serum, horse serum, etc.

It can be used alone or in combination with instruments, appliances, equipment or systems. It can be used for human in vitro diagnostic reagents in the process of disease prevention, diagnosis, treatment monitoring, prognosis observation, health status evaluation and prediction of genetic diseases.

Reagents, kits, calibrators (materials), quality control materials (materials), etc. for in vitro testing of body samples (various body fluids, cells, tissue samples, etc.).

Section 2 Company Profile and Main Financial Indicators

1. Company information

The Chinese name of the company: Zhengzhou Antu Bioengineering Co., Ltd.

The company’s Chinese abbreviation Antu Biotechnology

The company's foreign name AutobioDiagnosticsCO.,Ltd

The company's foreign name abbreviation Autobio

The legal representative of the company Yang Zengli

2. Contact person and contact information

Secretary of the Board of Directors Securities Affairs Representative

Name Fang Ruikuan Wang Lin

Contact address: No. 199, No. 15 Jingkai Street, Zhengzhou Economic and Technological Development Zone No. 199, No. 5 Fifth Street, Zhengzhou Economic and Technological Development Zone

Phone 0371-86506868 0371-86506868

Fax 0371-86506767 0371-86506767

E-mail [email protected] [email protected]

5/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

3. Introduction to changes in basic situation

Company registered address: No. 87, Jingbei 1st Road, Zhengzhou Economic and Technological Development Zone

Historical changes of the company’s registered address Not applicable

Company office address: No. 199, Jingkai 15th Street, Zhengzhou Economic and Technological Development Zone

Postal code of company office address 450016

Company website www.autobio.com.cn

Email [email protected]

Query index for changes during the reporting period Not applicable

4. Brief introduction to changes in information disclosure and storage location

"Shanghai Securities News" www.cnstock.com

The name of the newspaper selected by the company for information disclosure

"Securities Times" www.stcn.com

The website address for publishing the semi-annual report is www.sse.com.cn

The company's semi-annual report is prepared at the Securities Affairs Department

Query index for changes during the reporting period Not applicable

5. Brief introduction of company stocks

Stock type Stock listing exchange Stock abbreviation Stock code Stock abbreviation before change

A shares Shanghai Stock Exchange Antu Biotech 603658 None

6. Other relevant information

□Applicable √Not applicable

7. The company’s main accounting data and financial indicators

(1) Main accounting data

Unit: Yuan Currency: RMB Main accounting data for this reporting period compared with the same period last year

(January to June) Increase/decrease in the same period (%) Operating income 2,060,307,179.95 2,207,103,914.63 -6.65 Total profit 638,845,435.17 687,185,556.26 -7.03 Net profit attributable to shareholders of listed companies 571,001,185.83 619,513,343.19 -7.83 Deduction of non-recurring expenses attributable to shareholders of listed companies

546,316,646.83 598,933,715.72 -8.79 Net profit of profit and loss

Net cash flow generated from operating activities 410,183,925.35 495,490,846.33 -17.22 The end of this reporting period compared with the end of this reporting period The end of the previous year

Year-end increase or decrease (%) Net assets attributable to shareholders of listed companies 8,458,066,259.73 8,616,530,318.04 -1.84 Total assets 11,645,383,960.45 11,875,065,943.97 -1.93

(2) Main financial indicators

Main financial indicators of this reporting period This reporting period compared with the same period of the previous year

(January to June) Increase/decrease in the same period (%) Basic earnings per share (yuan/share) 1.02 1.09 -6.42 Diluted earnings per share (yuan/share) 1.02 1.09 -6.42

6/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Basic earnings per share after deducting non-recurring gains and losses

0.97 1.05 -7.62 (yuan/share)

Weighted average return on equity (%) 6.51 7.06 Decrease 0.55 percentage point Weighted average equity after deducting non-recurring gains and losses

6.23 6.83 Decrease 0.6 percentage points in yield rate (%)

Description of the company’s main accounting data and financial indicators

□Applicable √Not applicable

8. Differences in accounting data under domestic and foreign accounting standards

□Applicable √Not applicable

9. Non-recurring profit and loss items and amounts

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items of non-recurring gains and losses Amount Notes (if applicable) Gains and losses on disposal of non-current assets, including accrued asset impairment

-1,524,382.03 prepared write-off portion

Government subsidies included in the current profit and loss, but related to the company's normal operations

Closely related to the business, in compliance with national policies and regulations, and in accordance with the determined

The government enjoys the standard of 16,065,626.53 and has a continuous impact on the company’s profits and losses.

Except for subsidies

Except for effective hedging related to the company’s normal business operations

Outside of financial affairs, non-financial enterprises hold financial assets and financial liabilities

4,402,691.44 gains and losses from changes in fair value and disposal of financial assets and funds

Profit and loss arising from financial liabilities

Reversal of impairment provision for accounts receivable subject to separate impairment test 5,098,622.99 Other non-operating income and expenses other than the above items 3,596,987.28 Other profit and loss items that meet the definition of non-recurring gains and losses 755,731.29 Less: Amount of income tax impact 4,950,868.82 Amount of impact on minority shareholders' equity (after tax) -1,240,130.31

Total 24,684,539.00

The company recognizes items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies Publicly Offering Securities - Non-recurring Profit and Loss"

If it is determined as a non-recurring profit and loss item with a significant amount, and the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public"

The non-recurring profit and loss items listed in "Non-recurring Profit and Loss" are defined as recurring profit and loss items, and the reasons should be explained.

□Applicable √Not applicable

10. Companies with equity incentives and employee stock ownership plans may choose to disclose net profits after deducting the impact of share-based payments □ Applicable √ Not applicable

11. Others

□Applicable √Not applicable

7/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Section 3 Management Discussion and Analysis

1. Description of the company’s industry and main business during the reporting period

(1) Industry conditions of the company during the reporting period

The company's industry is the in vitro diagnostic product manufacturing industry. According to the "Industry Classification Guidelines for Listed Companies" issued by the China Securities Regulatory Commission, the in vitro diagnostic product manufacturing industry belongs to the "C27 Pharmaceutical Manufacturing Industry" in the "C Manufacturing Industry", specifically the in vitro diagnostic product manufacturing industry in the medical device industry.

In vitro diagnostics refers to products and services that obtain clinical diagnostic information by testing human samples (various body fluids, cells, tissue samples, etc.) outside the human body to determine diseases or body functions. It is collectively referred to as IVD (InVitroDiagnostic) internationally. Its application range is wide, and it runs through the entire process of disease treatment such as disease prevention, preliminary diagnosis, treatment plan selection, and efficacy evaluation. In recent years, as people's emphasis on health continues to increase and the aging of the population intensifies, the demand for in vitro diagnostics industry continues to grow. In the context of the rapid development of various new technologies and the gradual improvement of medical security policies in most countries, the in vitro diagnostic industry has developed rapidly and has become one of the most active and fastest-growing industries in the medical market.

1. Global in vitro diagnostics market

The global in vitro diagnostic market has continued to grow in recent years. According to the "The Worldwide Market for InVitro Diagnostic (IVD) Tests, 17th Edition" report published by Kalorama in 2024, the global in vitro diagnostic market size will be US$109.2 billion in 2024, of which US$4.9 billion will be used for COVID-19 testing and US$104.3 billion will be used for other IVD tests. It is expected that the global in vitro diagnostics market will maintain a steady growth trend in the next few years, and the global in vitro diagnostics market will reach US$140 billion by 20271.

From the perspective of subdivisions, in vitro diagnosis mainly includes immunodiagnosis, biochemical diagnosis, microbiology, molecular diagnosis, hematology diagnosis, POCT and other major aspects according to detection methods. The clinical immunodiagnosis and biochemical diagnosis markets in developed countries are close to maturity, and POCT and molecular diagnosis are the main growth points of the diagnostic market. The global chemiluminescence market size will be approximately US$14.7 billion in 2022, accounting for 33.3% of the immunodiagnostic market1. Immunodiagnosis has the characteristics of high sensitivity and low cost, and is widely used in testing items such as tumor markers, infectious diseases, and hormones. Driven by the chemiluminescence market, it has become the largest segment in the field of in vitro diagnostics with the most new varieties in recent years. Biochemical diagnosis mainly focuses on the detection of enzymes, sugars, lipids, protein and non-protein nitrogen, inorganic elements, liver function, kidney function, etc. It is the earliest and most mature in vitro diagnostic subdivision at home and abroad. Molecular diagnosis is mainly used in infectious diseases, tumor diagnosis, genetic disease diagnosis, eugenics and postnatal care, etc. It is a field with relatively cutting-edge technology and high diagnostic precision in the in vitro diagnostic industry. It is currently in the early stages of development and is small in scale, but growing rapidly.

From the perspective of regional market structure, North America is still the leading market (accounting for 40%), mainly benefiting from high medical expenditures and advanced technology applications (such as liquid biopsy, AI-assisted diagnosis). The Asia-Pacific region has the fastest growth rate (accounting for 10%, CAGR is 9.8%). Emerging markets such as China and India drive growth. China contributes 65% of the increase in the Asia-Pacific region. Due to the intensification of aging and the demand for chronic disease management, the IVD market in Europe is growing steadily (accounting for 20%, CAGR is 5.2%1).

From the perspective of competition landscape, driven by technological iteration, the global in vitro diagnostic market has shown a "polarized" development trend. On the one hand, the global in vitro diagnostic market industry is mature and highly concentrated, with top IVD companies accounting for the majority of IVD product sales.

1 "TheWorldwideMarketforInVitroDiagnostic(IVD)Tests,17thEdition"

8/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

This is a continuing trend over time1. The four giants, Roche, Abbott, Danaher, and Siemens, have consolidated technical barriers through continued mergers and acquisitions, and will occupy a combined 57.3% market share in 2023. According to annual report data: in 2024, Roche's diagnostics business revenue is expected to be US$17 billion, Danaher's diagnostics business revenue is expected to be US$9.9 billion, Abbott's diagnostics business revenue is expected to be US$16 billion, and Siemens' diagnostics business revenue is expected to be US$4.5 billion. These multinational medical groups rely on their advantages of stable product quality, high technology content and precision equipment manufacturing to occupy the majority of the global high-end in vitro diagnostic market. On the other hand, emerging companies have achieved overtaking by leveraging disruptive technologies such as microfluidic chips, CRISPR gene editing, and digital pathology. It is worth noting that the molecular diagnostic market segment leads the industry with a growth rate of 13.4%. With the breakthrough of liquid biopsy technology in the field of early tumor screening, the cost of single cancer detection has dropped to less than US$5001.

2. China’s in vitro diagnostics market

my country's in vitro diagnostic industry started in the 1980s. After recent years of development and growth, it has basically formed an industry pattern with comprehensive technologies, complete categories, and orderly competition. Enterprises in the industry have been able to produce and provide most of the in vitro diagnostic instruments and reagents required by the clinical market. At the same time, with the acceleration of industry mergers and acquisitions, a number of industry leading companies with large market scale and influence have grown. In many traditional testing fields such as biochemical testing, immune testing, hematology analysis, and body fluid analysis, as domestic companies have accumulated and upgraded their technology for many years, domestic products have been able to reach the same leading level in the world, and import substitution in some fields has quietly been realized. In 2023, China's in vitro diagnostics market size will reach 118.5 billion yuan, and it is expected that the market size of China's in vitro diagnostics industry will exceed 120 billion yuan in 20242. As the health literacy of domestic residents gradually improves, and the demand for early diagnosis and screening of serious diseases and serious diseases as well as precision medicine is gradually released, the in vitro diagnostic industry is facing huge growth opportunities. At the same time, China's IVD market has been significantly affected by centralized procurement policies in recent years, and companies are facing the challenges of price reduction pressure and intensifying market competition.

From the perspective of subdivisions, immunodiagnosis is the largest subdivision of in vitro diagnostics in my country, and chemiluminescent immunodiagnostic technology is the mainstream. In 2023, China's immunodiagnostic market size will be 50.3 billion yuan, a year-on-year increase of 13%, accounting for 42.45% of the market share. Among them, tumor markers, thyroid function, and infectious diseases are currently the three largest market segments in immunodiagnosis2. The biochemical diagnosis market size in 2023 will be 19 billion yuan, accounting for 16.03%. Biochemical diagnosis is the earliest and most mature technology in the field of in vitro diagnosis. It is mainly used to detect metabolites and physiological indicators in the human body. Molecular diagnostics is in a period of rapid growth and is one of the fastest growing subdivisions in the field of in vitro diagnostics. In 2023, China's molecular diagnostic market size will be 14.8 billion yuan, accounting for 12.49%. Molecular diagnosis has the advantages of short detection time, high sensitivity and strong specificity, and is widely used in infectious diseases, prenatal care, blood screening, genetic diseases, tumor companion diagnosis and other fields. POCT market share is 13.67%. Compared with the proportion of more than 30% in developed countries, there is still much room for development. POCT is widely used in fields such as infectious disease detection and blood sugar detection, especially in areas where medical infrastructure is not widespread and complete. It can assist doctors in diagnosing and treating patients in a timely and accurate manner2.

2 "China Medical Device Industry Blue Book (2024)"

9/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Chart 1: Market segmentation pattern of China’s in vitro diagnostic industry in 2023 (unit: 100 million yuan, %)

Source: "China Medical Device Industry Blue Book (2024)"

The competitive landscape of my country's in vitro diagnostic industry shows the coexistence of domestic and foreign companies. International giants such as Roche and Abbott dominate the high-end market, taking the lead with their technological advantages and global presence. Domestic leading companies are competitive in the mid-to-low-end market, continue to make breakthroughs in technological innovation, and rise rapidly through localized production and price advantages, gradually narrowing the gap with international giants. Taking the immunodiagnostic segment as an example, in 2023, more than half of my country's immunodiagnostic market will be occupied by foreign companies, of which Roche's market share will be more than a quarter, reaching 25.4%. Followed by Abbott, which occupies 13.5% of my country's immunodiagnostic market share, Siemens and Beckman occupy 5.3% and 5.2% respectively. The market share of domestic companies is less than 40%. Overall, there is considerable room for domestic substitution in my country’s immunodiagnostic industry2.

Competition for in vitro diagnostic products has evolved from a stand-alone model to a full laboratory assembly line model, and automated and intelligent overall solutions for testing laboratories have become a trend. In the future, with the continuous upgrading of in vitro diagnostic technology and the gradual transformation of cutting-edge technologies into clinical in vitro diagnostic applications, the layout and development of emerging technology fields will become the core driving force for the sustained and rapid development of my country's in vitro diagnostic industry. It is also the key to overtaking Chinese-made in vitro diagnostic products in the industry competition in the global in vitro diagnostic field.

At present, my country's in vitro diagnostic industry is entering a rare policy-intensive "promotion period". The national "14th Five-Year Plan" strategic plan clearly lists high-performance medical devices as a key development industry, and provides key support from the policy and financial levels. The National Health Commission and the Food and Drug Administration issued key projects for digital diagnostic and treatment equipment, "Made in China 2025", and various policies successively introduced at the national level are creating a golden development period for domestic outstanding in vitro diagnostic companies. The in vitro diagnostics market has broad prospects. The diversification of market demands and diversification of service methods have put forward higher requirements for industry supervision. Creating a standardized and orderly industry environment is the guarantee for the healthy and stable development of my country's in vitro diagnostics industry. In addition, the in vitro diagnostic industry is a technology-intensive industry, and industrial upgrading and innovation oriented by "precision medicine" will become the future development direction of the in vitro diagnostic industry.

In addition, in recent years, medical reform policies such as volume-based centralized procurement, sunshine procurement, and DRG in the field of in vitro diagnostics have been implemented one after another. On March 1, 2023, the National Medical Insurance Administration issued the "Notice of the Office of the National Medical Insurance Administration on Doing a Good Job in the Centralized Procurement and Price Management of Medicines in 2023" (hereinafter referred to as the "Notice"), which clearly requires unswervingly promoting centralized volume-based procurement, continuing to expand the coverage of centralized medicine procurement, and solidly promoting centralized volume-based procurement of consumables. The centralized procurement of drugs will be carried out at the national, inter-provincial alliance and provincial levels. The centralized procurement of consumables will be carried out in accordance with the "One

10/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

A new batch of national centralized procurement will be carried out based on the principle of "product is one policy", and it is emphasized that each province will carry out at least 1 batch of provincial centralized procurement of consumables. As of 2024, the IVD industry has carried out five rounds of provincial alliance centralized procurement, covering core varieties, provinces and cities, and it is expected to save procurement funds of more than 10 billion yuan each year. Centralized procurement of in vitro diagnostic reagents has become an important development trend in the industry. Centralized procurement has led to a continued decline in the price of IVD products. Sunshine procurement of reagents and DRG policies around medical insurance cost control are also constantly testing the company's ability to control costs and increase efficiency.

Although the centralized procurement policy has brought challenges to the IVD industry, the IVD industry still has broad room for development in the future, and its development trends are mainly concentrated in the following aspects:

(1) Technological innovation drives qualitative changes in the industry: In vitro diagnostic companies will continue to increase investment in research and development, focusing on high-precision, high-sensitivity, and high-specificity detection technologies, as well as the development of automated, intelligent, and remote detection equipment; in the field of molecular diagnosis, technologies such as gene sequencing and PCR will continue to Upgrade to meet the demand for accurate diagnosis of complex diseases; in the field of immunodiagnosis, chemiluminescence technology will continue to be optimized to improve the accuracy and efficiency of detection; in the field of POCT, miniaturized and portable testing equipment will continue to emerge to meet the needs of home testing and primary medical institutions.

(2) Policy-driven acceleration of domestic substitution: The Chinese government has issued a series of policies to support the development of the in vitro diagnostic industry, including encouraging corporate R&D and innovation, strengthening quality supervision, and promoting industry standardization, etc., which provide a strong guarantee for the healthy development of the industry; at the same time, volume-based centralized procurement, sunshine procurement, and DR G and other medical reform policies have accelerated the process of domestic substitution of IVD products and promoted changes in the market competition landscape in the field of in vitro diagnostics. Leading domestic IVD companies with complete product lines, sufficient production capacity, excellent performance and strong channel capabilities have competitive advantages, and the field of in vitro diagnostics is about to enter a period of industry consolidation.

(3) Product and service innovation based on market demand: With the aging of the population, the prevention and control of chronic diseases, early screening and accurate diagnosis of major diseases such as tumors have released huge market demand space, and also brought opportunities for innovative development in the field of in vitro diagnostics. In particular, molecular diagnostic technology has outstanding advantages in early diagnosis of diseases and personalized diagnosis and treatment. Driven by both technological innovation and market demand, molecular diagnostic technologies represented by PCR and gene sequencing will maintain a sustained growth trend in the future.

To sum up, my country's in vitro diagnostic industry has shown a trend of stable growth and sustainable development in terms of market size, subdivisions, and competition landscape. In the future, with the promotion of technological innovation, policy support and market demand, the in vitro diagnostic industry will face more development opportunities and challenges and make greater contributions to human health.

(2) Main business situation and business model

The company is in the pharmaceutical manufacturing industry, specifically the in vitro diagnostic product manufacturing industry in the medical device industry. Antu Biotechnology focuses on the research and development, manufacturing, integration and services of in vitro diagnostic reagents and instruments. Its products cover the fields of immunity, microbiology, biochemistry, molecules, coagulation and other testing fields, and extend to sequencing, mass spectrometry, quality control products, smart medical laboratories and the construction of close medical alliances. It can provide comprehensive product solutions and overall services for medical laboratories.

The company's main products are classified according to detection methods or application fields. In vitro diagnostic reagents and instruments are mainly divided into the following categories: Classification Subdivided according to detection methods or application fields

Enzyme-linked immunological diagnostic reagents, microplate chemiluminescence diagnostic reagents, magnetic micronized immunological diagnostic reagents

Chemiluminescence detection reagents, etc.

In vitro diagnostic reagents

Culture testing reagents, drug sensitivity testing reagents, identification testing reagents, rapid microbial testing reagents

Rapid detection reagents, sample pretreatment reagents, etc.

11/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Molecular diagnostic testing reagents Real-time fluorescence PCR testing reagents

Enzyme reagents, substrate reagents, ion reagents, special protein reagents, general biochemical detection reagents

Tong immunoturbidimetric reagents and latex immunoturbidimetric reagents, etc.

Mass spectrometry detection reagents: time-of-flight mass spectrometry detection reagents, liquid chromatography tandem mass spectrometry detection reagents, chemiluminescence immunoassay analyzer, microplate reader, fully automatic chemiluminescence immunoassay immunoassay instrument

instrument, fully automatic enzyme label analyzer, etc.

Joint detection analyzer, fully automatic microbial mass spectrometry detection system, fully automatic microbial microbial detection instrument, identification drug susceptibility analyzer, fully automatic reproductive tract secretion analyzer, microbial culture monitor, etc.

In vitro diagnostic equipment

Molecular detection instrument Fully automatic nucleic acid purification and real-time fluorescence PCR analysis system

Biochemical testing equipment Fully automatic biochemical analyzer

Mass spectrometry detection instruments Time-of-flight mass spectrometry detection system, liquid chromatography tandem mass spectrometry detection system

Plate washer, fully automatic sample addition system, fully automatic sample processing system, microbial testing auxiliary equipment

Sample pre-processing system, etc.

1. Procurement model

In order to ensure smooth production and supply, no backlog of inventory, and safe and risk-free capital flow. Based on the requirements of the quality management system, the company has formulated a series of procurement systems, mainly including: "Purchase Contract and Agreement Management System", "Supplier Review Management System", "Production Materials Procurement Management System", "Production Materials Procurement Cycle Management System", "Material Procurement Traceability Management System", "Requisition Cancellation and Change Management System", "Change Materials Procurement Management System", "Non-production Materials Procurement Cycle Management System", "Non-Production Conventional Materials Procurement Management System", etc. In actual work, they are strictly implemented in accordance with the provisions of the regulations.

(1) Procurement model of raw materials for reagent and instrument production

The procurement model of raw materials for reagent production and raw materials for instrument production is basically the same. It mainly includes the formulation of procurement plans, supplier evaluation and selection (including price comparison), contract management, acceptance, and payment. The specific process is as follows:

① Supplier evaluation and selection

Based on the importance of the impact on product quality, technical content and other factors, the company divides the purchased raw materials into three categories. The basis for classifying raw materials and the corresponding supplier evaluation and selection basis are as follows:

Classification of raw materials Importance Basis for supplier evaluation and selection

Important raw materials (relevant to product quality and performance, satisfaction and compliance with technical standards, legal qualifications of suppliers Category A

key material). and supply capabilities.

12/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

General raw materials (directly used in products and meeting and conforming to product technical standards, supplier’s legal qualification Category B

Materials that affect quality and performance). and supply capacity and cost-effectiveness of supply.

Simple raw materials (playing a simple auxiliary role in the product, cost-effectiveness of supply, legal qualifications of suppliers, supply capacity Category C

materials used). Adequacy and fulfillment and conformity of technical standards

Samples are organized when adding/changing suppliers. After the samples are qualified, the purchasing department fills out the "Supplier Admission Review Form" to review the supplier's operating status, production capacity, quality management system, delivery period, etc. The quality center evaluates product quality and admission conclusions, comprehensively evaluates suppliers, and reports the evaluation results step by step for approval, ultimately forming supplier admission opinions. The company conducts performance evaluations on material suppliers every year and eliminates unqualified suppliers based on the evaluation conclusions. In addition to annual reviews, the company will also implement dynamic management of suppliers, conduct on-site audits from time to time, and eliminate unqualified suppliers at any time.

②Quality management measures

In order to ensure smooth production and supply and meet product quality requirements, company documents have clear requirements for the following aspects: A. Raw material quality standards; B. Supplier supply capabilities; C. Supplier quality management status and qualifications. In order to ensure the traceability of raw materials, relevant procurement and usage records are filed and saved as required. After the materials arrive, they will be inspected for acceptance and quality. Once qualified, the materials will be put into storage. If the inspection fails, the "Control Procedure for Non-Conforming Products" will be implemented; if an abnormality occurs during use, the "Feedback Information Control Procedure" will be implemented. (2) Procurement model of agent products

The company's agent product procurement can be divided into two categories. The first type of company will sign an agency or distribution contract with the manufacturer for the agent product, which is divided into important strategic cooperation and general cooperation according to the importance and closeness of cooperation. For important strategic cooperation, the company will sign a long-term exclusive agency contract or a local general agent contract; for general cooperation, the company will sign an annual contract. The second category refers to sporadically purchasing reagents and instruments directly from third parties due to business needs and then providing them to the company's customers, and the company signs product purchase contracts with the third party.

2. production mode

The company's production center carries out production work around the existing product structure. Currently there are five types of core production lines. The details are as follows:

Production line classification Production product category

Enzyme-linked immunodiagnostic reagents, microplate chemiluminescence diagnostic reagents, magnetic particle chemiluminescence immunodiagnostic reagent production lines

Detection reagents, colloidal gold detection reagents, etc.

Microbial testing reagent production line: culture media reagents, drug susceptibility identification testing reagents, rapid testing reagents, etc.

Biochemical testing reagent production line Biochemical testing reagents, etc.

Molecular diagnostic testing reagent production line Molecular testing reagents

Immunological testing instruments, microbial testing instruments, biochemical testing instruments, molecular testing instruments, instrument production lines

Mass spectrometry detection instruments, inspection auxiliary instruments, etc.

The company's entire production process formulates production plans and organizes production based on the product sales forecast data output by the marketing department. The details of the production process are as follows:

13/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

3. sales model

(1) Domestic sales

At present, the national medical reform has had a profound impact on the in vitro diagnostic industry. The centralized and volume-based procurement model of medical testing projects has become the new normal. The reduction of medical charging prices for testing projects has been steadily promoted and gradually implemented. The state's policies to promote the high-quality development of public hospitals and comprehensively promote the construction of a close-knit county medical community will bring short-term pain but long-term benefits to the leading companies in the in vitro diagnostic industry. The company actively responds to policy changes, and through internal structural adjustments, in addition to continuously enriching product lines, it professionally deploys its marketing system around the needs of end customers and deepens the sales structure of "distribution as the mainstay, direct sales as the supplement". Through the functional division of specialized products/production lines, the company has in-depth insights into market demand and creates a more competitive product portfolio. With the help of regional and precise layout, the company develops marketing strategies based on local conditions. Promote the digital transformation and empowerment of marketing, build a three-dimensional marketing network covering multi-level medical markets, and comprehensively enhance the company's market influence and competitiveness.

(2) Overseas sales

Antu Biotech attaches great importance to the expansion of overseas business and continues to accelerate its global market layout. The company's products have entered Asia, Europe, North America, South America, Africa, etc., covering more than 100 countries and regions. The company will rely on overseas subsidiaries to establish complete sales channels and marketing networks to strengthen communication and exchanges with partners around the world and enhance the brand's visibility in the local market. At the same time, the company is also actively carrying out localization layout in relevant areas to provide overseas customers with more and better products.

14/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

The company has established subsidiaries in Hong Kong, Hungary, and Indonesia to steadily promote its global strategic layout and build international investment and financing channels. It aims to establish an industry dynamic monitoring system and local cooperation network globally, and strengthen the construction of a business and trade system in key medical and health fields. By optimizing channel strategies, increasing market penetration, and allocating resources efficiently, we provide solid strategic support for technological innovation transformation and global business expansion, and continue to enhance the company's competitive advantage in the international market.

Description of the company’s new important non-main business during the reporting period

□Applicable √Not applicable

2. Discussion and analysis of operating conditions

As the external environment changes, especially the deepening of medical reform, the company, under the leadership of the board of directors and management team, continues to maintain a proactive attitude: continue to focus on its main business and enhance its core competitive advantages to maintain the stable and healthy development of the company. In the first half of 2025, the company achieved operating income of 2.060 billion yuan, a year-on-year decrease of 6.65%, and net profit attributable to shareholders of listed companies of 571 million yuan, a year-on-year decrease of 7.83%.

In terms of innovation, the company will continue to increase investment in research and development in the first half of 2025, actively explore new fields and develop new products. During the reporting period, R&D investment was 350.0034 million yuan, accounting for 16.99% of operating income. On the basis of continuous high investment in R&D, the company has successively achieved a series of innovative results: as of June 30, 2025, the company has obtained 1,823 patents (including 51 international patents), of which domestic patent authorizations include 357 invention patents, 1,259 utility model patents, and 156 design patents; it has obtained 914 product registration (filing) certificates and obtained EU CE certification for 661 products. The company has undertaken 21 national projects, 20 provincial projects, and 28 city-level projects, completed 10 scientific and technological achievement appraisals (evaluations), and has fully participated in the formulation of 113 national/industry standards.

During the reporting period, the company continued to work intensively in the field of reagent research and development, successfully developed a number of new series of products, and obtained 88 new reagent product registration (filing) certificates, covering magnetic particle chemiluminescence method, liquid chromatography-tandem mass spectrometry, dry chemical enzymatic method, molecular diagnosis, etc. The testing projects cover thrombotic diseases, bone metabolism, tumors, hypertension, respiratory-related diseases, infectious diseases, eugenics and postnatal care, etc. The company's triple bacterial detection products have three products on the market, among which the nucleic acid detection "Burkholderia cepacia" is the first domestic product to obtain a registration certificate. This series of products can be equipped with fully automatic nucleic acid purification and real-time fluorescence PCR analysis systems to enable on-site inspection, further enriching the company's molecular respiratory product line and providing more accurate and rapid solutions for clinical use.

In terms of instrument products, the company also achieved fruitful results during the reporting period: it successfully launched a series of liquid chromatography-tandem mass spectrometry products, including the liquid chromatography-tandem mass spectrometry detection system AutomsTQ6000, fully automatic sample preprocessing equipment and its supporting reagents. On this basis, through the integration of pre-processing and tandem mass spectrometry, the company launched the first domestic liquid chromatography tandem mass spectrometry pipeline Automs Q600, which can provide users with multi-scenario comprehensive detection solutions. At the same time, the company's new products such as the AutofT series of microbial mass spectrometry detection systems, the fully automatic sample pre-processing system AutoMaster, the fully automatic chemiluminescence immunoanalyzer AutoLumoS900, and the microbial culture monitor BC120Plus have been certified and launched. In addition, the company's fully automatic biochemical analyzer AutoChemB2000 series won the 2025 German iF Design Award for its innovative design and product functions.

15/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

In terms of assembly line products, the company's Autolas B-1Star intelligent assembly line combines the advantages of extreme speed, sophistication, intelligence, and all-round application. It integrates sample pre- and post-processing functions and can be connected to biochemical, immunological, and coagulation series testing equipment to help solve space and efficiency problems in outpatient and emergency departments and small laboratories. In addition, after winning the German iF Design Award in 2023, AutolasX-1 won the 2025 China Appearance Design Excellence Award for its innovative appearance and functional design. This reflects that the company's products focus on testing performance, stability and other indicators while also taking into account product design and operating experience.

In terms of NGS platform, Sikun Biotechnology, a wholly-owned subsidiary, has completed the layout of Sikun's full range of products and launched Sikun2000, Sikun 1000, Sikun500, Sikun RapidGS480 four gene sequencers and a fully automatic pathogen analysis system (APAS), successfully entering the non-clinical market, and the fully automatic gene sequencing library preparation instrument AISPre3200 has successfully entered the trial production stage. Among them, the more compact and flexible Sikun Rapid GS480 sequencer will help promote the implementation of a sequencing system suitable for primary medical institutions.

The company has two professional reference laboratories in Zhengzhou and Beijing, both of which are accredited by the China National Accreditation Service for Conformity Assessment (CNAS). At present, Antu Biological Reference Laboratory has built three reference measurement platforms of spectrum, liquid chromatography tandem mass spectrometry, and ion chromatography, which can run 56 reference/reference measurement programs, involving multiple categories such as enzymes, non-peptide hormones, electrolytes, metabolites and substrates, and proteins. Among them, 25 reference measurement items have been recognized by the China National Accreditation Service for Conformity Assessment (CNAS), and 21 reference measurement items have entered the JCTLM reference measurement service list.

In terms of AI testing, the company has completed the localization deployment of DeepSeek, officially connected to the DeepSeek-R1 model, and completed the transformation and upgrade of the core functions of the "Antu AI Testing Clinical Assisted Decision-Making System". Antu Bio's "AI Testing Clinical Assisted Decision-Making System" includes functions such as testing knowledge base, knowledge map, clinical path query, report interpretation, and scientific research data analysis platform. It uses DeepSeek to conduct in-depth mining and analysis of huge medical knowledge and clinical data, and combines it with the existing disease risk prediction model in the AI ​​​​testing clinical auxiliary decision-making system to enhance the accuracy and comprehensiveness of disease risk assessment.

This system can be deeply integrated with the laboratory information system (LIS), inspection business, inspection instruments, etc. developed by the company, and uses artificial intelligence technology to solve actual business pain points. The structured inspection knowledge base runs through the entire process of the department, realizing all-round business and information management of the laboratory. It creates an intelligent inspection information platform with the core of "knowledge + service" to help the laboratory department reduce costs and increase efficiency, promote the improvement of scientific management levels, and provide quality services for inspection, clinical and patients.

Antu Biotech adheres to the corporate purpose of "committed to the popularization and improvement of medical laboratory technology and serving human health" and strives to provide medical laboratories with products and services with better performance-price ratio and quality-price ratio. "Becoming a provider of medical laboratory products and services with brand influence; rewarding employees, investors, and society" is the beautiful vision of Antu Biotech.

Major changes in the company's operating conditions during the reporting period, as well as events that occurred during the reporting period that have a significant impact on the company's operating conditions and are expected to have a significant impact in the future

□Applicable √Not applicable

3. Analysis of core competitiveness during the reporting period

√Applicable □Not applicable

After more than 20 years of exploration and accumulation in the in vitro diagnostic industry, Antu Biotech has made major breakthroughs in R&D innovation, comprehensive product solutions, market resource integration, and customer service integration, and continues to consolidate the company's core competitive advantages.

16/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(1) R&D and innovation positioning

1. Positional R&D strategy

While embracing the national centralized procurement policy, the company has further deployed positional R&D by upgrading its R&D strategy, and continues to create new high value-added products to form differentiated competitive advantages. The company's testing projects have gradually extended from traditional infectious diseases, tumors and other fields to precision testing fields such as autoimmune diseases, allergen screening, sequencing, and mass spectrometry, making the product line more complete and continuously consolidating the company's core competitiveness.

As of the end of the reporting period, the company had obtained 914 product registration (filing) certificates and obtained EU CE certification for 661 products. Its products cover many directions in the fields of immune testing, microbial testing, molecular diagnostic testing, biochemical testing, mass spectrometry platforms, etc. It is one of the companies with the most registration numbers and the most comprehensive product line in the industry.

In terms of R&D layout, the company continues to improve its technology R&D system with Zhengzhou as the center and Beijing, Shanghai, Shenzhen, Suzhou, and North American R&D centers as branches. It makes full use of local talents and technological advantages to form a high-quality R&D team and enter the development of cutting-edge technologies and products in the field of in vitro diagnostics.

2. R&D investment and technology platform support

The company attaches great importance to investment in R&D innovation. The R&D investment from 2022 to 2024 is 571.6948 million yuan, 656.1304 million yuan and 731.9328 million yuan respectively, accounting for 12.87%, 14.77% and 16.37% of the current operating income respectively. The continuous high investment in R&D has guaranteed the company's continuous technological innovation.

The company has established an immune detection reagent development platform, a microbial detection reagent development platform, a molecular diagnostic detection reagent development platform, a biochemical detection reagent development platform, a mass spectrometry detection reagent development platform, an antigen and antibody development platform, and an instrument development platform. In addition, the company has a nationally recognized enterprise technology center, a national engineering research center for the detection of emerging major infectious diseases, a national and local joint engineering laboratory for immunoassay automation, Henan In vitro diagnostic reagent engineering research center, Henan immunodiagnostic reagent engineering technology research center, and Henan mass spectrometry technology innovation The center, Henan Provincial In-Vitro Diagnostic Product Pilot Base, Henan Provincial In-Vitro Diagnostic Innovation Consortium, Henan Provincial In-Vitro Diagnostic Industry Research Institute, Antu Experimental Instruments (Zhengzhou) Co., Ltd. Technology Center, Zhengzhou Imino Biotechnology Co., Ltd. Technology Center and 3 municipal platforms have formed a complete scientific research and development system. The company's powerful technology development platform not only ensures product quality, but also makes it possible to provide customers with technical services in a timely manner.

3. R&D and upgrade of core materials

Bioactive materials (mainly including antigens, antibodies, etc.), as key raw materials for in vitro diagnostic reagents, directly affect the quality of the product. The company focuses on the research and development of core raw materials. After more than ten years of painstaking research and development and technology accumulation, the required core raw material antigens and antibodies have been basically self-sufficient, ensuring the stability and safety of the supply of core raw materials. The company has completed the optimization of a fully human antibody development platform based on phage display technology. It has the ability to rapidly develop monoclonal antibodies from multiple species such as mice, rabbits, sheep, and humans, and has improved the technical level of small molecule antibody and high-affinity antibody development. It has comprehensively laid out the field of autoimmune diagnostic raw materials, broke through the preparation problems of complex intramembrane and transmembrane proteins, and provided comprehensive underlying technical support and high-performance raw material support for autoimmune diagnostic reagents.

17/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(2) Comprehensive product solutions

The company has a rich product line and is committed to providing customers with comprehensive product solutions in multiple testing fields. Currently, in the field of testing applications, it can provide comprehensive solutions such as fully automatic assembly line testing, immunological testing, biochemical testing, microbial testing, molecular testing, precision testing and quality control product series.

1. Fully automatic assembly line overall solution

The company was the first to launch the AutolasA-1 series of fully automatic magnetic levitation assembly lines for medical laboratories in the Chinese market in 2017. In 2019, it launched the AutolasB-1 series of fully automatic biochemical immune assembly lines suitable for compact medical laboratories. In 2022, it launched the AutolasX-1 series of new independently developed and produced automated assembly lines. Through the "three-step" strategy of the assembly line, Antu Biotech has achieved a breakthrough in laboratory assembly line products from scratch, leaping from a local brand to local R&D and manufacturing, and has played a positive role in promoting the intelligent construction of medical laboratories in my country.

Independently developed and produced automated assembly lines, the AutolasX-1 series assembly lines feature customized design and services, integrating domestic and international high-end resources to create medical laboratory automation solutions that are more suitable for China's national conditions. This product realizes the complete localization of the assembly line body, improves many key performance indicators of the line body, and is the first to introduce an AI intelligent recognition and judgment system. The whole process AI intelligently identifies specimen information, centrifugation status, serum volume, serum quality, etc.; its intelligent specimen management system is very distinctive, equipped with a small body and large capacity low-voltage The Wen online refrigerator helps laboratories realize a series of intelligent specimen management functions such as automatic specimen archiving, automatic search, automatic retesting, automatic expiration and discarding, and advanced automatic quality control, simplifying work processes, improving laboratory efficiency, and opening up the "last mile" of automated assembly lines; it is equipped with the newly upgraded AutoLean® The overall lean management solution assists laboratories in carrying out lean improvement projects. In the process of improvement, waste is eliminated and value is enhanced. At the same time, it helps laboratory staff form a scientific problem-solving thinking, continue to make continuous improvements, and promote high-quality development of the laboratory.

During the reporting period, the company optimized and upgraded the AutolasB-1 assembly line and launched the AutolasB-1Star series of self-developed integrated intelligent assembly lines. This product relies on a centralized pre- and post-processing system to help outpatient and emergency departments and small laboratories solve space and efficiency problems.

18/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

2. Immunoassay solutions

The company's immune detection products have 421 registration (filing) certificates and have obtained EU CE certification for 363 products. The reagent varieties cover infectious diseases, tumors, reproductive endocrinology, thyroid function, liver fibrosis, eugenics and postnatal care, diabetes, hypertension, heart disease, bone metabolism, respiratory tract, autologous It covers multiple testing directions such as immunity and thrombotic diseases. The instruments cover chemiluminescence immunoassay analyzers, microplate readers, plate washers, fully automatic chemiluminescence immunoassay analyzers and other products. It is one of the companies in my country that provides more immune testing products and is also one of the companies in China that can provide comprehensive immune testing solutions.

Magnetic particle chemiluminescence immunoassay technology is currently the mainstream international advanced technology direction. The company has obtained registration (filing) certificates for 215 magnetic particle chemiluminescence diagnostic products, and launched the AutoLumo series of fully automatic chemiluminescence immunoassay analyzers based on single detection management. In order to meet the needs of different testing scenarios, the testing speeds of this series of instruments are divided into different specifications such as 600 tests/hour, 200 tests/hour, 180 tests/hour, etc., providing efficient, random, flexible and diverse automated immune detection solutions for clinical use.

The company's microplate immunoassay products (including enzyme-linked immunoassay products and microplate chemiluminescent products) have 91 registration (filing) certificates. These products can provide low-cost, high-throughput solutions for clinical hospitals, physical examinations, third-party independent laboratories, disease control, population and family planning and other markets.

3. Microbiological testing solutions

Antu Biotech has decades of rich technical accumulation in the field of microbial testing. Its products cover culture, identification, drug susceptibility and other aspects, and can provide a series of solutions for clinical microbial testing. The company's microbial testing products have 160 registration (filing) certificates and have obtained EU CE certification for 85 products. The reagent varieties cover multiple testing directions such as genitourinary tract diseases, respiratory diseases, bacterial isolation and culture, identification and drug susceptibility analysis. The company's medium plate series products have a high market share in my country. The launch of microbial culture monitors and supporting culture bottles has further established the company's market position in the domestic bacterial culture field. Instrument products include fully automatic microbial mass spectrometry detection systems, fully automatic microbial identification and drug susceptibility analyzers, joint detection analyzers, and fully automatic reproductive tract secretion analyzers.

19/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

analyzers, microbial culture monitors, automated blood culture systems, microbial pretreatment systems, etc., it is one of the domestic companies with a wide range of products in the field of microbial testing and rapid growth.

The company's fully automatic microbial mass spectrometry detection system is equipped with a fully automatic spotting system and a series of kits for mass spectrometry, forming an overall solution for microbial mass spectrometry. MALDI-TOF fully automatic microbial mass spectrometry detection system Autofms series products have the advantages of simple operation, fast, accurate and high-throughput detection, and are widely used in the detection of bacterial and fungal microorganisms in clinical, disease control, food and drug, marine and other application fields. On the basis of the above, the new-generation upgraded fully automatic microbial mass spectrometry detection system AutofT series further reduces the size and weight of the instrument, breaks through design limitations, and is equipped with intelligent and convenient operation. It moves from "mass spectrometry" to "smart spectrometry" and continues to improve customer experience.

In response to problems such as the lack of unified process management for automated testing in microbiology laboratories, Antu Biotech has launched the "Microbiology Laboratory Information Management System", which covers everything from sampling, inoculation to culture, identification, and drug susceptibility. It provides unified management of microbial blood culture, mass spectrometry, drug susceptibility and other data and information, achieving seamless connection of testing data for each microbial process, and assisting the intelligent construction of microbiology laboratories.

4. Biochemical testing solutions

The company's biochemical testing products have 203 registration (filing) certificates, of which 123 products have passed the EU CE certification. The products cover 12 major categories of biochemical testing, including liver disease, kidney disease, cardiovascular disease, glucose metabolism disease, immune disease, pancreatic disease, gastric screening, coagulation and fibrinolysis disorders, trace elements and ions, and tumors. The rich testing products can meet the various clinical biochemical testing needs of end users. Biochemical testing reagents are equipped with the company's two fully automatic biochemical analyzers, AutoChemB2000 series and AutoChemB800 series, or biochemical instrument products integrated by the joint company, providing more flexible and complete solutions for large medical laboratories, outpatient and emergency laboratories.

20/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

5. Molecular detection solutions

The molecular diagnostic project provides customers with one-stop nucleic acid detection solutions, and the developed product menu covers more than 60 items in 8 series and random fully automated nucleic acid (RT-PCR) detection systems. As of the end of the reporting period, the company's molecular testing products had obtained 35 registration (filing) certificates and obtained EU CE certification for 47 products, mainly for infectious pathogen testing products and human genome testing products. After years of research and development, the company has launched a series of fully automatic nucleic acid purification and real-time fluorescence PCR analysis systems, supporting new coronavirus (2019-nCoV), influenza A/B virus, syncytial virus, parainfluenza virus, Mycoplasma pneumoniae, Chlamydia pneumoniae, adenovirus, metapneumovirus, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Klebsiella pneumoniae , Pseudomonas aeruginosa, Haemophilus influenzae, Escherichia coli, Group B Streptococcus, Hepatitis C virus, Acinetobacter baumannii, Stenotrophomonas maltophilia, Burkholderia cepacia and ALDH2, CYP2C19 detection projects, realizing fully automatic extraction + system construction + amplification, suitable for application scenarios such as fever clinics, emergency departments, customs, ports, cardiovascular clinics, and hospitalizations.

21/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

6. Accurate detection solutions

In recent years, the company has actively promoted the application of precision detection technology, assisted the efficient development of the in vitro diagnostic industry, and provided more efficient and accurate product solutions for medical laboratories.

Based on the mass spectrometry detection technology platform, as of the end of the reporting period, the company had 8 registration (filing) certificates, mainly for nutrition and blood drug concentration monitoring products. The company's fully automated liquid chromatography tandem mass spectrometry detection system AutoChrom The system is equipped with testing items for 25-hydroxyvitamin D, tacrolimus, carbamazepine, and vancomycin, further enriching and improving the company's precision testing product line, and effectively assisting the continuous improvement of clinical precision testing capabilities.

Based on the gene sequencing platform, the Sikun series of next-generation high-throughput gene sequencers, a wholly-owned subsidiary of Sikun Biotechnology, was simultaneously launched in the non-clinical market. This series of instruments has the characteristics of fast, accurate, flexible and stable, and can complete a sequencing within 3.5 hours at the fastest. It currently has four series of products: Sikun2000, Sikun1000, Sikun500 and SikunRapidGS480, with a variety of throughput modes for users to flexibly choose.

7. Quality control product solutions

The company has mastered key core technologies in quality control product development to ensure product quality, and has developed a variety of quality control products and laboratory quality evaluation samples that meet clinical needs. As of the end of the reporting period, a total of 67 medical device registration (filing) certificates for quality control products have been obtained, and 90 national secondary reference material certificate numbers have been obtained, covering routine inspection items such as infectious diseases, tumors, reproductive endocrinology, thyroid function, liver fibrosis, eugenics, diabetes, hypertension, cardiac markers, lipids, specific proteins, coagulation, blood cell count, biochemistry, urine chemical analysis, mass spectrometry; it can provide medical laboratories with a rich quality control menu to solve the routine quality control needs of end users.

(3) Integration of market resources

22/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

In the process of fully improving its independent innovation capabilities and strengthening local manufacturing capabilities, the company attaches great importance to the optimization and integration of industry resources. Through the in-depth integration of industry technology research and development capabilities and innovative elements, and continuous expansion of the product matrix, we can provide medical laboratories with a richer range of products and services. At the same time, we will comprehensively improve the level of technical services and the professionalism of the marketing team, continue to deepen the optimization and integration of market resources, and strive to build a new industry ecosystem for collaborative advancement.

1. Create a professional marketing system to achieve precise market penetration

As the company's product lines continue to enrich and regional differences in market demand gradually become more prominent, in order to further promote the deep penetration and sustained growth of products in the market, the company continues to optimize the personnel structure of the regional product marketing department, increase the proportion of R&D personnel and application service personnel in the front line of marketing, deeply explore terminal needs and pain points, and provide comprehensive product empowerment training for marketing teams and dealer partners. At the same time, we carefully plan and implement special academic conferences and salon activities involving each product line, focusing on product strategy formulation, promotion and sales support for regional markets to ensure that the company's products can accurately meet the needs of various regional markets. Through this initiative, it can not only accurately meet market demand and effectively enhance product competitiveness and market share, but also further enhance brand influence and provide solid support for the company's long-term development. As of December 31, 2024, the company's products have entered more than 6,800 end users in secondary hospitals and above, including more than 2,500 in tertiary hospitals, accounting for 64.8% of the total number of tertiary hospitals in the country.

2. From single product line sales to multi-product combination marketing, seize the opportunities of centralized procurement to expand the market

In the centralized mass procurement of biochemical and immune projects announced in 2024, the company actively responded to the various centralized mass procurement efforts of the Medical Insurance Bureau, and successfully won the bids with its excellent product quality and comprehensive strength, becoming one of the companies participating in the most centralized mass procurement projects of biochemistry and immunity. In the first half of 2025, through centralized volume procurement, we will expand new customers on the basis of original users, accelerate market replacement of other brands, and further consolidate and increase market share.

In terms of innovative marketing, in the context of the gradual implementation of centralized procurement policies, the company has given full play to its advantages in extensive product line layout over the years and actively promoted innovation in multi-product portfolio marketing and overall solution marketing models. Through the creation of innovative marketing models such as smart laboratories and smart regional medical testing centers, Antu realizes the deep integration of smart information ecology and automation equipment, assists the construction of "Trinity" smart hospitals, actively responds to the policy call for high-quality development of public hospitals and the construction of close county medical communities and urban medical groups, provides smart empowerment for regional medical testing centers and medical laboratories, promotes mutual recognition of test results, and assists in the effective implementation of hierarchical diagnosis and treatment policies.

3. Build a multi-dimensional academic promotion platform to drive the coordinated development of market and R&D

As the medical field accelerates its transformation into a "patient-centered" direction, the company's Medical Affairs Department has also realized its positioning adjustment from a traditional scientific research support role to a strategic driver. This transformation is not only reflected in technical support levels such as scientific research cooperation, but also comprehensively runs through multiple key dimensions such as strategy formulation, academic promotion, and compliance assurance.

Through diversified cooperation models such as clinical scientific research cooperation, joint application for government projects, and comprehensive cooperation between institutions (schools) and enterprises, the company integrates intelligent laboratory elements such as the establishment of AI disease diagnosis and treatment prediction models, and transforms profound medical professional capabilities into strong market competitive advantages. Closely combine academic research results and industry trends to drive the continuous optimization of market strategies, provide the R&D department with first-hand research data from end users, provide the basis for the marketing department to formulate accurate and effective promotion plans, and ensure that every marketing activity has both scientific and commercial value. By building a multi-dimensional academic promotion platform, the company has not only improved its product innovation capabilities, but also further strengthened its academic brand influence, winning a more favorable position for the company in market competition.

23/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

4. Continue to improve product line layout to meet diverse medical needs

With the further advancement of the national hierarchical diagnosis and treatment policy and the continuous strengthening of the sinking of medical resources, the diagnostic demand of primary medical units has shown explosive growth. However, traditional testing equipment cannot effectively meet the actual needs of primary medical units and outpatient and emergency departments due to problems such as high instrument cost, large equipment volume, and insufficient operational convenience.

In order to effectively solve the pain points of this industry and meet the urgent needs of the primary medical market, the company has actively deployed product series such as colloidal gold and POCT chemiluminescence through independent research and development and strategic cooperation. The company's AutoFlex series of products are inherited from Antu Bio's mature and accurate magnetic particle luminescence platform. They have excellent performance advantages and can easily implement in-hospital and regional quality control management of POCT. They are compatible with various sample types such as whole blood, plasma, serum, urine, etc. Currently, 13 testing reagents have successfully obtained medical device registration (filing) certificates, and more reagent varieties will be added in the future to meet the testing needs of POCT in various application scenarios.

In terms of integrating product lines, the company actively expands its business areas and has reached an in-depth strategic cooperation with Hiken Medical in the field of coagulation testing. At present, the company has been able to provide users with one-stop product and service solutions covering high-throughput coagulation testing equipment, fully automatic coagulation assembly lines, and compatible coagulation testing reagents. Among them, the fully automatic coagulation analyzer AutoCimoC600 brings customers an excellent coagulation testing experience with its constant speed and stable detection performance.

(4) Integrated customer service

With the service concept of "Customer First, Creating Value", Antu Biotech adheres to being user-centered and continuously improves service standards and capabilities; while providing product technical services, it also provides laboratory quality control services, laboratory management services and laboratory intelligent services for medical laboratories.

1. Product technical services

The concept, team and process construction of product technology services are one of Antu Biotech's core competitiveness. Strong after-sales service and technical support ensure that the company can provide customers with detailed product consultation, product usage training and product after-sales service in a timely and professional manner, thus ensuring the smooth sales of the company's products and the stable use after sales.

2. Laboratory quality control services

While providing product technical services to users, Antu Biotech also takes improving the quality control of China's clinical laboratories as its mission and provides clinical laboratories with a series of quality control services such as professional quality control products, quality control software, ISO15189 quality management system accreditation, and quality education. Among them, BiQAS software realizes the mutual recognition function of test results, and the software platform has served thousands of medical laboratories.

3. Laboratory management services

The construction of Antu Bio's regional medical testing center focuses on relying on the hospital laboratory department as the main body to build a regional medical testing center. It uses the company's platform, regional LIS cloud and cold chain logistics to provide site planning and design, equipment upgrades, intensive supply, quality services, 6S lean management, and ISO15189 laboratory accreditation to achieve unified quality, mutual recognition of results, and clinical recognition, and promote the implementation of hierarchical diagnosis and treatment policies. At the same time, the company provides intensive supply services, carries out instrument configuration planning for clinical medical testing centers based on the use and demand, planning and business growth of existing testing equipment in the testing center, and upgrades some testing equipment to meet the needs of platform construction for new testing technologies and testing disciplines.

24/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

4. Laboratory smart services

Intelligence is an important direction for the development of medical laboratories. Antu Biotechnology utilizes the advantages of its own products and technologies to carry out in-depth work in the field of intelligence: striving to achieve product automation and IoT; using the laboratory information system (LIS) as the core to realize the interconnection of medical laboratory information systems; establishing a regional laboratory information system to realize the sharing of testing resources within the region; mining and intelligent analysis of testing big data to assist testing and clinical scientific decision-making, etc.

Based on the guidance of technological innovation, the company released an intelligent construction plan for the regional medical testing center. The plan includes eight modules: medical laboratory data monitoring platform, regional medical testing center laboratory information management system, supply chain and regional sample transmission platform, laboratory infrastructure construction plan, intelligent laboratory construction plan, subject capacity building plan, management capacity improvement plan and grassroots capacity improvement plan. Through the cloud interconnection platform, it forms an organic whole that complements and promotes each other. At the same time, Antu Biotechnology's "AI testing clinical auxiliary decision-making system" is tailor-made for medical laboratories and clinical decision-making. The system includes testing knowledge base, knowledge map, clinical path query, report interpretation, scientific research assistance and other functions, and is integrated with testing equipment to better improve laboratory consulting service capabilities and enhance testing value.

4. Main operating conditions during the reporting period

(1) Main business analysis

1. Analysis table of changes in relevant accounts of financial statements

Unit: Yuan Currency: RMB account Number for the current period Number for the same period last year Change ratio (%) Operating income 2,060,307,179.95 2,207,103,914.63 -6.65 Operating costs 732,834,381.85 768,276,556.47 -4.61 Sales expenses 389,039,334.86 364,700,186.63 6.67Administrative expenses 102,288,423.93 91,426,520.73 11.88Financial expenses 4,268,656.24 3,811,939.58 11.98R&D expenses 250,345,849.36 333,232,807.55 -24.87 Net cash flow from operating activities 410,183,925.35 495,490,846.33 -17.22 Net cash flow from investing activities 302,134,529.97 -591,755,735.47 151.06 Net cash flow generated from financing activities -713,283,280.74 -1,040,146,331.62 31.42

Explanation of reasons for changes in R&D expenses: Mainly due to the capitalization of R&D expenses in the current period;

Reasons for changes in net cash flow generated from investing activities: Mainly due to the larger amount of redemption of financial management in this period compared to the same period last year; Explanation of reasons for changes in net cash flow generated from financing activities: Mainly due to the larger cash flow received from letter of credit and bill financing business in this period compared to the same period last year.

2. Detailed description of major changes in the company’s business type, profit composition or profit sources during this period

□Applicable √Not applicable

(2) Explanation of significant changes in profits caused by non-main business

□Applicable √Not applicable

(3) Analysis of assets and liabilities

√Applicable □Not applicable

25/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

1. Assets and liabilities status

Unit: Yuan Current period End of current period

End of last year

The last amount accounts for the higher amount

Number of total assets

Project name Closing amount of the current period Total assets Closing amount of the previous year Changes at the end of the period Proportion of assets explained by the situation

proportion of dynamic proportion

(%)

(%) (%)

Mainly due to the purchase of treasury bonds in this period, reverse transaction finance

411,123,668.33 3.53 3,609,780.75 0.03 11,289.16 Repurchase and other financial assets

Due to the increase in products.

Mainly due to the settlement of accounts receivable from other units and other receivables 26,461,172.03 0.23 80,180,790.84 0.68 -67.00 received during the period.

Mainly due to long-term equity investment in joint-stock companies in this period 17,844,095.28 0.15 11,656,048.18 0.10 53.09

Due to the increase in capital investment.

Mainly due to investment in projects under construction in the current period 435,944,003.56 3.74 987,283,594.17 8.31 -55.84

It is caused by the use of solidification.

Mainly due to the capitalization of research and development expenses in the current period 93,253,332.83 0.80 100.00. Mainly due to unsatisfied income as other non-current

700,379,020.38 6.01 443,223,212.42 3.73 58.02 Assets subject to this recognition condition

The number of issued instruments is increased.

Mainly due to the amount of short-term bank loans due for repayment in the current period 113,699,702.22 0.98 232,377,977.25 1.96 -51.07

This is due to the higher amount of new borrowings in the current period.

Mainly due to bills payable in the current period of bill financing industry 935,761,334.77 8.04 469,500,000.00 3.95 99.31

Due to the increase in services.

Mainly due to the payment of employee salaries payable in this period to the end of last year 105,837,183.34 0.91 210,127,628.38 1.77 -49.63

Remuneration is due to bonus accrual.

Due within one year Mainly due to non-current liabilities in the current period 10,217,917.35 0.09 295,983,348.75 2.49 -96.55 Repayment of debts due within one year Long-term debt due within one year

26/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Due to borrowing. The main department has not yet

Meet other non-current income recognized

207,488,679.84 1.78 139,570,254.65 1.17 48.66 Conditional issuance liabilities

Add instruments

Add.

Other instructions

None

2. Overseas assets

√Applicable □Not applicable

(1). Asset scale

Among them: overseas assets 1,532.30 (unit: 10,000 yuan, currency: RMB), accounting for 0.13% of total assets.

(2). Relevant explanations on the high proportion of overseas assets

□Applicable √Not applicable

Other instructions

None

3. Restrictions on major assets as of the end of the reporting period

√Applicable □Not applicable

Unit: Yuan Currency: RMB End of Period Beginning of Period

Book Balance Book Value Subject to Subject Book Balance Book Value Subject to Subject

limited limited limited items

type of situation type of situation type of situation type of situation swap swap futures guarantee guarantee

Certificates and coins frozen

22,671,354.15 22,671,354.15 Gold 13,314,774.21 13,314,774.21 Financial balance

and gold

ETC ETC circle is deposited and its large amount is frozen and deposited 130,000,000.00 130,000,000.00 410,000,000.00 410,000,000.00

Moving statement, statement, qualification, property pledge, pledge not yet secured

Do it, do it

734,680,463.01 734,680,463.01 Completed 1,054,303,826.56 1,054,303,826.56 Completed

produce produce

right

27/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Certificate investment is not properly handled

21,929,946.80 21,929,946.80

Real estate title certificate

887,351,817.16 887,351,817.16 // 1,499,548,547.57 1,499,548,547.57 // Total

4. Other instructions

□Applicable √Not applicable

(4) Investment status analysis

1. Overall analysis of external equity investment

√Applicable □Not applicable

Investment amount during the reporting period (10,000 yuan) Investment amount in the same period last year (10,000 yuan) Change range (10,000 yuan) 800.00 981.35 -181.35

As of the end of the reporting period, the company's investment balance in other equity instruments was RMB 160.8836 million. For details, please see Note VII. 18 Investment in Other Equity Instruments to the Financial Statements;

The long-term equity investment balance of the parent company is RMB 551,647,300. For details, please refer to Note 19.3 Long-term Equity Investment in the Financial Statements.

(1).Significant equity investment

□Applicable √Not applicable

(2).Significant non-equity investment

□Applicable √Not applicable

(3).Financial assets measured at fair value

□Applicable √Not applicable

Securities investment situation

□Applicable √Not applicable

Explanation of securities investment situation

□Applicable √Not applicable

Private equity fund investment situation

√Applicable □Not applicable

On July 23, 2023, as passed by the company's investment committee meeting, the company participated in investing in Suzhou Jinhe Fund as a limited partner, with a subscription amount of RMB 100 million, and signed the "Suzhou Jinhe Phase III Equity Fund" with the relevant partners on July 26, 2023.

28/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Investment Partnership (Limited Partnership) Partnership Agreement" and "Supplementary Agreement", investing 50 million yuan in 2023 and 2024 respectively.

30 million yuan. As of the end of June 2025, the company has invested a total of 80 million yuan.

Derivatives investment situation

√Applicable □Not applicable

(1). Derivative investments for the purpose of hedging during the reporting period

√Applicable □Not applicable

Unit: 10,000 yuan Currency: RMB

plan

enter

end of period rights

book profit

worth this period

Occupy the public

fair tired

Derivative investment Initial investment Book value at the beginning of the reporting period During the reporting period Book value at the end of the reporting period Company reported value Calculation

Type Amount Value Amount purchased Amount sold Value Changes during reporting period Announcement

Ending net profit and loss allowed

asset price

Proportional value

(%) change

move

Foreign exchange swap 12,317.21 12,678.19 -5.41 31,458.81 10,988.18 33,143.41 3.88Total 12,317.21 12,678.19 -5.41 31,458.81 10,988.18 33,143.41 3.88 Settlement during the reporting period

Hedging business

accounting policy

policy, accounting

Calculate the specific original

No

then, and with

last reporting period

Compared to whether to send

major changes

description

Actual during the reporting period In order to avoid and prevent the operating risks brought to the company by fluctuations in foreign exchange rates and improve the efficiency of the use of foreign exchange funds, the company's profit and loss was appropriately carried out according to the operating conditions, and the foreign exchange swap business was conducted appropriately. At the end of the reporting period, the company's foreign exchange swap fair value changes showed a net profit of RMB 3.5557 million.

Hedging effectiveness

At the end of the reporting period, the company's gain from changes in fair value of foreign exchange swaps was RMB 3.5557 million.

Description of the fruit

Derivatives Investment

Own funds

Source of funds

Derivatives during the reporting period 1. The company uses its own funds to carry out foreign exchange swap business transactions, and strictly follows the approved risk transaction limits of foreign exchange derivatives positions, controls the scale of funds, and must not affect the company's normal operations. It has agreed with financial institutions on a fixed-term forward risk analysis and control of the transaction exchange rate to prevent large fluctuations in exchange rates from affecting the company's performance.

Description of control measures 2. The company is only allowed to conduct transactions with financial institutions approved by the State Administration of Foreign Exchange and the People's Bank of China that have foreign exchange hedging business (including but not operating qualifications), and shall not conduct market risk transactions with other organizations or individuals other than the aforementioned financial institutions.

insurance, liquidity 3. The company has formulated the "Foreign Exchange Hedging Business Management System" to standardize the company's foreign exchange hedging business and

29/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Risk and credit related information disclosure work, strengthen the management of foreign exchange hedging business, prevent investment risks, effectively prevent and control foreign currency exchange rate risks, and ensure the safety of the company's assets. risk, legal

risks, etc.)

Invested in derivatives

product reporting period

market price or

fair price of product

value changes

situation, for derivatives

The fair value of items with changes in fair value is determined every quarter based on the foreign currency spot exchange rate in the external financial market.

The analysis should cover

reveal specific uses

methods and phases

Hypotheses and parameters

number setting

Involvement in litigation

Not applicable

(if applicable)

Derivatives Investment

Approval Board of Directors

January 22, 2025

Announcement Disclosure Date

period (if any)

Derivatives Investment

Approval of shareholders meeting

Announcement Disclosure Date

period (if any)

(2). Derivative investments for speculative purposes during the reporting period □ Applicable √ Not applicable

Other instructions

None

(5) Major assets and equity sales

□Applicable √Not applicable

(6) Analysis of major holding and participating companies

√Applicable □Not applicable

Unit: 10,000 yuan Currency: RMB Shareholding ratio Company abbreviation Registered capital Total assets Net assets Net profit (%) Antu Instruments 5,000.00 100 213,774.45 135,896.06 16,616.60

Antu Technology 5,000.00 100 119,892.25 36,095.97 1,290.75

Major subsidiaries and joint-stock companies that affect the company’s net profit by more than 10% □ Applicable √ Not applicable

Acquisition and disposal of subsidiaries during the reporting period

√Applicable □Not applicable

Company name How to acquire and dispose of subsidiaries during the reporting period Impact on overall production operations and performance

30/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

This deregistration will not have any impact on the company’s overall business, Zhengzhou Antumobi Molecular Diagnostic Technology.

Canceling a company that has a material impact on its development and profitability

ring.

Other instructions

□Applicable √Not applicable

(7) Structured entities controlled by the company

□Applicable √Not applicable

5. Other disclosure matters

(1) Possible risks

√Applicable □Not applicable

1. Risks of industry policy changes

The state implements a strict classification management and production licensing system for the in vitro diagnostic industry. The State Food and Drug Administration is the highest authority in the in vitro diagnostic industry in my country and is responsible for basic management functions such as supervision of the in vitro diagnostic industry, industry standards, product market access, production enterprise qualifications, product advertising, product clinical trials, and product registration. National industry policies stipulate that related products involving important fields such as biological products require national compulsory certification and have corresponding access mechanisms. If national industrial policies, industry access policies and related standards change adversely to the company in the future, it may have an adverse impact on the company's production and operations. In recent years, the new medical system reform has proposed corresponding reform measures in terms of the medical management system, operating mechanism and medical security system. The National Medical Products Administration and other regulatory authorities are also continuing to improve relevant industry laws and regulations, and strengthen supervision over the quality control, supply qualifications, procurement and bidding of medical device products. If the company fails to make corresponding adjustments in its business strategies according to changes in national medical reform and regulatory policies, it will have an adverse impact on the company's operations.

The company has always adhered to legal and compliant operations. In the face of industry policy changes, the company has also continued to improve its operation and management level and continuously improved the management and control system of R&D, production, quality management, sales and other links to actively adapt to the needs of new policies and fully reduce operating risks caused by policy changes.

2. Market risk

In recent years, under the environment of the rapid development of various new technologies and the gradual improvement of medical security policies in most countries, the in vitro diagnostic industry has developed rapidly and has become one of the most active and fastest-growing industries in the medical market. Against the backdrop of my country's huge population base and rapidly growing economy, the in vitro diagnostic industry has become one of the fields with the greatest potential for development. The rapidly growing in vitro diagnostic market has attracted many domestic and foreign in vitro diagnostic manufacturers to join the competition, and the industry competition is relatively fierce. From the perspective of the competitive environment, international multinational companies occupy a relatively monopolistic position in my country's high-end in vitro diagnostic market. They use their advantages in products, technologies, and services to continuously increase investment in China, especially in high-end markets such as domestic tertiary hospitals. Most domestic companies mainly produce mid- to low-end diagnostic products and have not yet formed a stable market structure. Domestic leading companies are also accelerating the implementation of product diversification development strategies, actively integrating with high-end markets, and participating in high-end market or international market competition. The domestic in vitro diagnostic industry is in the transition stage from the cultivation period to the rapid growth period. With high industry profit margins and broad market development space,

31/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

More manufacturers will be attracted to enter the industry, and market competition will further intensify. If the company cannot continue to maintain its advantages in technology, market, brand, customer trust and other aspects in the industry in the future, the fierce market competition environment may have an adverse impact on the company's production, operations and profitability.

The company will rely on its strong technical research and development capabilities and rich industry experience to continue to maintain its advantages in technology, market, brand, customer trust and other aspects in the industry to cope with industry competition.

3. Risks of technology iteration

The in vitro diagnostic industry is a technology-intensive industry, and the upgrading of product technology is the driving force for industry development. The company's current field of chemiluminescence is the mainstream of clinical immunoassay technology. With the emergence of new product technologies in the future, if the company cannot accurately predict the technical direction of product development and the level of R&D technology is slow to improve, new product launches will be slow and decoupled from the mainstream of the market, which will have a greater impact on the company's production and operations.

The company's strategic marketing and R&D departments will actively pay attention to the in vitro diagnostic market trends, understand the latest in vitro diagnostic industry trends, comprehensively plan product layout, continue to increase investment in the research and development of new products and new technologies, and enable the company's product upgrades to keep up with the development direction of the industry.

(2) Other disclosure matters

□Applicable √Not applicable

32/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Section 4 Corporate Governance, Environment and Society

1. Changes in directors, supervisors and senior managers of the company

√Applicable □Not applicable

Name Position held Changes Gu Jun Independent Director Resigned

Qiao Hailing Independent Director Election

Description of changes in directors, supervisors and senior managers of the company

√Applicable □Not applicable

The company's board of directors received a written resignation report from independent director Mr. Gu Jun on December 20, 2024. Mr. Gu Jun applied to resign as an independent director of the company's fifth board of directors due to personal reasons. He also resigned from relevant positions in the special committee of the company's board of directors. After his resignation, he will no longer hold any position in the company. For details, please refer to the "Antu Biotech Announcement on the Resignation of Independent Directors" (Announcement No.: 2024-099) disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn).

The company held the first extraordinary general meeting of shareholders in 2025 on February 17, 2025, and reviewed and approved the "Proposal on the Supplementary Electing of Independent Directors and Adjusting the Members of Relevant Special Committees of the Board of Directors", and agreed to elect Mr. Qiao Hailing as an independent director of the company's fifth board of directors. He also serves as the chairman of the Remuneration and Assessment Committee, a member of the Nomination Committee, and a member of the Strategic Development Committee of the company's fifth board of directors. His term is consistent with the term of the company's fifth board of directors. For details, please refer to the "Announcement on the Resolution of the First Extraordinary General Meeting of Shareholders of Antu Biotech in 2025" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) (announcement number: 2025-010)

2. Profit distribution or capital reserve conversion plan

The profit distribution plan and the plan for converting public reserve funds into share capital prepared in the semi-annual period

Whether to distribute or transfer No

Number of bonus shares for every 10 shares (shares) 0

Dividend amount per 10 shares (yuan) (tax included) 0

Number of shares transferred per 10 shares (shares) 0

Explanation of relevant information on profit distribution or capital reserve conversion plan

Not involved

3. The situation and impact of the company’s equity incentive plan, employee stock ownership plan or other employee incentive measures

(1) Relevant equity incentive matters have been disclosed in temporary announcements and there is no progress or change in subsequent implementation

□Applicable √Not applicable

(2) Incentives not disclosed in temporary announcements or with subsequent progress

Equity incentives

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

Employee stock ownership plan status

□Applicable √Not applicable

33/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Other incentives

□Applicable √Not applicable

4. Environmental information of listed companies and their major subsidiaries included in the list of companies that disclose environmental information in accordance with the law

√Applicable □Not applicable

Number of companies included in the list of companies that disclose environmental information according to law

(number)

Serial number Company name Query index of environmental information disclosure report according to law

Corporate Environmental Information Disclosure System (Henan)

1 Zhengzhou Antu Bioengineering Co., Ltd. http://222.143.24.250:8247/enpInfo/enpOverview?

enterId=914100007167932103001C

Other instructions

□Applicable √Not applicable

5. Consolidate and expand the results of poverty alleviation, rural revitalization and other work specific situations

√Applicable □Not applicable

While achieving good development, the company actively participates in public welfare undertakings, fulfills social responsibilities, and thoroughly implements the country's major decisions and arrangements on consolidating and expanding the results of poverty alleviation, with special emphasis on consolidating the results of poverty alleviation.

In November 2007, the company established the "Antu Advance Scholarship" for the first time in the Department of Medical Laboratory Medicine of Zhengzhou University, aiming to provide rewards or funding for outstanding and needy students majoring in laboratory testing in colleges and universities, and encourage students to study hard and serve the country. As of the end of the reporting period, the "Antu Advance Scholarship" has been established in the inspection majors of 31 colleges and universities across the country, benefiting more than 2,000 students with both academic and moral excellence. Among them, 4 new colleges will be established in the first half of 2025. The overall donation work in 2025 will be implemented in the second half of the year.

In August 2017, the company established the "Antu Advance Veterans Solace Fund" in Nanzhao County, Nanyang, Henan Province, providing cash assistance of 5,000 yuan per person per year to more than a hundred veterans in need in Nanzhao County who participated in the Anti-Japanese War, the War of Liberation, the War to Resist US Aggression and Aid Korea, etc., to help them enjoy their old age. As of the end of the reporting period, the company has supported a total of 893 veterans for 9 consecutive years; the donation for 130 veterans in 2025 has been completed before August 1.

34/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Section 5 Important Matters

1. Fulfillment of commitments

(1) Commitments made by the company’s actual controller, shareholders, related parties, acquirers and the company and other relevant parties during the reporting period or continuing into the reporting period

√Applicable □Not applicable

If not, if not

Timeliness and ability

Whether the action should be performed on time

Yes

Commitment Commitment Commitment When Commitment Commitment Timely Explanation Action

The promised party performs

Background Type Content Time Period Strict Unfinished Description Line

Fulfillment completed next issue

OK, step limit

specific plan

Reasons Miao Yongjun, Zhang Yaxun,

Wu Xuewei and Yang Zengli promised to transfer the issuer shares directly or indirectly held by them every year during their term of office, not exceeding the amount of their respective shares.

2014

Shares Fu Guangyu and Feng Chaojie hold 25% of the total shares of the issuer; they will not be transferred directly or indirectly within six months after resignation. Discomfort Discomfort

April No Long term Yes

Restricted sale of shares of the issuer held by Qin Yun, Liu Cong and Fang; the shares transferred within 12 months after six months of resignation shall not exceed personal use.

25th

Together with Shu Ruikuan and Han Mingming, they directly or indirectly hold 50% of the total shares of the issuer.

Cigong Liu Wei

Development will make an announcement three trading days in advance before committing to reduce its holdings of Antu Biotech shares, and in 2014

Shareholding before public issuance Not suitable Not suitable for the industry Others Complete within 6 months, and perform information disclosure timely and accurately in accordance with the rules of the Shanghai Stock Exchange April 2020 No Long-term Yes

Shareholders with more than 5% share the relevant disclosure obligations. 25th

Commitment 1. Without the written consent of Antu Bio’s board of directors and/or general meeting of shareholders, I/the company will not be located in China

Solution Domestic alone or with others, in any form (including but not limited to investment, mergers and acquisitions, joint ventures, joint ventures, joint ventures, joint ventures, etc. 2013

Controlling shareholder and actual Not suitable Not suitable for peers (investment, cooperation, partnership, contracting or leasing operation, shareholding) directly or indirectly engage in or participate in or associate May 2020 No Long-term Yes

Controller uses competition to assist in engaging in or participating in any current and future activities with Antu Biotech and its controlled subsidiaries. 31st

Business or activities that constitute or may constitute competition;

35/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

2. I/the company promise not to support in any form in China any other person other than Antu Biotech and its controlled subsidiaries to engage in business that competes or may compete with the current and future main business of Antu Biotech and its controlled subsidiaries, or otherwise participate (whether directly or indirectly) in any business or activity that competes or may compete with the current and future main business of Antu Biotech and its controlled subsidiaries;

3. If I/our company has any competitive business opportunities, I shall immediately notify Antu Biotech and will make every effort within the scope of its legal rights to first promote the business opportunity to be provided to Antu Biotech on terms no less favorable than those provided to me/our company;

4. I/the company will fully respect the independent legal person status of Antu Biotech and ensure the independent operation and independent decision-making of Antu Biotech and its controlled subsidiaries. I/our company will strictly comply with the provisions of the Company Law and the Articles of Association of Antu Biotech, and urge the directors of Antu Biotech and its controlled subsidiaries to perform their due responsibilities of integrity and diligence in accordance with the law;

5. I/the company promise not to seek illegitimate interests as the actual controller/controlling shareholder of Antu Biotech, thereby harming the rights and interests of other shareholders of Antu Biotech. If the rights and interests of Antu Biotech and its controlled subsidiaries are damaged due to a violation of the above statements and commitments by a company or other organization controlled by me/our company, I/our company will fully compensate Antu Biotech in the form of cash for the losses caused to Antu Biotech due to the breach of commitments;

6. This commitment will take effect from the date of signing and will continue to be valid while I/the company is the actual controller/controlling shareholder of Antu Biotech. This commitment will constitute a legal document binding on me/the company during the validity period. If you violate this commitment, I/our company are willing to bear legal responsibility.

7. I/our company and other companies or other organizations controlled by me will strictly abide by the system regulations of Antu Biotech and do not require Antu Biotech to advance wages, benefits, insurance, advertising and other expenses for me/our company and other companies or other organizations controlled by me; or bear costs or other expenses on behalf of me/our company and other companies or other organizations controlled by me;

Solution 2. I/the company and other companies or other organizations controlled by me will strictly abide by the system regulations of Antu Biotech’s 2013 controlling shareholder and actual Unsuitable connection, and will not occupy Antu Biotech’s resources, funds or engage in other behaviors that damage the interests of Antu Biotech and its May 2013 No Long-term Controller Use Transactions Small and medium-sized shareholders and creditors; 31st

3. I/the company and other companies or other organizations controlled by me will strictly abide by Antu Biotech's articles of association and its related-party transaction decision-making system, and make corresponding decisions in accordance with the decision-making procedures and authority determined in Antu Biotech's articles of association and related-party transactions;

4. I/our company and other companies or other organizations controlled by me have any relationship with Antu Biotech.

36/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

The following principles will be implemented when conducting joint transactions: pricing of related-party transactions shall be handled according to market-oriented principles; there is no market

price, based on cost plus pricing; when the traded goods do not have a market price, and it is impossible or impossible to

If it is suitable for cost-plus pricing calculation, the price shall be determined by both parties to the transaction;

5. After Antu Biotech is listed, I/our company and other companies or other organizations controlled by me will

Strictly comply with the relevant requirements of relevant laws, regulations and normative documents, and urge Antu Biotech to strictly

Implement decision-making procedures for related-party transactions and perform information disclosure obligations; ensure pricing of related-party transactions

On the basis of fairness and impartiality, further strictly regulate and disclose myself/the company and the company in accordance with the rules.

Related transactions between other companies or other organizations controlled by the person and Antu Biotechnology;

6. This commitment will take effect from the date of signing. Once it takes effect, it will be binding on me/our company.

Legal documents. If you violate this commitment, I/our company are willing to bear legal responsibility.

1. The company’s controlling shareholders and actual controllers can obtain benefits from the company’s measures to make up for the company’s diluted immediate returns.

Actual control and implementation of commitments made

The controller, the company’s controlling shareholder Antu Industrial, and the actual controller Miao Yongjun have taken measures to ensure that the company can replenish returns.

The controlling shares can be effectively fulfilled and the following commitments have been made:

east promise

(1) Not to interfere with the company’s business management activities beyond its authority and not to encroach on the company’s interests;

Time:

(2) From the date of issuance of the promisor’s commitment to the completion of the company’s public issuance of convertible bonds, if

In 2018, the China Securities Regulatory Commission issued other new regulatory provisions on supplementary return measures and commitments, and

If the above commitments cannot meet the requirements of the China Securities Regulatory Commission in 2011, the promisee will then comply with the requirements of the China Securities Regulatory Commission.

Issue a supplementary commitment in accordance with the latest provisions of the meeting on September 9th; until the actual controller, controlling date; financing (3) The commitment person promises to earnestly implement the relevant compensation return measures formulated by the company and any commitments made by the commitment party regarding the compensation return measures to shareholders of convertible bond shares and company directors. Not suitable. Other If investors cause losses, the promisee is willing to bear the liability for compensation to the company or investors in accordance with the law. Completion of employee-level management commitments. As one of the responsible entities related to compensation measures, if you violate the above commitments or refuse to perform the above

Personnel undertakes the undertaking, and the undertaking agrees that securities regulatory authorities such as the China Securities Regulatory Commission and the Shanghai Stock Exchange shall comply with their

The relevant regulations and rules formulated or issued by the promise shall impose relevant penalties or adopt relevant supervision on the promisee.

Time: measures.

2018

2. The directors and senior managers of the company will take measures to dilute the current returns of the issuance of convertible bonds.

Year 11 filling measure commitments

On March 19, as a director and senior manager of the company, in order to ensure that the company’s supplementary return measures can be effectively

day

To fulfill, the company and all shareholders will make the following commitments:

(1) I promise not to transfer benefits to other units or individuals for free or on unfair terms,

37/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

nor harm the company's interests in other ways;

(2) I promise to restrict my personal consumption behavior;

(3) I promise not to use company assets to engage in investment or consumption activities unrelated to the performance of my duties;

(4) I promise that the remuneration system formulated by the board of directors or the remuneration committee will be linked to the implementation of the company's supplementary return measures;

(5) If the company implements an equity incentive plan in the future, I promise that the exercise conditions of the future equity incentive plan will be linked to the implementation of the company's top-up return measures;

(6) I promise to earnestly implement the relevant supplementary return measures formulated by the company and any commitments I make regarding the supplementary return measures. If I violate these commitments and cause losses to the company or investors, I am willing to bear the liability for compensation to the company or investors in accordance with the law;

(7) From the date of this commitment to the completion of the company’s public issuance of convertible bonds, if the China Securities Regulatory Commission issues other new regulatory regulations on supplementary return measures and commitments, and the above commitments cannot meet these regulations of the China Securities Regulatory Commission, I will issue a supplementary commitment in accordance with the latest regulations of the China Securities Regulatory Commission;

As one of the parties responsible for the repayment measures, if I violate the above commitments or refuse to perform the above commitments, I agree that securities regulatory agencies such as the China Securities Regulatory Commission and the Shanghai Stock Exchange will impose relevant penalties on me or take relevant regulatory measures in accordance with the relevant regulations and rules formulated or issued by them.

1. The company’s actual controller and controlling shareholder’s commitment to take compensation measures to dilute immediate returns from non-public issuance of stocks

In order to ensure that the company's filling measures to dilute current returns from this issuance are effectively implemented, the company's actual controller Miao Yongjun and the controlling shareholder Antu Industrial have made the following commitments: Non-public

(1) Not to interfere with the company’s business management activities beyond its authority, and not to misappropriate the company’s interests; to develop the actual controller and control 2013

(2) From the date of the issuance of my (the company's) commitment to the completion of the non-public issuance of shares by the company's shareholders and the company's directors in May 2020, if the China Securities Regulatory Commission makes other new regulatory regulations on supplementary return measures and commitments, and the above commitments cannot meet these regulations of the China Securities Regulatory Commission, I (the company) will be the member of the CSRC upon completion of the implementation.

A supplementary commitment will be issued in accordance with the latest regulations of the China Securities Regulatory Commission;

(3) I (the company) promise to earnestly implement the relevant compensation return measures formulated by the company and any commitments I (the company) make regarding the compensation return measures. If I violate these commitments and cause losses to the company or investors, I (the company) are willing to bear the liability for compensation to the company or investors in accordance with the law.

38/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

As one of the parties responsible for the repayment measures, if I violate the above commitments or refuse to perform the above commitments, I (the Company) agree that securities regulatory agencies such as the China Securities Regulatory Commission and the Shanghai Stock Exchange will impose relevant penalties or take relevant regulatory measures on me (the Company) in accordance with the relevant regulations and rules formulated or issued by them.

2. Commitment of directors and senior managers of the company on taking compensation measures to dilute immediate returns from non-public issuance of stocks

The company's directors and senior managers promise to perform their duties faithfully and diligently, and make the following commitments to ensure that the company's immediate return measures can be effectively implemented:

(1) I promise not to transfer benefits to other units or individuals for free or on unfair terms, nor to harm the interests of the company in other ways;

(2) I promise to restrict my personal consumption behavior;

(3) I promise not to use company assets to engage in investment or consumption activities unrelated to the performance of my duties;

(4) I promise that the remuneration system formulated by the board of directors or the remuneration committee will be linked to the implementation of the company's supplementary return measures;

(5) If the company implements an equity incentive plan in the future, I promise that the exercise conditions of the future equity incentive plan will be linked to the implementation of the company's top-up return measures;

(6) I promise to earnestly implement the relevant supplementary return measures formulated by the company and any commitments I make regarding the supplementary return measures. If I violate these commitments and cause losses to the company or investors, I am willing to bear the liability for compensation to the company or investors in accordance with the law;

(7) From the date of this commitment to the completion of the company’s non-public issuance of shares, if the China Securities Regulatory Commission makes other new regulatory provisions on supplementary return measures and commitments, and the above commitments cannot meet these provisions of the China Securities Regulatory Commission, I will issue a supplementary commitment in accordance with the latest regulations of the China Securities Regulatory Commission;

As one of the parties responsible for the repayment measures, if I violate the above commitments or refuse to perform the above commitments, I agree that securities regulatory agencies such as the China Securities Regulatory Commission and the Shanghai Stock Exchange will impose relevant penalties on me or take relevant regulatory measures in accordance with the relevant regulations and rules formulated or issued by them.

1. In view of the possible problems that may exist after the completion of the IVD target project invested by this industrial investment fund and the listing in 2021.

Others Regarding the company's periodic horizontal competition, Antu Industrial's competition in April 2019 was based on current laws, regulations and relevant policies. Not suitable for peers. Controlling shareholder No Long-term Yes Commitment requirements, in the first 30 days recognized by the listed company and in compliance with applicable laws, regulations and relevant regulatory rules at that time. Use competition

Under the premise, it is conducive to the development of listed companies and safeguarding the interests of shareholders, especially the interests of small and medium-sized shareholders.

39/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

The problem of horizontal competition should be solved in principle and the specific ways to solve the problem of horizontal competition are as follows:

(1) When there is horizontal competition (or potential horizontal competition) with a listed company, by signing an entrustment agreement, Antu Industrial will entrust the voting rights and daily operation and management rights (if any) generated by the investment in the target project to the listed company for exercise, and pay management fees (the specific charging standards are determined according to the fair market price, and shall be subject to the agreement signed by both parties).

(2) Under the same conditions, the listed company has the right of first refusal. Once the uncertainty risk of the industrial investment fund IVD target project is eliminated and the investment and business development needs of the listed company can be met according to the specific conditions at that time, the listed company can preferentially acquire the target project in a manner permitted by laws and regulations; if the target project If the risk of uncertainty in purpose cannot be eliminated, or if the risk of uncertainty is eliminated but cannot meet the investment and business development needs of the listed company based on the specific circumstances at that time, Antu Industrial will eliminate the horizontal competition that exists between Antu Industrial and the listed company through business transfer or asset divestiture and other methods permitted by laws and regulations.

(3) Based on the investment and business development needs of the listed company, Antu Industrial promises to actively promote the priority transfer of the target project to the listed company at a price not higher than the asset appraisal value.

(4) Other feasible solutions within the scope permitted by laws, regulations and relevant policies.

2. During the period when there is horizontal competition (or potential horizontal competition) between the IVD target project invested by the industrial investment fund and the listed company, Antu Industrial will take appropriate measures permitted by laws and regulations to ensure that it will not have a significant adverse impact on the listed company.

3. Antu Industrial guarantees to strictly abide by laws, regulations, the articles of association of listed companies and its relevant management systems, and will not use the status of the controlling shareholder of the listed company to seek improper interests, thereby damaging the rights and interests of other shareholders of the listed company.

4. The above commitments are valid while Antu Industrial has control of the listed company. If there is a violation of the above commitments that causes damage to the rights and interests of the listed company, Antu Industrial is willing to bear the corresponding liability for damages.

2. Non-operating capital occupation by controlling shareholders and other related parties during the reporting period

□Applicable √Not applicable

3. Illegal guarantee situation

□Applicable √Not applicable

40/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

4. Audit status of semi-annual report

□Applicable √Not applicable

5. Changes and handling of matters involved in non-standard audit opinions in last year’s annual report □ Applicable √ Not applicable

6. Matters related to bankruptcy and reorganization

□Applicable √Not applicable

7. Major litigation and arbitration matters

□The company has major litigation and arbitration matters during this reporting period √The company has no major litigation and arbitration matters during this reporting period

8. Listed companies and their directors, supervisors, senior managers, controlling shareholders, and actual controllers are suspected of violating laws and regulations and have been punished

and rectification status

□Applicable √Not applicable

9. Explanation of the integrity status of the company, its controlling shareholders and actual controllers during the reporting period □ Applicable √ Not applicable

10. Major related transactions

(1) Related transactions related to daily operations

1. Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation □Applicable √Not applicable

2. Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation □ Applicable √ Not applicable

3. Matters not disclosed in temporary announcements

□Applicable √Not applicable

(2) Related transactions arising from asset acquisition or equity acquisition or sale

1. Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation □Applicable √Not applicable

2. Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation □ Applicable √ Not applicable

3. Matters not disclosed in temporary announcements

□Applicable √Not applicable

4. If a performance agreement is involved, the performance achievement during the reporting period should be disclosed □Applicable √Not applicable

41/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(3) Major related transactions of joint external investments

1. Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation □Applicable √Not applicable

2. Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation □ Applicable √ Not applicable

3. Matters not disclosed in temporary announcements

□Applicable √Not applicable

(4) Related credit and debt transactions

1. Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation □Applicable √Not applicable

2. Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation □ Applicable √ Not applicable

3. Matters not disclosed in temporary announcements

□Applicable √Not applicable

(5) Financial business between the company and related financial companies, company-controlled financial companies and related parties □ Applicable √ Not applicable

(6) Other major related transactions

□Applicable √Not applicable

(7) Others

□Applicable √Not applicable

11. Major contracts and their performance

(1) Custody, contracting and leasing matters

□Applicable √Not applicable

42/202 Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(2) Major guarantees performed and not yet completed during the reporting period

□Applicable √Not applicable

43/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(3) Other major contracts

□Applicable √Not applicable

12. Instructions on usage progress

√Applicable □Not applicable

(1) Overall use of raised funds

√Applicable □Not applicable

Unit: RMB 10,000 prospectus or Including: As of the reporting period As of the reporting period This year

As of report

Raising instructions Over-raised funds to the reporting period Raising at the end of the period Over-raising at the end of the period Investment funds Change use

Total investment for the year at the end of the period

Raised funds Raised funds Raised funds Raised funds Total amount raised in the book (3) End of Super Fund Raising Accumulated Funds Accumulated Funds Proportion of Total Funds Raised

Investment amount raised

Source Availability Time Total Net Amount (1) Fund Commitment = (1) - Accumulated Fund Investment Investment Progress Investment Progress (%) Raised Funds

Total funds (8)

Total investment (2) Total income (%) (6) (%) (7) (9) Total amount (4)

(2) (5) =(4)/(1) =(5)/(3) =(8)/(1) Issuance can be transferred June 2019

68,297.94 67,476.49 68,297.94 59,577.38 88.29 2,221.91 3.29 Exchange of bonds on the 28th of the month

to a specific pair

2020

Like issued shares 308,000.00 305,173.54 308,000.00 175,830.30 57.62 11,813.57 3.87 November 3

ticket

Other instructions

□Applicable √Not applicable

(2) Details of fundraising projects

√Applicable □Not applicable

1. Detailed use of raised funds

√Applicable □Not applicable

Unit: 10,000 yuan

44/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Is the investment project feasible? The nature of investment is

Yes This item

Stock certificates are not issued as of the date of filing.

No item already

Or by the end of the reporting period, it has been achieved Yes Yes The investment progress of the major projects involved has been achieved

Raising Raising Raised funds Cumulative cumulative investment at the end of the period Scheduled No No Major change project objectives and The investment this year did not meet the plan The effect achieved this year

Fund Description Planned investment, input and raising, investment progress, the specific reasons for the change in the name of the savings amount, the amount of savings, or the benefits that have been met.

Source Total amount in the book (1) Total amount of funds (%) Usage status Combination Quality Change Reason Researcher

The inheritance (2) (3)= state day item calculation is,

Make a profit

Nuotou (2)/(1) period please tell me

Xiang Guo

A clear and purposeful approach to capital projects

degree in vitro

issue diagnostic

2024

Transferable reagent production

Yes No 31,185.52 1,010.25 29,055.42 93.17 years 7 No Yes / 10,429.86 / No 2,130.10 Debt exchange Production capacity construction

month

Voucher expansion

Project

Antu

biology

Diagnosis

instrument

Distribution industry production

2024

Can be transferred to garden property

Yes No 36,290.97 1,211.66 30,521.96 84.10 years 12 No Yes / / / No 5,769.01 Debt exchange project

month

Voucher (body design

Outpatient consultation

Breaking instrument

Qiyan

in progress

45/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

heart)

Antu

biology

in vitro

Diagnosis

Industry

Xiangte Garden

Life-determined pair (three 2028 production period) Yes No 142,193.11 6,405.65 58,797.54 41.35 years 12 No Yes / / / No 83,395.57 CCB shares Project monthly establishment vote - entity

Outpatient consultation

discontinue production

Products

Can expand

Big

Antu

biology

in vitro

Diagnosis

Industry

Xiangte Garden

Life-determined pair (three 2029 production period) Yes No 82,535.60 4,448.17 39,414.48 47.75 years 7 No Yes / / / No 43,121.12 CCB shares Project monthly vote - entity

Outpatient consultation

discontinue production

Pinyan

in progress

heart

46/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Antu

biology

Diagnosis

Xiangte

Instruments 2025

Industry Product Development Yes No 20,004.61 959.75 17,178.06 85.87 Year 12 No Yes / / / No 2,826.55

Yuanzhi Construction Bank Stock Month

Marketing ticketing

network

construction

Project

Xiangte

Supplementary pair Supplementary

Liuxiangfa flow Yes No 60,440.22 60,440.22 100.00 / Yes Yes / / / No

Returning shares funds

loan note

2. Detailed usage of excess raised funds □Applicable √Not applicable

(3) Changes or terminations of investment during the reporting period □ Applicable √ Not applicable

47/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(4) Other uses of raised funds during the reporting period

1. Advance investment and replacement of raised funds in investment projects

√Applicable □Not applicable

1. On July 4, 2019, the seventh meeting of the company’s third board of directors and the sixth meeting of the third board of supervisors respectively reviewed and approved the “Proposal on the Company’s Use of Raised Funds to Replace Pre-invested Self-raised Funds”, and agreed that the company would use RMB 23.4748 million of raised funds to replace self-raised funds pre-invested in investment projects with raised funds. The company's independent directors issued agreed independent opinions on this matter. According to the Prospectus for the Public Issuance of A-Share Convertible Corporate Bonds, before the funds raised this time are in place, the company will first invest with self-raised funds based on the actual progress of the investment project with raised funds, and will replace them in accordance with relevant procedures after the raised funds are in place. According to the relevant provisions of the "Management Measures for Raised Funds of Listed Companies on the Shanghai Stock Exchange (Revised in 2013)" and the relevant instructions of the company's "Public Issuance of A-Share Convertible Corporate Bonds Prospectus", the company decided to use the raised funds to replace the funds pre-invested in the investment project.

2. On November 16, 2020, the 20th meeting of the company’s third board of directors and the 18th meeting of the third board of supervisors respectively reviewed and approved the “Proposal on the Company’s Use of Raised Funds to Replace Pre-invested Self-raised Funds”, and agreed that the company would use RMB 59.5877 million of raised funds to replace self-raised funds pre-invested in investment projects with raised funds. The company's independent directors issued agreed independent opinions on this matter. According to the "2020 Non-public Issuance of Stock Plan (Revised Draft)", before the funds raised this time are in place, the company will first invest with self-raised funds based on the actual progress of the investment project with raised funds, and will replace them in accordance with relevant procedures after the raised funds are in place. According to the relevant provisions of the "Shanghai Stock Exchange Listed Companies' Raised Funds Management Measures (2013 Revision)" and the relevant instructions of the company's "2020 Non-Public Issuance of Stock Plan (Revised Draft)", the company decided to replace the funds pre-invested in the fundraising project with the raised funds.

3. Use idle raised funds to temporarily supplement working capital

□Applicable √Not applicable

3. Cash management of idle raised funds and investment in related products

√Applicable □Not applicable

Unit: 100 million yuan Currency: RMB raised funds

During the reporting period, the maximum amount of cash spent during the period was

Closing Cash Balance Whether Board of Directors Review Date Management Has Start Date End Date

Management surplus exceeds authorized review amount

amount amount

degree

December 11, 2024 18.70 December 11, 2024 December 10, 2025 16.00 No other instructions

None

4. Others

□Applicable √Not applicable

48/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(5) The concluding opinions of the intermediary agency on the special verification and verification of the storage and use of raised funds □ Applicable √ Not applicable

Check the relevant description of the abnormality

□Applicable √Not applicable

(6) Subsequent rectification of unauthorized changes in the use of raised funds and illegal occupation of raised funds

□Applicable √Not applicable

13. Description of other major matters

□Applicable √Not applicable

Section 6 Changes in Shares and Shareholders

1. Changes in share capital

(1) Statement of changes in shares

1. Statement of changes in shares

Unit: Share capital before this change Increase or decrease (+, -) After this change

send

Accumulate

Proportion OK Send

Quantity Gold Others Subtotal Quantity Ratio (%) (%) New Shares

turn

shares

shares

1. Not yet

Listing flow 0 0.00 0 0 0 0 0 0 0.00 shares

1. Initiate

0 0.00 0 0 0 0 0 0 0.00 shares

Among them:

country

Home holds 0 0.00 0 0 0 0 0 0 0.00 shares

environment

Internal legal person

0 0.00 0 0 0 0 0 0 0.00 shares held

portion

environment

foreign legal person

0 0.00 0 0 0 0 0 0 0.00 shares held

portion

Others 0 0.00 0 0 0 0 0 0 0.00

2. Recruitment

Legal person shares 0 0.00 0 0 0 0 0 0 0.00

portion

3. Internal 0 0.00 0 0 0 0 0 0 0.00

49/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

employee shares

4. Priority

shares or their 0 0.00 0 0 0 0 0 0 0.00

him

2. Already

Listing flow 581,011,346 100.00 0 0 0 -9,586,578 -9,586,578 571,424,768 100.00 shares

1. People

Coin ordinary 581,011,346 100.00 0 0 0 -9,586,578 -9,586,578 571,424,768 100.00

shares

2. Domestic

Listed 0 0.00 0 0 0 0 0 0 0.00 foreign shares

3. Overseas

Listed 0 0.00 0 0 0 0 0 0 0.00 foreign shares

4. Others 0 0.00 0 0 0 0 0 0 0.00

3. Shares

581,011,346 100.00 0 0 0 -9,586,578 -9,586,578 571,424,768 100.00 Total copies

2. Description of changes in shares

√Applicable □Not applicable

On February 20, 2025, the company submitted an application for cancellation of repurchased shares to the Shanghai Stock Exchange, and the shares repurchased by the company were

9,586,578 company shares were cancelled. China Securities Depository and Clearing Co., Ltd. responded to this part on February 21, 2025

The purchased shares were cancelled, and the company's total share capital was reduced from 581,011,346 shares to 571,424,768 shares. For details, please refer to the company’s disclosure in

"Antu Biotech's Announcement on the Implementation Results of Share Repurchase and Share Changes" on the Shanghai Stock Exchange website (www.sse.com.cn)

(Announcement Number: 2025-011).

3. The impact of changes in shares between the reporting period and the disclosure date of the semi-annual report on financial indicators such as earnings per share and net assets per share (if any)

□Applicable √Not applicable

4. Other content that the company deems necessary or required to be disclosed by securities regulatory authorities

□Applicable √Not applicable

(2) Changes in restricted shares

□Applicable √Not applicable

2. Shareholder situation

(1) Total number of shareholders:

Total number of common shareholders (households) as of the end of the reporting period 34,178 Total number of preference shareholders (households) with voting rights restored as of the end of the reporting period 0

50/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(2) Shareholding status of the top ten shareholders and top ten tradable shareholders (or shareholders without selling restrictions) as of the end of the reporting period

Unit: Shareholding status of the top ten shareholders (excluding shares lent through refinancing)

Hold a pledge, mark

Name of shareholder Number of shares held at the end of the reporting period Ratio Sales restriction or freezing situation

Nature of shareholder (full name) Increase or decrease (%) Number of shares Number of shares

quantity status quantity

Zhengzhou Antu Industrial Group Co., Ltd. has domestic non-state

0 329,445,773 57.65 0 None 0

Co., Ltd. has legal person Z&FINTERNATIONAL

-260,000 76,632,416 13.41 0 None 0 Overseas legal person TRADINGLIMITED

Orient Securities Co., Ltd.-

Zhonggeng Value Pioneer Equity Securities -136,750 9,253,368 1.62 0 None 0 Other investment funds

Bank of China Co., Ltd.-

Huabao CSI Medical Trading Open -1,831,336 5,742,870 1.01 0 None 0 Other Index Securities Investment Funds

Agricultural Bank of China Co., Ltd.

Company - Dacheng Ruixiang Hybrid Securities 3,850,260 3,850,260 0.67 0 None 0 Other investment funds

GF Securities Co., Ltd.-

Zhonggeng Small Cap Value Equity Securities -746,340 3,362,460 0.59 0 None 0 Other Investment Funds

Zhang Zhenqing 81,850 3,128,940 0.55 0 None 0 Others Hong Kong Securities Clearing Company Limited -9,007,389 2,934,136 0.51 0 None 0 Others Ge Jinjia 190,000 2,830,000 0.50 0 None 0 Others Industrial and Commercial Bank of China Limited

Company-Dacheng Competitive Advantage Hybrid 2,710,651 2,710,651 0.47 0 None 0 Other securities investment funds

Shareholding status of the top ten shareholders without selling restrictions (excluding shares lent through refinancing)

Type and number of shares held without selling conditions. Name of shareholder.

Number of common shares Type Quantity Zhengzhou Antu Industrial Group Co., Ltd. 329,445,773 RMB ordinary shares 329,445,773 Z&FINTERNATIONALTRADING

76,632,416 RMB ordinary shares 76,632,416 LIMITED

Orient Securities Co., Ltd.-Zhonggeng Value Pioneer

9,253,368 RMB ordinary shares 9,253,368 Equity securities investment funds

Bank of China Co., Ltd. - Huabao CSI Medical

5,742,870 RMB ordinary shares 5,742,870 Exchange-traded open-end index securities investment funds

Agricultural Bank of China Co., Ltd.-Dacheng Ruixiang

3,850,260 RMB ordinary shares 3,850,260 Hybrid securities investment funds

GF Securities Co., Ltd.-Zhonggeng Small Cap Value

3,362,460 RMB ordinary shares 3,362,460 Equity securities investment funds

Zhang Zhenqing 3,128,940 RMB ordinary shares 3,128,940 Hong Kong Securities Clearing Company Limited 2,934,136 RMB ordinary shares 2,934,136 Ge Jinjia 2,830,000 RMB ordinary shares 2,830,000 Industrial and Commercial Bank of China Limited - Dacheng Competition

2,710,651 RMB ordinary shares 2,710,651 Advantage hybrid securities investment funds

Description of special repurchase accounts among the top ten shareholders None

51/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

The above-mentioned shareholders have entrusted voting rights, entrusted voting rights, delegated

None

Explanation on abstaining from voting

The company’s controlling shareholder Zhengzhou Antu Industrial Group Co., Ltd. and shareholders

Z&FINTERNATIONALTRADINGLIMITED has no explanation about the related relationship or concerted actions of the above shareholders.

relationship. The company does not know who among the other top ten shareholders of unrestricted tradable shares are

Whether there is an associated relationship or a relationship between persons acting in concert. Preference shareholders whose voting rights have been restored and the number of shares they hold

Not applicable

Description

Situation of shareholders holding more than 5% of the shares, the top ten shareholders and the top ten shareholders of unrestricted tradable shares participating in the refinancing business and lending shares □Applicable √Not applicable

The top ten shareholders and the top ten shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning □ Applicable √ Not applicable

Number of shares held by the top ten shareholders subject to selling restrictions and conditions for selling restrictions

□Applicable √Not applicable

(3) Strategic investors or general legal persons become the top ten shareholders due to the placement of new shares □Applicable √Not applicable

3. Directors, supervisors and senior managers

(1) Changes in shareholdings of current and departing directors, supervisors and senior managers during the reporting period □Applicable √Not applicable

Other situation description

□Applicable √Not applicable

(2) Equity incentives granted to directors, supervisors and senior managers during the reporting period □Applicable √Not applicable

(3) Other instructions

□Applicable √Not applicable

4. Changes in controlling shareholders or actual controllers

□Applicable √Not applicable

5. Relevant information on preference shares

□Applicable √Not applicable

52/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Section 7 Bond-Related Information

1. Corporate bonds (including corporate bonds) and non-financial corporate debt financing instruments □ Applicable √ Not applicable

2. Convertible corporate bonds

□Applicable √Not applicable

53/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Section 8 Financial Report

1. Audit report

□Applicable √Not applicable

2. Financial statements

Consolidated Balance Sheet

June 30, 2025

Prepared by: Zhengzhou Antu Bioengineering Co., Ltd.

Unit: Yuan Currency: RMB

Item Notes June 30, 2025 Current assets as of December 31, 2024:

Monetary funds 477,011,134.98 465,373,123.02 Settlement reserves

Loan funds

Trading financial assets 411,123,668.33 3,609,780.75 Derivative financial assets

Notes receivable 19,048,198.73 22,171,566.14 Accounts receivable 1,200,910,461.23 1,138,995,430.17 Accounts receivable financing 12,485,684.89 15,933,064.72 Advance payments 51,677,231.88 44,118,391.57 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 26,461,172.03 80,180,790.84 Including: interest receivable

Dividends receivable 194,694.60 194,694.60 Financial assets purchased under resale agreements

Inventory 1,096,083,256.43 1,153,089,499.27 Including: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 2,635,878,861.66 3,619,297,345.02

Total current assets 5,930,679,670.16 6,542,768,991.50 Non-current assets:

Grant loans and advances

debt investment

Other debt investments

long-term receivables

Long-term equity investment 17,844,095.28 11,656,048.18 Other equity instrument investment 160,883,561.50 160,883,561.50 Other non-current financial assets

Investment real estate 25,533,906.79 23,173,144.67 Fixed assets 3,533,706,214.36 2,963,741,984.32 Construction in progress 435,944,003.56 987,283,594.17 Productive biological assets

54/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

oil and gas assets

Right-of-use assets 26,787,844.81 30,934,137.03 Intangible assets 133,322,438.22 136,085,803.35 Including: data resources

Development expenditure 93,253,332.83

Among them: data resources

Goodwill 164,648,504.26 164,648,504.26 Long-term deferred expenses 66,333,146.34 75,009,641.35 Deferred income tax assets 356,068,221.96 335,657,321.22 Other non-current assets 700,379,020.38 443,223,212.42 Total non-current assets 5,714,704,290.29 5,332,296,952.47

Total assets 11,645,383,960.45 11,875,065,943.97 Current liabilities:

Short-term borrowings 113,699,702.22 232,377,977.25 Borrowings from the central bank

borrowing funds

Trading financial liabilities

Derivative financial liabilities

Notes payable 935,761,334.77 469,500,000.00 Accounts payable 644,026,993.30 665,779,505.17 Advance payments

Contract liabilities 78,045,015.07 87,139,442.46 Financial assets sold and repurchased

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable 105,837,183.34 210,127,628.38 Taxes payable 125,404,716.96 136,376,852.62 Other payables 434,410,458.04 463,823,633.39 Including: interest payable

Dividends payable

Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year 10,217,917.35 295,983,348.75 Other current liabilities 84,277,716.48 98,438,962.95

Total current liabilities 2,531,681,037.53 2,659,547,350.97 Non-current liabilities:

insurance contract reserves

long term borrowing

bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 18,310,311.90 20,631,497.39 Long-term payables

Long-term employee benefits payable

Estimated liabilities 5,124,829.29 4,253,371.08 Deferred income 67,538,431.84 75,078,067.19

55/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Deferred income tax liabilities 264,307,783.51 284,189,549.76 Other non-current liabilities 207,488,679.84 139,570,254.65 Total non-current liabilities 562,770,036.38 523,722,740.07

Total liabilities 3,094,451,073.91 3,183,270,091.04 Owners’ equity (or shareholders’ equity):

Paid-in capital (or equity) 571,424,768.00 581,011,346.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 3,358,127,469.50 3,819,031,801.78 Less: treasury shares 461,029,295.83 Other comprehensive income 1,128,623.95 1,137,045.96 Special reserves

Surplus reserve 293,162,011.78 293,162,011.78 General risk reserve

Undistributed profits 4,234,223,386.50 4,383,217,408.35 Attributable to the owners’ equity of the parent company

8,458,066,259.73 8,616,530,318.04 (or shareholders’ equity) total

Minority shareholders’ equity 92,866,626.81 75,265,534.89 Owner’s equity (or shareholder’s rights

8,550,932,886.54 8,691,795,852.93 profit) total

Liabilities and Owner's Equity (or

11,645,383,960.45 11,875,065,943.97 shareholders’ equity) total

Person in charge of the company: Yang Zengli Person in charge of accounting work: Sister Feng Chao Person in charge of the accounting department: Yang Yuhong

Parent company balance sheet

June 30, 2025

Prepared by: Zhengzhou Antu Bioengineering Co., Ltd.

Unit: Yuan Currency: RMB

Item Notes June 30, 2025 Current assets as of December 31, 2024:

Monetary funds 230,660,601.46 277,991,225.52 Trading financial assets 391,171,309.00 3,218,700.00 Derivative financial assets

Notes receivable 8,507,271.79 7,806,756.00 Accounts receivable 531,292,380.48 553,610,640.42 Accounts receivable financing

Prepayments 10,081,767.40 10,399,606.57 Other receivables 622,063,037.81 683,774,895.23 Including: interest receivable

Dividends receivable

Inventory 607,523,401.87 691,509,594.77 Including: data resources

contract assets

Assets held for sale

Non-current assets due within one year

56/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Other current assets 2,366,937,781.18 3,254,726,792.07

Total current assets 4,768,237,550.99 5,483,038,210.58 Non-current assets:

debt investment

Other debt investments

long-term receivables

Long-term equity investment 551,647,282.72 606,401,066.81 Other equity instrument investment 160,883,561.50 160,883,561.50 Other non-current financial assets

Investment real estate 1,770,868.61 1,243,197.87 Fixed assets 2,675,162,802.89 2,144,349,211.25 Construction in progress 421,777,238.49 993,573,175.27 Productive biological assets

oil and gas assets

Right-of-use assets 6,563,245.34 7,332,054.92 Intangible assets 117,123,824.15 121,972,830.85 Including: data resources

Development expenditure 48,735,116.74

Among them: data resources

goodwill

Long-term deferred expenses 17,924,165.43 20,095,888.62 Deferred income tax assets 63,104,805.75 55,625,499.27 Other non-current assets 829,025,932.92 455,332,552.27 Total non-current assets 4,893,718,844.54 4,566,809,038.63

Total assets 9,661,956,395.53 10,049,847,249.21 Current liabilities:

Short-term borrowings 72,047,281.66 150,104,041.67 Trading financial liabilities

Derivative financial liabilities

Notes payable 760,961,000.00 369,500,000.00 Accounts payable 616,456,203.45 680,211,559.59 Advance payments

Contract liabilities 61,820,271.06 67,146,815.64 Employee benefits payable 59,358,110.10 134,869,530.81 Taxes payable 98,406,325.04 100,259,142.05 Other payables 259,408,999.63 301,248,630.08 including: interest payable

Dividends payable

Liabilities held for sale

Non-current liabilities due within one year 2,764,191.30 235,155,688.60 Other current liabilities 89,517,028.38 103,075,203.68

Total current liabilities 2,020,739,410.62 2,141,570,612.12 Non-current liabilities:

long term borrowing

bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 2,407,726.24 3,222,835.14

57/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

long-term payables

Long-term employee benefits payable

Estimated liabilities

Deferred income 39,908,933.21 44,654,793.60 Deferred income tax liabilities 206,538,028.68 232,930,534.14 Other non-current liabilities 111,430,210.22 59,874,042.76 Total non-current liabilities 360,284,898.35 340,682,205.64

Total liabilities 2,381,024,308.97 2,482,252,817.76 Owners’ equity (or shareholders’ equity):

Paid-in capital (or equity) 571,424,768.00 581,011,346.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 3,414,181,043.57 3,875,085,375.85 Less: treasury shares 461,029,295.83 Other comprehensive income

special reserve

Surplus reserve 293,136,128.00 293,136,128.00 Undistributed profits 3,002,190,146.99 3,279,390,877.43 Owner’s equity (or shareholder’s rights

7,280,932,086.56 7,567,594,431.45 profit) total

Liabilities and Owner's Equity (or

9,661,956,395.53 10,049,847,249.21 shareholders’ equity) total

Person in charge of the company: Yang Zengli Person in charge of accounting work: Sister Feng Chao Person in charge of the accounting department: Yang Yuhong

consolidated income statement

January-June 2025

Unit: Yuan Currency: RMB

Item Notes 2025 Half Year 2024 Half Year

1. Total operating income 2,060,307,179.95 2,207,103,914.63 Including: operating income 2,060,307,179.95 2,207,103,914.63 Interest income

Premiums earned

Fee and commission income

2. Total operating costs 1,506,453,270.45 1,583,246,923.90 Including: operating costs 732,834,381.85 768,276,556.47 Interest expenses

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges 27,676,624.21 21,798,912.94 Sales expenses 389,039,334.86 364,700,186.63 Administrative expenses 102,288,423.93 91,426,520.73

58/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Research and development expenses 250,345,849.36 333,232,807.55 Financial expenses 4,268,656.24 3,811,939.58 Including: interest expenses 9,517,542.81 11,625,874.44

Interest income 2,480,460.15 9,302,802.12 plus: other income 28,025,398.61 43,101,208.78 Investment income (losses are filled in with "-"

67,250,439.05 38,094,731.87 columns)

Of which: for associates and joint ventures

-1,311,952.90 -2,846,306.48 investment income

Finance measured at amortized cost

Income from derecognition of assets (losses are filled in with "-"

column)

Exchange gains (losses are filled in with "-"

column)

Net exposure hedging gains (losses marked with "-"

(Fill in the number)

Gains from changes in fair value (losses calculated as

-54,112.42 7,035,162.86 (Fill in “-”)

Credit impairment losses (losses are marked with "-"

1,913,032.00 -15,665,898.88 (fill in the column)

Asset impairment losses (losses are marked with "-"

-14,215,837.01 -7,323,484.60 fill in the column)

Asset disposal income (losses are represented by “-”

38,609.84 No. 1,334.78 (please fill in)

3. Operating profit (losses are listed with "-") 636,811,439.57 689,100,045.54 plus: non-operating income 9,879,032.70 3,023,712.48 minus: non-operating expenses 7,845,037.10 4,938,201.76

4. Total profit (total loss is filled in with "-"

638,845,435.17 687,185,556.26 columns)

Less: Income tax expense 60,808,445.42 60,208,317.18

5. Net profit (net loss is listed with "-") 578,036,989.75 626,977,239.08

(1) Classification by business continuity

1. Net profit from continuing operations (net loss divided by

578,036,989.75 626,977,239.08 (Fill in “-”)

2. Net profit from discontinued operations (net loss equal to

Fill in the column with "-" sign)

(2) Classification according to ownership ownership

1. Net profit attributable to shareholders of the parent company

571,001,185.83 619,513,343.19 (Net loss is listed with "-")

2. Profit and loss of minority shareholders (net loss is represented by “-”

No. 7,035,803.92 7,463,895.89 (please fill in the list)

6. Net after-tax amount of other comprehensive income -8,422.01 70,245.37

(1) Other comprehensive assets attributable to the owners of the parent company

-8,422.01 70,245.37 Net after-tax income

1. Other comprehensive items that cannot be reclassified into profit or loss

combined income

(1) Remeasurement of changes in defined benefit plan

(2) Other comprehensive assets that cannot be transferred to profit or loss under the equity method

combined income

59/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(3) Changes in fair value of investments in other equity instruments

move

(4) Changes in the fair value of the enterprise’s own credit risk

move

2. Other comprehensive items that will be reclassified into profit and loss

-8,422.01 70,245.37 income

(1) Other comprehensive convertible profits and losses under the equity method

income

(2) Changes in fair value of other debt investments

(3) Financial assets are reclassified into other comprehensive

Amount of income

(4) Credit impairment provisions for other debt investments

(5) Cash flow hedging reserve

(6) Translation difference of foreign currency financial statements -8,422.01 70,245.37 (7) Others

(2) Other comprehensive assets attributable to minority shareholders

Earnings, net of taxes

7. Total comprehensive income 578,028,567.74 627,047,484.45

(1) Comprehensive assets attributable to owners of the parent company

570,992,763.82 619,583,588.56 Total income

(2) Comprehensive income attributable to minority shareholders

7,035,803.92 7,463,895.89 total

8. Earnings per share:

(1) Basic earnings per share (yuan/share) 1.02 1.09

(2) Diluted earnings per share (yuan/share) 1.02 1.09

If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0.00 yuan, and the net profit realized by the merged party in the previous period is: 0.00 yuan.

Person in charge of the company: Yang Zengli Person in charge of accounting work: Sister Feng Chao Person in charge of the accounting department: Yang Yuhong

Parent company income statement

January-June 2025

Unit: Yuan Currency: RMB

Item Notes 2025 Half Year 2024 Half Year

1. Operating income 1,670,288,838.69 1,741,466,617.68 Less: Operating costs 769,487,820.61 743,267,839.25 Taxes and surcharges 15,904,990.79 11,722,838.62 Sales expenses 276,233,728.65 254,349,329.43 Administrative expenses 68,031,563.43 63,267,517.33 Research and development expenses 107,294,575.09 167,948,676.73 Financial expenses -520,626.03 -878,969.95 Including: interest expense 3,410,073.67 7,299,107.95

Interest income 1,506,445.46 8,277,827.88 Plus: other income 6,732,982.46 22,343,299.32 Investment income (losses are filled in with "-"

116,029,051.16 40,820,480.40 columns)

Of which: for associates and joint ventures

-38,392.69

investment income

60/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Income from derecognition of financial assets measured at amortized cost (losses are listed with a “-” sign)

Net exposure hedging income (losses are listed with a “-” sign)

Gains from changes in fair value (losses calculated as

-77,391.00 7,035,162.86 (Fill in “-”)

Credit impairment losses (losses are marked with "-"

-68,599,883.32 -34,174,442.03 fill in the column)

Asset impairment losses (losses are marked with "-"

-3,381,716.91 2,841,924.46 fill in the column)

Asset disposal income (losses are represented by “-”

-45.82 No. 1,199.65 (please fill in the column)

2. Operating profit (losses are listed with "-") 484,559,782.72 540,657,010.93 Add: non-operating income 9,806,162.19 1,848,206.61

Less: Non-operating expenses 4,580,821.66 4,739,252.07

3. Total profits (total losses are marked with “-”

489,785,123.25 537,765,965.47 fill in the column)

Less: Income tax expense 46,990,646.01 58,583,831.69

4. Net profit (net loss is listed with "-") 442,794,477.24 479,182,133.78

(1) Net profit from continuing operations (net loss divided by

442,794,477.24 479,182,133.78 (Fill in “-”)

(2) Net profit from discontinued operations (net loss is listed with "-")

5. Net amount of other comprehensive income after tax

(1) Other comprehensive income that cannot be reclassified into profit or loss

1. Remeasure changes in defined benefit plans

Um

2. Others that cannot be transferred to profit or loss under the equity method

Comprehensive income

3. Fair value of other equity instrument investments

change

4. Fair value of the company’s own credit risk

change

(2) Other comprehensive income that will be reclassified into profit and loss

1. Other comprehensive items that can be transferred to profits and losses under the equity method

combined income

2. Changes in fair value of other debt investments

3. Financial assets are reclassified into other comprehensive

Amount of combined income

4. Credit impairment provisions for other debt investments

5. Cash flow hedging reserve

6. Translation differences of foreign currency financial statements

7.Others

6. Total comprehensive income 442,794,477.24 479,182,133.78

7. Earnings per share:

(1) Basic earnings per share (yuan/share)

61/202 Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(2) Diluted earnings per share (yuan/share)

Person in charge of the company: Yang Zengli Person in charge of accounting work: Sister Feng Chao Person in charge of the accounting department: Yang Yuhong

Consolidated Cash Flow Statement January-June 2025

Unit: Yuan Currency: RMB Item Notes 2025 Half Year 2024 Half Year

1. Cash flow generated from operating activities:

Cash received from selling goods and rendering services

2,198,247,562.32 2,339,625,080.31 gold

Net deposits from customers and deposits from banks and other banks

increase

Net increase in borrowing from the central bank

Net borrowings from other financial institutions

increase

Obtained by receiving premiums from the original insurance contract

Cash

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash that charges interest, fees and commissions

gold

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from securities trading as an agent

Um

Tax refunds received 8,453,225.55 10,122,136.73 Other tax refunds related to business activities received

113,353,151.96 128,452,313.75 cash

Subtotal of cash inflows from operating activities 2,320,053,939.83 2,478,199,530.79 Cash for purchasing goods and receiving payment for services

727,322,634.79 729,562,199.06 gold

Net increase in loans and advances to customers

Net deposits with the central bank and inter-bank

increase

Payment of compensation from the original insurance contract

Cash

Net increase in lending funds

Cash for payment of interest, fees and commissions

gold

Cash payment for policy dividends

Payments made to and for employees

673,170,786.68 664,054,533.79 cash

Various taxes and fees paid 262,991,988.17 290,305,656.70 Paid other taxes related to business activities

246,384,604.84 298,786,294.91 cash

Subtotal of cash outflows from operating activities 1,909,870,014.48 1,982,708,684.46

62/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

cash flow from operating activities

410,183,925.35 495,490,846.33 Net amount

2. Cash flow generated from investing activities:

Recover cash received on investments

Cash received from investment income 894,348.00

Disposal of fixed assets, intangible assets and other

10,082.30 114,942.48 Net cash received from other long-term assets

Disposal of subsidiaries and other business units

Net cash received

Receive other information related to investment activities

2,767,068,985.84 741,339,132.96 cash

Subtotal of cash inflows from investing activities 2,767,973,416.14 741,454,075.44 Purchase and construction of fixed assets, intangible assets and other

326,499,808.64 382,739,810.53 Cash paid for his long-term assets

Cash paid for investment 7,500,000.00 7,500,000.00 Net increase in pledged loans

Acquire subsidiaries and other business units

1,761,567.47 Net cash paid

Payments related to other investment activities

2,131,839,077.53 941,208,432.91 cash

Subtotal of cash outflows from investing activities 2,465,838,886.17 1,333,209,810.91 Cash flow generated from investing activities

302,134,529.97 -591,755,735.47 Net amount

3. Cash flow generated from financing activities:

Cash received from investment 14,455,000.00

Among them: subsidiaries absorb minority shareholders’ investment

14,455,000.00

cash received

Cash received from borrowings 361,670,786.89 500,000,000.00 Other cash received related to financing activities

919,397,210.85 300,000,000.00 cash

Subtotal of cash inflows from financing activities 1,295,522,997.74 800,000,000.00 Cash paid to repay debts 779,970,786.89 648,000,000.00 Distribution of dividends, profits or interest payments

727,179,676.69 620,277,045.47 Cash paid

Of which: Subsidiary payments to minority shareholders

Dividends and profits of 2,102,100.00 3,930,600.00

Make other payments related to financing activities

501,655,814.90 571,869,286.15 cash

Subtotal of cash outflows from financing activities 2,008,806,278.48 1,840,146,331.62 Cash flow generated from financing activities

-713,283,280.74 -1,040,146,331.62 Net amount

4. Exchange rate changes on cash and cash equivalents

3,246,257.44 143,425.80 Influence of things

5. Net increase in cash and cash equivalents 2,281,432.02 -1,136,267,794.96 plus: opening balance of cash and cash equivalents

452,058,348.81 1,485,369,305.45

6. Balance of cash and cash equivalents at the end of the period 454,339,780.83 349,101,510.49

Person in charge of the company: Yang Zengli Person in charge of accounting work: Sister Feng Chao Person in charge of the accounting department: Yang Yuhong

63/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Parent company cash flow statement

January-June 2025

Unit: Yuan Currency: RMB Item Notes 2025 Half Year 2024 Half Year

1. Cash flow generated from operating activities:

Cash received from selling goods and rendering services

1,845,155,230.82 1,918,616,599.23 gold

Tax refunds received 2,274,143.26 Other tax refunds related to business activities received

94,014,352.48 84,447,814.03 cash

Subtotal of cash inflows from operating activities 1,939,169,583.30 2,005,338,556.52 Cash for purchasing goods and receiving payment for services

571,296,781.54 470,434,968.01 gold

Payments made to and for employees

401,875,375.38 408,527,725.77 cash

Various taxes and fees paid 168,193,309.65 187,329,186.34 Paid other taxes related to business activities

218,297,344.53 261,778,535.56 cash

Subtotal of cash outflows from operating activities 1,359,662,811.10 1,328,070,415.68 Net cash flow from operating activities

579,506,772.20 677,268,140.84 amount

2. Cash flow generated from investing activities:

Cash received from recovery of investment 4,637,877.95

Cash received from investment income 114,108,100.00 2,009,400.00 Disposal of fixed assets, intangible assets and other

3,982.30 1,500.00 Net cash received from other long-term assets

Disposal of subsidiaries and other business units

Net cash received

Receive other information related to investment activities

2,645,712,692.95 804,397,471.58 cash

Subtotal of cash inflows from investing activities 2,764,462,653.20 806,408,371.58 Purchase and construction of fixed assets, intangible assets and other

198,932,409.05 437,205,960.03 Cash paid for his long-term assets

Cash paid for investment 29,536,148.74 114,813,482.36 Acquisition of subsidiaries and other business units

Net cash paid

Payments related to other investment activities

2,119,171,645.92 957,619,419.06 cash

Subtotal of cash outflows from investing activities 2,347,640,203.71 1,509,638,861.45 Cash flow generated from investing activities

416,822,449.49 -703,230,489.87 Net amount

3. Cash flow generated from financing activities:

Absorbing cash received from investments

Cash received from borrowings 361,670,786.89 390,000,000.00 Other cash received related to financing activities

Cash

Subtotal of cash inflows from financing activities 361,670,786.89 390,000,000.00

64/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Cash paid to repay debts 673,970,786.89 593,000,000.00 Distribution of dividends, profits or payment of interest

723,378,896.85 615,219,770.19 Cash paid

Make other payments related to financing activities

11,010,152.50 219,764,003.07 cash

Subtotal of cash outflows from financing activities 1,408,359,836.24 1,427,983,773.26 Cash flow generated from financing activities

-1,046,689,049.35 -1,037,983,773.26 Net amount

4. Exchange rate changes on cash and cash equivalents

3,029,203.60 63,273.80 Influence of things

5. Net increase in cash and cash equivalents -47,330,624.06 -1,063,882,848.49 plus: balance of cash and cash equivalents at the beginning of the period

277,972,317.52 1,246,345,482.97

6. Balance of cash and cash equivalents at the end of the period 230,641,693.46 182,462,634.48

Person in charge of the company: Yang Zengli Person in charge of accounting work: Sister Feng Chao Person in charge of the accounting department: Yang Yuhong

65/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Consolidated Statement of Changes in Owner's Equity

January-June 2025

Unit: Yuan Currency: RMB 2025 Half Year

Owner's equity attributable to parent company

Other rights and interests

Tool 1

Items Minority shareholders’ rights Consolidated owners’ equity General

Paid-in capital Other comprehensive income Total capital reserve Less: treasury stock items Surplus reserve Undistributed profits Other subtotal (or equity) Preferred income

Other savings insurance, he will continue first

He is ready

stocks bonds

Prepare

1.

Previous year 581,011,34 3,819,031,80 461,029,295 1,137,045 293,162,01 4,383,217,40 8,616,530,31 75,265,53 8,691,795,85 End of Period 6.00 1.78 .83 .96 1.78 8.35 8.04 4.89 2.93Balance

Add:

accounting

policy

change

Early stage

Error

Correction

Others

2.

This year 581,011,34 3,819,031,80 461,029,295 1,137,045 293,162,01 4,383,217,40 8,616,530,31 75,265,53 8,691,795,85 Beginning of period 6.00 1.78 .83 .96 1.78 8.35 8.04 4.89 2.93Balance

3.

-9,586,578. -460,904,332 -461,029,29 -148,994,021 -158,464,058 17,601,09 -140,862,966This period -8,422.01

00 .28 5.83 .85 .31 1.92 .39 increase or decrease

66/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Amount of changes (decreases are indicated with a “-” sign)

(1) Comprehensive 571,001,185. 570,992,763. 7,035,803. 578,028,567.

-8,422.01Income 83 82 92 74Total

(2) Owner’s investment -9,586,578. -460,904,332 -461,029,29 -9,461,614.4 14,455,00

4,993,385.55 Income and 00.28 5.83 5 0.00 Capital reduction 1. owner

-9,586,578. -460,904,332 -461,029,29 -9,461,614.4 14,455,00 investment 4,993,385.55

00 .28 5.83 5 0.00 common stock 2. Capital invested by other equity instrument holders 3. Share-based payment included in owner’s equity

67/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

4. Others

(3)

-719,995,207 -719,995,207 -2,102,100 -722,097,307Profit

.68 .68 .00 .68Assignment1. Withdraw surplus reserve 2. Extract general risk reserves 3. Distribution to owners (or -719,995,207 -719,995,207 -2,102,100 -722,097,307 shares .68 .68 .00 .68 shares) 4. Others

(4) Internal carryover of owners’ equity 1. Conversion of capital reserve to capital increase

68/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Capital (or share capital) 2. Convert surplus reserves to capital (or share capital) 3. Surplus reserve to make up for losses 4. The amount of changes in the defined benefit plan is carried forward to retained earnings 5. Other comprehensive income is carried forward to retained earnings 6. Others

(5) Special projects

69/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

reserve

1. Ben

Periodic withdrawal

take

2. Ben

envoy

use

(6) -1,787,612 -1,787,612.0Others .00 0

4.

Current period 571,424,76 3,358,127,46 1,128,623 293,162,01 4,234,223,38 8,458,066,25 92,866,62 8,550,932,88 End of period 8.00 9.50 .95 1.78 6.50 9.73 6.81 6.54 Balance

2024 half year

Owner's equity attributable to parent company

Other rights and interests

Tool 1

Items Minority shareholders’ rights Consolidated owners’ equity General

Paid-in capital (or other comprehensive income) Total capital reserve less: treasury stock items Surplus reserve wind Undistributed profits Other subtotal equity) Excellent income

Other savings insurance, he will continue first

He is ready

stocks bonds

Prepare

1.

Previous year 586,272,25 4,100,730,96 243,300,00 1,030,635 293,162,01 3,797,565,66 8,535,461,51 130,869,81 8,666,331,33 End of period 6.00 0.39 8.68 .29 1.78 3.25 8.03 9.85 7.88Balance

Add:

accounting

policy

change

Early stage

Error

70/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Correction

Others

2.

Current year 586,272,25 4,100,730,96 243,300,00 1,030,635 293,162,01 3,797,565,66 8,535,461,51 130,869,81 8,666,331,33 Beginning of period 6.00 0.39 8.68 .29 1.78 3.25 8.03 9.85 7.88Balance

3.

This issue

increase or decrease

change

Amount -43,660,059. 216,035,72 10,713,178.5 -248,912,358 -52,921,75 -301,834,117

70,245.37

(Minus 93 2.40 7.39 9.21 .60 less than

"-"

Fill in the number

column)

(1)

Comprehensive 619,513,343. 619,583,588. 7,463,895.8 627,047,484.

70,245.37

Revenue 19 56 9 45Total

(2)

all

Investors invested -43,660,059. 216,035,72 -259,695,782 -259,695,782 and 93 2.40 .33 .33 decreased

capital

1. place

Those who have

-43,660,059. 216,035,72 -259,695,782 -259,695,782Input

93 2.40 .33 .33 in general

common stock

2. its

other rights

YiGong

hold

71/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Those who have invested capital 3. The amount of share-based payment included in owners’ equity 4. Others

(3)

-608,800,164 -608,800,164 -3,930,600. -612,730,764Profit

.62 .62 00 .62Assignment1. Withdraw surplus reserve 2. Extract general risk reserves 3. Distribution to owners (or -608,800,164 -608,800,164 -3,930,600. -612,730,764 shares .62 .62 00 .62 shares) 4. Others

72/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(4) Internal carryover of owners’ equity 1. Convert capital reserve to capital (or share capital) 2. Convert surplus reserves to capital (or share capital) 3. Surplus reserve to make up for losses 4. The amount of changes in the defined benefit plan is carried forward to retained earnings 5. its

73/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

He comprehensive

combine

Yi Jie

transfer

Deposit and receive

benefit

6. its

him

(5)

Special

reserve

1. Ben

Periodic withdrawal

take

2. Ben

envoy

use

(6) -56,455,05 -56,455,055. Others 5.10 10

4.

Current period 586,272,25 4,057,070,90 459,335,73 1,100,880 293,162,01 3,808,278,84 8,286,549,15 77,948,060. 8,364,497,22 End of period 6.00 0.46 1.08 .66 1.78 1.82 9.64 64 0.28Balance

Person in charge of the company: Yang Zengli Person in charge of accounting work: Sister Feng Chao Person in charge of the accounting department: Yang Yuhong

Statement of changes in owner's equity of the parent company

January-June 2025

Unit: Yuan Currency: RMB 2025 semi-annual items Paid-in capital Other equity instruments Other comprehensive Undistributed profits Ownership capital reserve Less: treasury shares Special reserves Surplus reserves (or equity) Preferred shares Perpetual bonds Other income Total profits

74/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

581,011,3 3,875,08 461,029,2 293,136, 3,279,39 7,567,59

1. Ending balance of the previous year

46.00 5,375.85 95.83 128.00 0,877.43 4,431.45 plus: changes in accounting policies

Early error correction

Others

581,011,3 3,875,08 461,029,2 293,136, 3,279,39 7,567,59

2. Opening balance of this year

46.00 5,375.85 95.83 128.00 0,877.43 4,431.45

3. Amount of increases and decreases in the current period (minus -9,586,57 -460,904, -461,029, -277,200 -286,662, filled in with "-") 8.00 332.28 295.83,730.44 344.89

442,794, 442,794,

(1) Total comprehensive income

477.24 477.24

(2) Owner’s investment and capital reduction -9,586,57 -460,904, -461,029, -9,461,61 8.00 332.28 295.83 4.45

-9,586,57 -460,904, -461,029, -9,461,61 1. Common stock invested by owners

8.00 332.28 295.83 4.45 2. Investments from other equity instrument holders

capital

3. Share-based payments are included in owners’ equity

amount of

4. Others

-719,995 -719,995,

(3) Profit distribution

,207.68 207.68 1. Withdrawal from surplus reserve

2. Distribution to owners (or shareholders) -719,995 -719,995, distribution, 207.68 207.68 3. Others

(4) Internal carryover of owners’ equity

1. Conversion of capital reserves into capital (or shares)

this)

2. Conversion of surplus reserves into capital (or shares)

this)

3. Surplus reserve to cover losses

4. Carrying forward changes in defined benefit plans

retained earnings

75/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

5. Other comprehensive income carried forward and retained

benefit

6. Others

(5) Special reserves

1. Extract this period

2. Used in this issue

(6) Others

571,424,7 3,414,18 293,136, 3,002,19 7,280,93

4. Ending balance of the current period

68.00 1,043.57 128.00 0,146.99 2,086.56

2024 half year

Items Paid-in capital Other equity instruments Other comprehensive Undistributed profits Ownership capital reserve Less: treasury shares Special reserves Surplus reserve

(or equity) Preferred shares Perpetual bonds Other income Total profit

586,272,2 4,113,12 243,300,0 293,136, 2,984,10 7,733,33

1. Ending balance of the previous year

56.00 4,474.53 08.68 128.00 0,912.31 3,762.16 plus: changes in accounting policies

Early error correction

Others

586,272,2 4,113,12 243,300,0 293,136, 2,984,10 7,733,33

2. Opening balance of this year

56.00 4,474.53 08.68 128.00 0,912.31 3,762.16

3. Amount of increase or decrease in the current period (minus 216,035,7 -129,618 -345,653, less filled in with "-") 22.40,030.84 753.24

479,182, 479,182,

(1) Total comprehensive income

133.78 133.78

(2) Owner’s investment and capital reduction 216,035,7 -216,035, capital 22.40 722.40

216,035,7 -216,035, 1. Common stock invested by owners

22.40 722.40 2. Investments from other equity instrument holders

capital

3. Share-based payments are included in owners’ equity

amount of

76/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

4. Others

-608,800 -608,800,

(3) Profit distribution

,164.62 164.62 1. Withdrawal from surplus reserve

2. Distribution to owners (or shareholders) -608,800 -608,800, allocation ,164.62 164.62 3. Others

(4) Internal carryover of owners’ equity

1. Conversion of capital reserves into capital (or shares)

this)

2. Conversion of surplus reserves into capital (or shares)

this)

3. Surplus reserve to cover losses

4. Carrying forward changes in defined benefit plans

retained earnings

5. Other comprehensive income carried forward and retained

benefit

6. Others

(5) Special reserves

1. Extract this period

2. Used in this issue

(6) Others

586,272,2 4,113,12 459,335,7 293,136, 2,854,48 7,387,68

4. Ending balance of the current period

56.00 4,474.53 31.08 128.00 2,881.47 0,008.92

Person in charge of the company: Yang Zengli Person in charge of accounting work: Sister Feng Chao Person in charge of the accounting department: Yang Yuhong

77/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

3. Basic situation of the company

1. Company profile

√Applicable □Not applicable

1. History

Zhengzhou Antu Bioengineering Co., Ltd. (hereinafter referred to as the "Company" or the "Company") was formerly known as Zhengzhou Lvke Bioengineering Co., Ltd. and was established on September 15, 1999. The registered capital at the time of establishment was 1,000,000.00 yuan. After successive capital increases and equity transfers, the company's registered capital as of September 30, 2012 was RMB 20,000,000.00.

According to the resolution of the first shareholders' meeting on November 13, 2012, the "Report on the promoters converting the book net asset value corresponding to the equity held by them in Zhengzhou Antu Lvke Bioengineering Co., Ltd. into Zhengzhou Antu Bioengineering Co., Ltd." was reviewed and approved. The company uses September 30, 2012 as the audit base date for the overall change into a joint-stock company and the overall change into a joint-stock company; it is agreed that each shareholder shall enjoy the net assets according to their existing shareholding ratio in the company, and shall enjoy the shareholding ratio of the promoters of the joint-stock company according to the existing shareholding ratio. The audited net assets of the company as of September 30, 2012 were RMB 179,929,328.63, equivalent to a registered capital (share capital) of RMB 159,000,000.00. The excess of the registered capital (share capital) was included in the capital reserve. On December 20, 2012, the industrial and commercial change registration procedures were completed at the Henan Provincial Administration for Industry and Commerce.

According to the resolution of the shareholders' meeting on April 9, 2015, it was approved that the company applied for an additional registered capital of RMB 219,000,000.00. The company used capital reserve funds and undistributed profits to transfer a total of 219,000,000.00 shares to all shareholders, with a par value of RMB 1.00 per share, and a total increase in share capital of RMB 219,000,000.00. As of April 9, 2015, the registered capital after the change was RMB 378,000,000.00, and the accumulated paid-in capital (share capital) was RMB 378,000,000.00.

According to the resolution of the company’s 2015 Annual General Meeting of Shareholders and approved by the China Securities Regulatory Commission’s “Reply on the Approval of the Initial Public Offering of Stocks by Zhengzhou Antu Bioengineering Co., Ltd.” [CSRC License [2016] No. 1759), the company publicly issued shares with a par value of RMB 1 per share to the public. There are 42 million common shares. The company's shares were listed for trading on the Shanghai Stock Exchange on September 1, 2016. The above-mentioned capital increase business was verified by Zhongqin Wanxin Accounting Firm (Special General Partnership), and Qinxin Yanzi [2016] No. 1120 Capital Verification Report was issued on August 26, 2016. After this issuance, the company's share capital was changed to RMB 420,000,000.00.

On June 28, 2019, the company publicly issued 682.979 million yuan of convertible corporate bonds with a term of 6 years, and was listed and traded on the Shanghai Stock Exchange on July 22, 2019. According to relevant regulations and the prospectus, starting from 2020 They can be converted into company stocks starting from January 6, 2020. As resolved at the 11th meeting of the company’s third board of directors, the company’s bonds will be redeemed on February 18, 2020, as the redemption registration date, and all “Antu Convertible Bonds” registered on the redemption registration date will be redeemed. From January 6, 2020 to February 18, 2020, the company's cumulative convertible corporate bonds of RMB 679,807,000.00 have been converted into company stocks. The cumulative number of shares converted is 10,602,899.00 shares, increasing the share capital by RMB 10,602,899.00, and the registered capital after the change is RMB 430,602,899.00.

According to the resolutions of the company’s 14th meeting of the third session of the board of directors on June 15, 2020 and the first extraordinary shareholders’ meeting of 2020 on July 1, 2020, and approved by the China Securities Regulatory Commission’s “Reply on Approval of the Non-public Issuance of Stocks by Zhengzhou Antu Bioengineering Co., Ltd.” (CSRC License [2020] No. 2079), the company’s non-public issuance of no more than 43,060,289.00 new shares was approved. According to the issuance results, the company non-publicly issued 20,375,760.00 shares to 10 specific targets, with a face value of 1 yuan per share. The above capital increase business

78/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

It was verified by Zhongqin Wanxin Accounting Firm (Special General Partnership) and issued Qinxin Yanzi [2020] No. 0063 Capital Verification Report on November 4, 2020. After this issuance, the company's share capital was changed to RMB 450,978,659.00.

According to the resolutions of the 22nd meeting of the company's third session of the Board of Directors on April 21, 2021 and the 2020 Annual General Meeting of Shareholders on May 13, 2021, the company will convert capital reserves to share capital by converting 3 shares for every 10 shares of all shareholders, and the total amount will be increased by 3 shares.

135,293,597.00 shares. After the conversion, the company's total share capital changed to RMB 586,272,256.00.

In accordance with the relevant provisions of laws, regulations and normative documents such as the Company Law, the Stock Listing Rules of the Shanghai Stock Exchange, the Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 - Repurchase of Shares, and the Articles of Association, the company will change the purpose of the shares repurchased in the 2022 repurchase plan based on changes in the capital market, as well as its own actual situation, development strategy and time limits for treasury shares. The purpose of the repurchased shares was changed from "used to implement employee stock ownership plans or equity incentives" to "used to cancel and reduce the company's registered capital". In 2024, 5,260,910 treasury shares repurchased were canceled and the company's registered capital was correspondingly reduced. The company's share capital changed after cancellation. It was RMB 581,011,346.00. On February 21, 2025, 9,586,578 treasury shares repurchased were canceled and the company's registered capital was reduced accordingly. After the cancellation, the company's share capital was changed to RMB 571,424,768.00.

2. Company registration place and headquarters address

Registration place: No. 87, Jingbei 1st Road, Zhengzhou Economic and Technological Development Zone;

Headquarters address: No. 199, Jingkai 15th Street, Zhengzhou Economic and Technological Development Zone.

3. The business nature of the enterprise

The company's industry is pharmaceutical manufacturing, and its sub-industry is the in vitro diagnostic industry.

4. Main business activities

The main business activities are: production of Class III medical devices; operation of Class III medical devices; production of Class II medical devices; leasing of Class III medical devices; road cargo transportation (excluding dangerous goods); international road cargo transportation (projects that require approval according to law can only be carried out after approval by relevant departments) Business activities, specific business projects are subject to approval documents or licenses from relevant departments) General projects: sales of Class II medical devices; production of Class I medical devices; sales of Class I medical devices; leasing of Class II medical devices; leasing of Class I medical devices; leasing of non-residential real estate; engineering and technology Technical research and experimental development; biochemical product technology research and development; experimental analysis instrument manufacturing; experimental analysis instrument sales; office equipment sales; office equipment consumables sales; computer software, hardware and auxiliary equipment retail; information system integration services; plastic product manufacturing; special chemical product manufacturing (excluding Hazardous chemicals); sales of new organic active materials; sales of new automobiles; import and export of goods; import and export of technology; technical services, technology development, technical consultation, technology exchange, technology transfer, and technology promotion (except for projects that require approval according to law, business activities can be carried out independently with a business license in accordance with the law)

(2) Scope of consolidated financial statements

As of June 30, 2025, the Company has a total of 12 subsidiaries included in the scope of consolidation. For details, please see Note 10. Equity in other entities.

For details of changes in the scope of consolidation during the reporting period, please refer to Note 9. Changes in the Scope of Consolidation.

This financial statement was approved by the company's board of directors on August 21, 2025.

79/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

4. Basis for preparation of financial statements

1. Basics of preparation

These financial statements are prepared based on actual transactions and events and in accordance with the "Accounting Standards for Business Enterprises - Basic Standards", specific accounting standards for enterprises, application guidelines for accounting standards for enterprises, interpretations of accounting standards for enterprises and other relevant regulations promulgated by the Ministry of Finance (hereinafter collectively referred to as "Accounting Standards for Business Enterprises"), as well as the disclosure provisions of the China Securities Regulatory Commission's "Information Disclosure and Preparation Rules No. 15 of Companies that Offer Securities to the Public - General Provisions for Financial Reports".

In accordance with the relevant provisions of the Accounting Standards for Business Enterprises, the Company's accounting is based on the accrual basis. Except for certain financial instruments, these financial statements are measured on the basis of historical cost. If an asset is impaired, corresponding impairment provisions will be made in accordance with relevant regulations.

2. Continuous operation

√Applicable □Not applicable

The company has evaluated the company's ability to continue operating for 12 months from the end of the reporting period, and has found no issues that affect the company's ability to continue operating. It is reasonable for the company to prepare financial statements based on going concern.

5. Important accounting policies and accounting estimates

Specific accounting policies and accounting estimation tips:

√Applicable □Not applicable

Details are as follows:

1. Statement on compliance with corporate accounting standards

The financial statements prepared by the company comply with the requirements of the Accounting Standards for Business Enterprises and truly and completely reflect the company's financial status, operating results, changes in shareholders' equity, cash flow and other relevant information.

2. Accounting period

The company's fiscal year begins on January 1 and ends on December 31 of the Gregorian calendar.

3. Business cycle

√Applicable □Not applicable

The normal operating cycle refers to the period from the purchase of assets for processing to the realization of cash or cash equivalents. The company uses 12 months as an operating cycle and uses it as the liquidity classification standard for assets and liabilities.

4. Accounting standard currency

The company's accounting standard currency is RMB.

5. Determination method and selection basis of materiality criteria

√Applicable □Not applicable

Item Importance standard: Important single-item receivables with provision for bad debts. Important receivables with individual amounts exceeding 10 million yuan. Recovery or transfer of bad debt provisions for the current period. Individual amounts exceeding 10 million yuan.

80/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Um

Write-off of important accounts receivable with a single amount exceeding RMB 10 million

Operating income accounts for more than 10% of the operating income in the consolidated statement or belongs to important non-wholly owned subsidiaries

The net profit of listed companies exceeds 50 million yuan

Important joint ventures or associates whose net profit attributable to the listed company exceeds 50 million yuan

Important prepayments aged more than 1 year with a single amount exceeding 10 million yuan

Important accounts payable aged more than 1 year with a single amount exceeding 10 million yuan

Important contract liabilities aged more than 1 year with a single amount exceeding RMB 10 million

There is a significant change in the book value of contract liabilities and the individual amount exceeds 10 million yuan

Important other payables aged more than 1 year with a single amount exceeding RMB 20 million

Important financial products with a single transaction amount exceeding 100 million yuan

Cash received related to important investment activities accounts for more than 5% of the net asset balance

Cash paid for important investment activities accounts for more than 5% of the net asset balance

6. Accounting treatment methods for business combinations under the same control and those not under the same control

√Applicable □Not applicable

(1) Business merger under common control

The assets and liabilities acquired by the Company in a business merger are measured at the book value of the merged party in the consolidated financial statements of the ultimate controlling party on the merger date. Among them, if the accounting policies adopted by the merged party and the company before the business merger are different, the accounting policies will be unified based on the principle of importance, that is, the book value of the assets and liabilities of the merged party will be adjusted in accordance with the company's accounting policies. The assets and liabilities acquired by the merging party in the business combination (including the goodwill formed by the ultimate controlling party's acquisition of the merged party) are measured based on the book value of the merged party's assets and liabilities in the ultimate controlling party's consolidated financial statements on the merger date. The difference between the book value of the net assets acquired in the merger and the book value of the merger consideration paid (or the total face value of the shares issued) is adjusted to the equity premium in the capital reserve. If the equity premium in the capital reserve is insufficient to offset it, the retained earnings are adjusted.

(2) Business merger not under common control

The identifiable assets and liabilities of the purchased party acquired by the Company in a business combination are measured at their fair value on the acquisition date. Among them, if the accounting policies adopted by the purchased party and the company before the business merger are different, the accounting policies will be unified based on the principle of importance, that is, the book value of the assets and liabilities of the purchased party will be adjusted in accordance with the company's accounting policies. The merger cost is the fair value of the assets, liabilities incurred or assumed, and equity securities issued by the purchaser to obtain control of the purchased party on the purchase date. The difference between the merger cost and the fair value of the acquiree's identifiable net assets acquired in the merger is recognized as goodwill; the difference between the merger cost and the fair value of the acquiree's identifiable net assets acquired in the merger is included in the current profit and loss. All identifiable assets, liabilities and contingent liabilities of the acquiree acquired in the merger that meet the recognition conditions are measured at fair value on the acquisition date. (3) Related expenses incurred for the merger

Directly related expenses incurred for a business merger are included in the current profits and losses when incurred; transaction costs for the issuance of equity securities or debt securities for a business merger are included in the initial recognition amount of equity securities or debt securities.

7. Judgment standards for control and preparation methods of consolidated financial statements

√Applicable □Not applicable

(1) Judgment criteria for control

81/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

The Company has power over the investee, enjoys variable returns by participating in the investee's related activities, and has the ability to use its power over the investee to affect the amount of returns.

(2) Principles for determining the scope of consolidated financial statements

The scope of consolidation in consolidated financial statements is determined on the basis of control, including not only subsidiaries determined based on voting rights (or similar voting rights) alone or in combination with other arrangements, but also structured entities determined based on one or more contractual arrangements.

Control means that the company has power over the investee, enjoys variable returns by participating in the investee's relevant activities, and has the ability to use its power over the investee to affect the amount of returns. The scope of consolidation includes the company and all its subsidiaries. Subsidiaries refer to entities controlled by the company (including divisible parts of enterprises, investee units, and structured entities controlled by enterprises, etc.). Structured entities refer to entities designed without voting rights or similar rights as a decisive factor when determining their controllers (note: sometimes also called special purpose entities).

(3) Merger procedure

The company prepares consolidated financial statements based on its own and its subsidiaries' financial statements and other relevant information. The Company prepares consolidated financial statements, treating the entire enterprise group as an accounting entity, and prepares consolidated financial statements in accordance with the recognition, measurement and presentation requirements of relevant accounting standards for enterprises and in accordance with unified accounting policies to reflect the overall financial status, operating results and cash flow of the Company Group. If the accounting policies and accounting periods adopted by subsidiaries are inconsistent with those of the Company, necessary adjustments shall be made in accordance with the Company's accounting policies and accounting periods when preparing consolidated financial statements. All significant intra-company balances, transactions and unrealized profits are eliminated when preparing consolidated financial statements. If internal transactions indicate that impairment losses have occurred on related assets, the losses shall be recognized in full.

The owner's equity of subsidiaries, current net profit and loss and current comprehensive income belonging to minority shareholders are presented separately under the owner's equity item in the consolidated balance sheet, the net profit item and the total comprehensive income item in the consolidated income statement. If the current losses shared by the minority shareholders of a subsidiary exceed the minority shareholders' share of the subsidiary's opening owner's equity, the balance is offset against the minority shareholders' equity.

(4) Processing of adding subsidiaries or businesses

During the reporting period, for subsidiaries acquired through business mergers under common control, the operating results and cash flows of the subsidiaries from the beginning of the current period to the end of the reporting period will be included in the consolidated financial statements. At the same time, the opening numbers of the consolidated financial statements and relevant items in the comparative statements will be adjusted. The post-merger reporting entity will be deemed to have existed from the time when the ultimate controlling party began to control.

If it is possible to control an investee under the same control due to additional investment or other reasons, the equity investment held before obtaining control of the merged party has recognized relevant profits and losses, other comprehensive income and other changes in net assets between the date of acquisition of the original equity and the date when the merging party and the merged party are under the same control, whichever is later, to the date of merger, and shall offset the opening retained earnings or current profits and losses of the comparative statement period respectively.

During the reporting period, if a subsidiary or business is added due to a business combination not under common control, the fair value of each identifiable asset, liability and contingent liability determined on the date of purchase will be included in the consolidated financial statements from the date of purchase.

If it is possible to exercise control over an investee not under the same control due to additional investment or other reasons, the equity of the purchased party held before the purchase date shall be remeasured according to the fair value of the equity on the purchase date, and the difference between the fair value and its book value shall be included in the calculation.

82/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Current investment income. Other comprehensive income related to the equity of the purchased party held before the purchase date that can be reclassified into profit and loss later, and other changes in owner's equity under equity method accounting are converted into investment income for the current period on the purchase date.

From the date when it obtains actual control over the net assets and production and operation decisions of a subsidiary, the Company begins to include them in the scope of consolidation; from the date when it loses actual control, it ceases to be included in the scope of consolidation. For subsidiaries disposed of, the operating results and cash flows before the date of disposal have been appropriately included in the consolidated income statement and consolidated cash flow statement; for subsidiaries disposed of in the current period, the opening balance of the consolidated balance sheet will not be adjusted. For subsidiaries added through business combinations not under common control, their operating results and cash flows after the acquisition date have been appropriately included in the consolidated income statement and consolidated cash flow statement, and the opening numbers and comparative numbers of the consolidated financial statements will not be adjusted.

(5) Disposal of subsidiaries

When the company loses control over its original subsidiaries due to the disposal of part of its equity investments or other reasons, the remaining equity will be remeasured according to its fair value on the date when control is lost. The difference between the sum of the consideration obtained for disposing of the equity and the fair value of the remaining equity, minus the sum of the share of the original subsidiary's net assets calculated continuously from the date of purchase or merger based on the original shareholding ratio and the sum of goodwill, shall be included in the investment income in the period when control is lost. Other comprehensive income related to the equity investment in the original subsidiary that can be reclassified into profit and loss in the future and other changes in owner's equity under equity method accounting shall be accounted for on the same basis as the purchased party's direct disposal of relevant assets or liabilities when control is lost. Thereafter, the remaining equity will be subsequently measured in accordance with relevant regulations such as "Accounting Standards for Business Enterprises No. 2 - Long-term Equity Investment" or "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments". For details, see Note 5.19 "Long-term Equity Investment" or Note 5.11 "Financial Instruments".

If the company disposes of its equity investment in a subsidiary step by step through multiple transactions until it loses control, it needs to distinguish whether each transaction in which it disposes its equity investment in its subsidiary until it loses control is a package deal. The terms, conditions and economic impact of various transactions for the disposal of equity investments in subsidiaries meet one or more of the following circumstances, which usually indicate that multiple transactions should be accounted for as a package deal: ① These transactions are entered into at the same time or with consideration of each other's influence; ② Only these transactions as a whole can achieve a complete business result; ③ The occurrence of a transaction depends on the occurrence of at least one other transaction; ④ A transaction is uneconomical when viewed alone, but it is economical when considered together with other transactions. If it does not belong to a package deal, each transaction will be accounted for in accordance with the applicable principles of "partial disposal of long-term equity investment in a subsidiary without losing control" (see Note V. 19 "Long-term equity investment" (2)④ for details) and "loss of control over the original subsidiary due to disposal of part of the equity investment or other reasons" (see the previous paragraph for details). If the various transactions involving the disposal of equity investments in a subsidiary until the loss of control belong to a package transaction, each transaction will be accounted for as a transaction in which the subsidiary is disposed of and control is lost; however, the difference between the price of each disposal and the share of the net assets of the subsidiary corresponding to the disposal investment before the loss of control is recognized as other comprehensive income in the consolidated financial statements, and is transferred to the profit and loss of the current period when control is lost.

(6) Special considerations in merger elimination

① The long-term equity investment held by a subsidiary of the company shall be regarded as the company's treasury shares, and shall be listed as "less: treasury shares" under the owner's equity item in the consolidated balance sheet as a deduction from the owner's equity.

For long-term equity investments held by subsidiaries among each other, the long-term equity investment and its corresponding share of the owner's equity of the subsidiary are offset against each other in accordance with the offsetting method for the company's equity investments in subsidiaries.

83/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

② Since the "special reserves" and "general risk reserves" items are neither paid-in capital (or equity) nor capital reserves, nor are they different from retained earnings and undistributed profits, after the long-term equity investment and the subsidiary's owner's equity are offset, they will be restored according to the share attributable to the owners of the parent company.

③ If there is a temporary difference between the book value of assets and liabilities in the consolidated balance sheet and the tax base of the taxable entity due to the offsetting of unrealized internal sales profits and losses, deferred income tax assets or deferred income tax liabilities will be recognized in the consolidated balance sheet, and the income tax expenses in the consolidated income statement will be adjusted at the same time, except for deferred income taxes related to transactions or events directly included in owner's equity and business mergers.

④ Unrealized internal transaction gains and losses arising from the company's sale of assets to subsidiaries shall be fully offset against "net profits attributable to owners of the parent company". Unrealized internal transaction profits and losses arising from the sale of assets by a subsidiary to the company shall be allocated and offset between "net profits attributable to owners of the parent company" and "minority shareholders' profits and losses" in accordance with the company's distribution ratio to the subsidiary. Unrealized internal transaction profits and losses arising from the sale of assets between subsidiaries shall be allocated and offset between "net profits attributable to owners of the parent company" and "minority shareholders' profits and losses" in accordance with the company's distribution ratio to the selling subsidiary.

⑤ If the current loss shared by the minority shareholders of a subsidiary exceeds the minority shareholders' share of the subsidiary's opening owner's equity, the balance should still be offset against the minority shareholders' equity.

(7) Accounting treatment of special transactions

①Purchase minority shareholders’ equity

The company purchases the subsidiary's equity owned by minority shareholders. In individual financial statements, the investment cost of the newly acquired long-term equity investment for the purchase of the minority equity is measured according to the fair value of the consideration paid. In the consolidated financial statements, the difference between the newly acquired long-term equity investment due to the purchase of minority equity and the share of the subsidiary's net assets calculated continuously from the date of purchase or merger based on the new shareholding ratio shall be adjusted to the capital reserve (capital premium or equity premium). If the capital reserve is insufficient to offset, the surplus reserve and undistributed profits shall be offset in sequence.

② Obtaining control of a subsidiary step by step through multiple transactions

A. Merger of enterprises under common control through multiple transactions step by step

On the merger date, the company determines the initial investment cost of the long-term equity investment in its individual financial statements based on the share of the book value of the subsidiary's net assets in the ultimate controlling party's consolidated financial statements that it will enjoy after the merger; the initial investment cost is the same as the long-term equity before the merger. The difference between the book value of the investment and the book value of the newly paid consideration for further shares acquired on the merger date is adjusted to the capital reserve (capital premium or equity premium). If the capital reserve (capital premium or equity premium) is insufficient to offset, the surplus reserve and undistributed profits are offset in sequence.

In the consolidated financial statements, the assets and liabilities of the merged party obtained by the combining party during the merger are measured according to their book value in the consolidated financial statements of the ultimate controlling party on the date of merger, except for adjustments due to different accounting policies. The difference between the book value of the investments held before the merger plus the book value of the new consideration paid on the date of merger and the book value of the net assets acquired in the merger is adjusted to the capital reserve (equity premium/capital premium). If the capital reserve is insufficient for offset, the retained earnings are adjusted.

84/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

For equity investments held by the merging party before obtaining control of the merged party and calculated according to the equity method, relevant profits and losses, other comprehensive income and other changes in owner's equity have been recognized between the date of acquisition of the original equity and the date when the merging party and the merged party are under the final control of the same party, whichever is later, to the merger date, and the opening retained earnings of the comparative statement period shall be offset respectively.

B. Merger of enterprises not under common control is realized step by step through multiple transactions.

On the merger date, in individual financial statements, the sum of the book value of the original long-term equity investment plus the new investment cost on the merger date will be regarded as the initial investment cost of the long-term equity investment on the merger date.

In the consolidated financial statements, the equity of the purchased party held before the acquisition date is remeasured according to the fair value of the equity on the acquisition date, and the difference between the fair value and its book value is included in the investment income of the current period; if the equity of the acquired party held before the acquisition date involves other comprehensive income under equity method accounting, the other comprehensive income related to it is converted into the income of the current period on the acquisition date, except for other comprehensive income generated due to the remeasurement of the net assets or net liabilities of the defined benefit plan by the merged party. The company discloses in the notes the fair value of the equity of the purchased party it held before the purchase date on the purchase date, and the amount of related gains or losses resulting from remeasurement at fair value.

③The company disposes of long-term equity investment in subsidiaries but does not lose control

If the parent company partially disposes of its long-term equity investment in a subsidiary without losing control, in the consolidated financial statements, the difference between the disposal price and the share of the subsidiary's net assets continuously calculated from the date of purchase or merger will be adjusted to the capital reserve (capital premium or equity premium). If the capital reserve is insufficient for offset, the retained earnings will be adjusted.

④The company disposes of its long-term equity investment in the subsidiary and loses control

A. One transaction disposal

If the company loses control over the investee due to disposal of part of its equity investment or other reasons, when preparing consolidated financial statements, the remaining equity will be remeasured according to its fair value on the date when control is lost. The difference between the sum of the consideration obtained for disposing of the equity and the fair value of the remaining equity, minus the share of the original subsidiary's net assets calculated continuously from the date of purchase or merger based on the original shareholding ratio, shall be included in the investment income in the period when control is lost.

Other comprehensive income and other changes in owner's equity related to the equity investment of the atomic company will be transferred to the current profit and loss when control is lost, except for other comprehensive income arising from the investee's remeasurement of the net liabilities or changes in net assets of the defined benefit plan. B. Step-by-step disposal of multiple transactions

In the consolidated financial statements, we should first determine whether the step-by-step transaction is a "package transaction".

If the step-by-step transaction does not belong to a "package transaction", in the individual financial statements, for each transaction before the loss of control of the subsidiary, the book value of the long-term equity investment corresponding to each equity disposal will be carried forward, and the difference between the proceeds and the book value of the long-term equity investment disposed shall be included in the investment income of the current period; in the consolidated financial statements, it shall be handled in accordance with the relevant provisions of "the parent company disposes of the long-term equity investment in the subsidiary without losing control."

If the step-by-step transaction is a "package transaction", each transaction should be accounted for as a transaction in which the subsidiary is disposed of and control is lost; in individual financial statements, the difference between each disposal price before the loss of control and the book value of the long-term equity investment corresponding to the equity disposed is first recognized as other comprehensive income, and then transferred to the current profit and loss when control is lost; in the consolidated financial statements, for each transaction before the loss of control, the disposal price and disposal

85/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

The difference in the share of the subsidiary's net assets corresponding to the investment shall be recognized as other comprehensive income, and shall be transferred to the profits and losses of the current period when control is lost.

If the terms, conditions and economic impact of each transaction meet one or more of the following conditions, multiple transactions are usually accounted for as a "package transaction":

(a) The transactions were entered into simultaneously or with consideration of their influence on each other.

(b) These transactions as a whole can achieve a complete business result.

(c) The occurrence of a transaction depends on the occurrence of at least one other transaction.

(d) A transaction that is uneconomical when considered alone is economical when considered together with other transactions.

⑤ Dilution of the equity ratio owned by the parent company due to capital increase by minority shareholders of the sub-company

Other shareholders (minority shareholders) of the subsidiary increase capital in the subsidiary, thereby diluting the parent company's equity ratio in the subsidiary. In the consolidated financial statements, the share of the subsidiary's book net assets before the capital increase is calculated based on the parent company's equity ratio before the capital increase. The difference between this share and the subsidiary's share of the subsidiary's book net assets after the capital increase calculated based on the parent company's shareholding ratio after the capital increase is adjusted to the capital reserve (capital premium or equity premium). If the capital reserve (capital premium or equity premium) is insufficient to offset, the retained earnings are adjusted.

8. Classification of joint arrangements and accounting treatment of joint operations

√Applicable □Not applicable

A joint arrangement refers to an arrangement that is jointly controlled by two or more parties. The Company divides joint arrangements into joint operations and joint ventures based on the rights enjoyed and obligations assumed in the joint arrangements. Joint operation refers to a joint arrangement in which the company enjoys the relevant assets of the arrangement and assumes the relevant liabilities of the arrangement. A joint venture refers to a joint arrangement in which the Company only has rights to the net assets of the arrangement.

The Company's investment in joint ventures is accounted for using the equity method and is handled in accordance with the accounting policies described in Note 5.19 "Long-term Equity Investment".

The Company recognizes joint operations. The Company recognizes the following items related to its share of interests in joint operations, and performs accounting treatments in accordance with relevant accounting standards for enterprises: recognizes separately held assets, separately assumed liabilities, and recognizes jointly held assets and jointly assumed liabilities based on the Company's share; recognizes income generated from the sale of the Company's share of joint operation output; recognizes income generated by joint operations from the sale of output based on the Company's share; recognizes expenses incurred by the Company alone, and recognizes expenses incurred from joint operations based on the Company's share.

When the company invests or sells assets to a joint operation as a joint venture (the assets do not constitute a business, the same below), or purchases assets from the joint operation, before the assets are sold to a third party, the company only recognizes the portion of the profits and losses arising from the transaction that are attributable to other participants in the joint operation. If such assets suffer asset impairment losses that comply with the provisions of "Accounting Standards for Business Enterprises No. 8 - Asset Impairment" and other regulations, the company will recognize the loss in full if the company invests or sells the assets to the joint operation; if the company purchases assets from the joint operation, the company will recognize the loss based on its share.

86/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

9. Determination standards for cash and cash equivalents

When the company prepares the cash flow statement, cash refers to the company's cash on hand and deposits that can be used for payment at any time. Cash equivalents refer to investments that are held with a short term (generally due within three months from the date of purchase), are highly liquid, are easily convertible into known amounts of cash, and have little risk of changes in value.

10. Foreign currency business and foreign currency statement conversion

√Applicable □Not applicable

(1) Foreign currency business

When the Company's foreign currency transactions are initially recognized, they are converted into the amount in the recording currency based on the spot exchange rate on the transaction date or an exchange rate determined in accordance with a systematic and reasonable method that is similar to the spot exchange rate on the date of the transaction. However, the company's foreign currency exchange business or transactions involving foreign currency exchange are converted into the amount in the accounting functional currency based on the actual exchange rate.

On the balance sheet date, foreign currency monetary items are translated using the spot exchange rate on the balance sheet date. Exchange differences arising from differences between the spot exchange rate on the balance sheet date and the spot exchange rate at the time of initial recognition or the previous balance sheet date are included in the current profit and loss. Foreign currency non-monetary items measured at historical cost are still measured using the amount in the recording currency converted at the spot exchange rate on the date of the transaction. Foreign currency non-monetary items measured at fair value are converted using the spot exchange rate on the date when the fair value is determined. The difference between the converted accounting currency amount and the original accounting functional currency amount is included in the current profit and loss or other comprehensive income.

(2) Conversion of foreign currency statements

Before converting the financial statements of an enterprise's overseas operations, the accounting period and accounting policies of the overseas operations must be adjusted to make them consistent with the enterprise's accounting period and accounting policies, and then financial statements in the corresponding currency (currency other than the accounting standard currency) shall be prepared based on the adjusted accounting policies and accounting periods. table, and then convert the overseas operating financial statements according to the following method: the asset and liability items in the balance sheet are converted using the spot exchange rate on the balance sheet date; shareholders' equity items, except for the "undistributed profits" item, are converted using the spot exchange rate at the time of occurrence. Income and expense items in the income statement are translated using the spot exchange rate or the approximate spot exchange rate on the date of transaction. Foreign currency cash flows and cash flows of overseas subsidiaries are translated using the spot exchange rate or the approximate spot exchange rate on the date when the cash flows occur. The impact of exchange rate changes on cash is presented separately in the cash flow statement as an adjustment item.

The undistributed profit at the beginning of the year is the undistributed profit at the end of the period after conversion of the previous year; the undistributed profit at the end of the year is calculated and presented according to the converted profit distribution items; the difference between the asset items after conversion and the total number of liability items and shareholders' equity items is regarded as the conversion difference of foreign currency statements and is recognized as other comprehensive income. The opening figures and actual figures for the previous period are presented based on the amounts after conversion of the financial statements for the previous period.

When an overseas operation is disposed of and control is lost, the translation differences of foreign currency statements listed under the shareholders' equity items in the balance sheet and related to the overseas operation shall be transferred to the current profit and loss of the disposal in full or in proportion to the disposal of the overseas operation.

When the company disposes of all the owners' equity of the company's overseas operations or loses control of the overseas operations due to the disposal of part of the equity investment or other reasons, the translation differences of foreign currency statements listed under the shareholders' equity/owner's equity items in the balance sheet and related to the overseas operation and attributable to the owners' equity of the parent company will all be transferred to the profits and losses of the current period of disposal.

When the proportion of overseas operating equity held is reduced due to the disposal of part of the equity investment or other reasons but the control of the overseas operation is not lost, the foreign currency statement translation difference related to the disposal of the overseas operation will be attributed to the minority shareholders' equity and will not be transferred to the current profit and loss.

87/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

When disposing of part of the equity of an overseas operation that is an associate or joint venture, the translation difference of foreign currency statements related to the overseas operation shall be transferred to the current profit and loss of the disposal in proportion to the disposal of the overseas operation.

If there are foreign currency monetary items that essentially constitute a net investment in overseas operations, in the consolidated financial statements, the exchange differences arising from exchange rate changes are recognized as other comprehensive income as "foreign currency statement translation differences"; when disposing of overseas operations, they are included in the current profit and loss of disposal.

11. Financial instruments

√Applicable □Not applicable

A financial asset or financial liability is recognized when the Company becomes a party to a financial instrument contract.

(1) Classification, recognition and measurement of financial assets

Based on the business model of managing financial assets and the contractual cash flow characteristics of financial assets, the company divides financial assets into: financial assets measured at amortized cost; financial assets measured at fair value with changes included in other comprehensive income; financial assets measured at fair value with changes included in current profits and losses.

Financial assets are measured at fair value upon initial recognition. For financial assets measured at fair value and whose changes are included in the current profit and loss, the relevant transaction costs are directly included in the current profit and loss; for other types of financial assets, the relevant transaction costs are included in the initial recognition amount. For accounts receivable or notes receivable arising from the sale of products or provision of services that do not include or take into account significant financing components, the amount of consideration that the company is expected to be entitled to receive shall be regarded as the initial recognition amount.

①Financial assets measured at amortized cost

The Company's business model for managing financial assets measured at amortized cost is to collect contractual cash flows as the goal, and the contractual cash flow characteristics of such financial assets are consistent with the basic lending arrangements, that is, the cash flows generated on a specific date are only payments of principal and interest based on the outstanding principal amount. For such financial assets, the Company adopts the actual interest rate method and conducts subsequent measurement at amortized cost. Gains or losses arising from amortization or impairment are included in the current profits and losses.

②Financial assets measured at fair value and changes included in other comprehensive income

The Company's business model for managing such financial assets aims at both collecting contractual cash flows and selling them, and the contractual cash flow characteristics of such financial assets are consistent with the basic lending arrangements. The Company measures such financial assets at fair value and changes in them are included in other comprehensive income, but impairment losses or gains, exchange gains and losses and interest income calculated according to the effective interest method are included in the current profit and loss.

In addition, the Company designates certain investments in non-trading equity instruments as financial assets measured at fair value through other comprehensive income. The company includes the relevant dividend income of this type of financial assets in the current profit and loss, and the changes in fair value are included in other comprehensive income. When the financial asset is derecognised, the accumulated gains or losses previously included in other comprehensive income will be transferred from other comprehensive income to retained earnings and will not be included in the current profit or loss.

③Financial assets measured at fair value and changes included in current profits and losses

The Company classifies financial assets other than the above-mentioned financial assets measured at amortized cost and financial assets measured at fair value through other comprehensive income as financial assets measured at fair value through profit or loss for the current period. In addition, at the time of initial recognition, in order to eliminate or significantly reduce accounting mismatches, the Company designated some financial assets as measured at fair value and their changes

88/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Financial assets that are automatically included in current profits and losses. For such financial assets, the company uses fair value for subsequent measurement, and changes in fair value are included in the current profit and loss.

(2) Classification, recognition and measurement of financial liabilities

Financial liabilities are classified upon initial recognition into financial liabilities measured at fair value through profit or loss and other financial liabilities. For financial liabilities measured at fair value and whose changes are included in the current profit and loss, the relevant transaction costs are directly included in the current profit and loss, and the relevant transaction costs of other financial liabilities are included in their initial recognition amount.

①Financial liabilities measured at fair value and changes included in current profits and losses

Financial liabilities at fair value through profit or loss include trading financial liabilities (including derivatives that are financial liabilities) and financial liabilities designated at fair value through profit or loss upon initial recognition.

Trading financial liabilities (including derivatives belonging to financial liabilities) are subsequently measured at fair value. Except for those related to hedging accounting, changes in fair value are included in current profits and losses.

For a financial liability designated as a financial liability measured at fair value through profit or loss for the current period, changes in the fair value of this liability caused by changes in the company's own credit risk are included in other comprehensive income. When the liability is derecognised, the accumulated changes in its fair value caused by changes in its own credit risk included in other comprehensive income are transferred to retained earnings. The remaining changes in fair value are included in the current profit and loss. If handling the impact of changes in the credit risk of such financial liabilities in the above manner will cause or expand accounting mismatches in profits and losses, the company will include all gains or losses from the financial liabilities (including the amount affected by changes in the company's own credit risk) into the profits and losses of the current period. ②Other financial liabilities

Except for financial liabilities and financial guarantee contracts formed by the transfer of financial assets that do not meet the conditions for termination of recognition or continued involvement in the transferred financial assets, other financial liabilities are classified as financial liabilities measured at amortized cost, and are subsequently measured at amortized cost. Gains or losses arising from termination of recognition or amortization are included in the current profit and loss.

(3) Derecognition of financial assets and transfer of financial assets

Financial assets that meet one of the following conditions shall be derecognized: ① The contractual right to receive cash flows from the financial asset terminates; ② The financial asset has been transferred, and almost all the risks and rewards of the ownership of the financial asset are transferred to the transferee; ③ The financial asset has been transferred, and although the enterprise neither transfers nor retains almost all the risks and rewards of the ownership of the financial asset, it has given up control of the financial asset.

If an enterprise neither transfers nor retains substantially all the risks and rewards of ownership of a financial asset, and does not give up control of the financial asset, the relevant financial assets will be recognized to the extent of its continued involvement in the transferred financial assets, and the relevant liabilities will be recognized accordingly. The degree of continued involvement in the transferred financial assets refers to the level of risk faced by the enterprise due to changes in the value of the financial assets.

If the overall transfer of financial assets meets the conditions for derecognition, the difference between the book value of the transferred financial assets and the sum of the consideration received for the transfer and the cumulative amount of changes in fair value originally included in other comprehensive income will be included in the current profit and loss.

If the partial transfer of financial assets meets the conditions for derecognition, the book value of the transferred financial assets will be apportioned between the derecognized and non-derecognized parts according to their relative fair values, and the difference between the sum of the consideration received for the transfer and the cumulative amount of changes in fair value originally included in other comprehensive income that should be apportioned to the derecognized part and the apportioned aforementioned book amount shall be included in the current profit and loss.

89/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

When the company sells financial assets with recourse, or endorses and transfers financial assets it holds, it needs to determine whether substantially all the risks and rewards of ownership of the financial assets have been transferred. If almost all the risks and rewards of the ownership of the financial asset have been transferred to the transferee, the financial asset will be derecognised; if almost all the risks and rewards of the ownership of the financial asset have been retained, the recognition of the financial asset will not be deactivated; if almost all the risks and rewards of the ownership of the financial asset have neither been transferred nor retained, the company will continue to judge whether the enterprise retains control over the asset, and perform accounting treatment according to the principles described in the previous paragraphs.

(4) Derecognition of financial liabilities

If the current obligation of a financial liability (or part thereof) has been discharged, the Company shall terminate the recognition of the financial liability (or part thereof). The company (borrower) signs an agreement with the lender to replace the original financial liability by assuming a new financial liability, and if the contract terms of the new financial liability are substantially different from the original financial liability, the original financial liability will be terminated and a new financial liability will be recognized at the same time. If the company makes substantial modifications to the contract terms of the original financial liability (or part thereof), it will terminate the recognition of the original financial liability and recognize a new financial liability in accordance with the modified terms.

If a financial liability (or part thereof) is derecognised, the company will include the difference between its book value and the consideration paid (including non-cash assets transferred out or liabilities assumed) into the current profit and loss.

(5) Offset of financial assets and financial liabilities

When the company has the legal right to offset the recognized amount of financial assets and financial liabilities, and the legal right is currently enforceable, and the company plans to settle on a net basis or realize the financial assets and pay off the financial liabilities at the same time, the financial assets and financial liabilities will be listed in the balance sheet as the net amount after offsetting each other. Otherwise, financial assets and financial liabilities are presented separately in the balance sheet and are not offset against each other.

(6) Determination method of fair value of financial assets and financial liabilities

Fair value refers to the price that can be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. If there is an active market for a financial instrument, the company uses the quoted price in the active market to determine its fair value. Quotes in active markets refer to prices that are easily obtained from exchanges, brokers, industry associations, pricing service agencies, etc. on a regular basis, and represent the prices of market transactions that actually occur in fair transactions. If there is no active market for a financial instrument, the Company uses valuation techniques to determine its fair value. Valuation techniques include reference to prices used in recent market transactions between parties who are familiar with the situation and voluntary transactions, reference to the current fair value of other financial instruments that are substantially the same, discounted cash flow methods and option pricing models, etc. When valuing, the Company adopts valuation techniques that are applicable under the current circumstances and supported by sufficient available data and other information, selects input values ​​that are consistent with the characteristics of the assets or liabilities considered by market participants in transactions of related assets or liabilities, and gives priority to the use of relevant observable input values ​​whenever possible. Non-inputable values ​​are used when the relevant observable input values ​​cannot be obtained or are impracticable to obtain.

(7) Equity instruments

Equity instruments are contracts that evidence ownership of a residual interest in the company's assets after deducting all liabilities. The company's issuance (including refinancing), repurchase, sale or cancellation of equity instruments is treated as a change in equity, and transaction costs related to equity transactions are deducted from equity. The Company does not recognize changes in the fair value of equity instruments.

90/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

If the company's equity instruments distribute dividends (including "interest" generated by instruments classified as equity instruments) during their existence, they will be treated as profit distribution.

(8) Impairment of financial assets

The financial assets that the company needs to confirm impairment losses are financial assets measured at amortized cost, debt instruments measured at fair value with changes included in other comprehensive income, and lease receivables, which mainly include notes receivable, accounts receivable, receivable financing, other receivables, debt investments, other debt investments, long-term receivables, etc. In addition, for contract assets, lease receivables and some financial guarantee contracts, impairment provisions are made and credit impairment losses are recognized in accordance with the accounting policies described in this section.

①Measurement of expected credit losses

Based on expected credit losses, the Company makes impairment provisions and recognizes credit impairment losses for each of the above items in accordance with its applicable expected credit loss measurement method (general method or simplified method).

Expected credit losses refer to the weighted average of the credit losses of financial instruments with the risk of default as the weight. Credit loss refers to the difference between all contractual cash flows receivable under the contract and all cash flows expected to be received by the company, discounted at the original actual interest rate, that is, the present value of all cash shortfalls. Among them, for purchased or originated financial assets that have suffered credit impairment, the company discounts them according to the credit-adjusted actual interest rate of the financial assets.

The general method of measuring expected credit losses means that the company evaluates on each balance sheet date whether the credit risk of financial assets (including contract assets and other applicable items, the same below) has increased significantly since initial recognition. If the credit risk has increased significantly since initial recognition, the company measures loss provisions at an amount equivalent to the expected credit losses during the entire duration; if the credit risk has not increased significantly since initial recognition, the company measures loss provisions at an amount equivalent to the expected credit losses within the next 12 months. The Company considers all reasonable and evidence-based information, including forward-looking information, when assessing expected credit losses.

For financial instruments with low credit risk on the balance sheet date, the Company assumes that its credit risk has not increased significantly since initial recognition, and chooses to measure loss provisions based on expected credit losses within the next 12 months.

②Criteria for judging whether credit risk has increased significantly since initial recognition

If the default probability of a financial asset within the expected duration determined on the balance sheet date is significantly higher than the default probability within the expected duration determined at initial recognition, it indicates that the credit risk of the financial asset has increased significantly. Except for special circumstances, the Company uses the change in default risk within the next 12 months as a reasonable estimate of the change in default risk throughout the entire duration to determine whether credit risk has increased significantly since initial recognition.

③ Portfolio method to assess expected credit risk on a portfolio basis

The Company evaluates the credit risk of financial assets with significantly different credit risks individually, such as: accounts receivable from related parties; accounts receivable that are in dispute with the other party or involved in litigation or arbitration; accounts receivable that have obvious signs that the debtor is likely to be unable to fulfill its repayment obligations, etc.

In addition to financial assets that assess credit risk individually, the Company divides financial assets into different groups based on common risk characteristics and assesses credit risk on a combined basis.

④Accounting treatment method for impairment of financial assets

91/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

At the end of the period, the Company calculates the estimated credit losses of various financial assets. If the estimated credit losses are greater than the carrying amount of the current impairment provisions, the difference will be recognized as impairment losses; if it is less than the current carrying amount of the impairment provisions, the difference will be recognized as impairment gains. For financial assets measured at amortized cost, the loss provision is deducted from the book value of the financial asset listed in the balance sheet; for debt investments measured at fair value with changes included in other comprehensive income, the company recognizes its loss provision in other comprehensive income and does not deduct the book value of the financial asset.

If the company no longer reasonably expects that the contractual cash flows of a financial asset can be fully or partially recovered, it will directly write down the book balance of the financial asset. Such a write-down constitutes the derecognition of the relevant financial asset. This situation typically occurs when the Company determines that the debtor does not have the assets or sources of income to generate sufficient cash flow to repay the amount that will be written down.

⑤Methods for determining credit losses of various financial assets

A． Notes receivable

The Company measures loss provisions for notes receivable based on an amount equivalent to the expected credit losses during the entire duration. Based on the credit risk characteristics of notes receivable, they are divided into different combinations:

Project Basis for determining combination

Bank acceptance bill The acceptor is a bank with low credit risk

Commercial acceptance bills should be classified according to the credit risk of the acceptor, which should be the same as the "accounts receivable" portfolio.

B. Accounts receivable and contract assets

For receivables and contract assets that do not contain significant financing components, the Company measures loss provisions based on an amount equivalent to the expected credit losses during the entire duration.

For receivables and contract assets that contain significant financing components, the Company chooses to always measure loss provisions at an amount equivalent to the expected credit losses during the duration.

In addition to accounts receivable for individual assessment of credit risk, they are divided into different combinations based on their credit risk characteristics:

For receivables whose individual amounts are not significant on the balance sheet date, the

Accounts receivable that are not impaired after individual testing are aged together as a similar credit risk aging analysis method.

Characteristics are divided into several combinations, and then based on the proportion of the closing amount of these receivable combinations

Impairment losses are calculated and determined at a fixed ratio, and bad debt provisions are made.

C. Other receivables

The company measures impairment losses based on whether the credit risk of other receivables has increased significantly since initial recognition, and uses an amount equivalent to the expected credit losses in the next 12 months or the entire duration. In addition to other receivables whose credit risk is assessed individually, they are divided into different combinations based on their credit risk characteristics:

92/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

For receivables whose individual amounts are not significant on the balance sheet date, the

Accounts receivable that are not impaired after individual testing are aged together as a similar credit risk aging analysis method.

The characteristics are divided into several combinations, and then impairment losses are calculated and determined based on a certain proportion of the closing amounts of these receivable combinations, and bad debt provisions are made.

D. Debt investment

Debt investment mainly accounts for bond investments measured at amortized cost, etc. The company measures impairment losses based on whether its credit risk has increased significantly since initial recognition, using an amount equivalent to the expected credit losses in the next 12 months or the entire duration. E. Debt investment, other debt investment

The company measures impairment losses based on whether its credit risk has increased significantly since initial recognition, using an amount equivalent to the expected credit losses in the next 12 months or the entire duration.

F. Long-term receivables

The company measures impairment losses based on whether its credit risk has increased significantly since initial recognition, using an amount equivalent to the expected credit losses in the next 12 months or the entire duration.

12. Notes receivable

√Applicable □Not applicable

Combination categories and determination basis for bad debt provisions based on credit risk characteristics √ Applicable □ Not applicable

For details, please see Note 5.11, "Financial Instruments"

Account aging calculation method based on aging confirmation credit risk characteristic combination

√Applicable □Not applicable

For details, please see Note 5.11, "Financial Instruments"

Judgment criteria for individual provision of bad debt provisions based on individual provision

√Applicable □Not applicable

For details, please see Note 5.11, "Financial Instruments"

13. Accounts receivable

√Applicable □Not applicable

Combination categories and determination basis for bad debt provisions based on credit risk characteristics √ Applicable □ Not applicable

For details, please see Note 5.11, "Financial Instruments"

Account aging calculation method based on aging confirmation credit risk characteristic combination

√Applicable □Not applicable

For details, please see Note 5.11, "Financial Instruments"

Judgment criteria for single provision based on the determination of individual provision for bad debts

√Applicable □Not applicable

93/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

For details, please see Note 5.11, "Financial Instruments"

14. Receivables Financing

√Applicable □Not applicable

Combination categories and determination basis for bad debt provisions based on credit risk characteristics √ Applicable □ Not applicable

For details, please see Note 5.11, "Financial Instruments"

Account aging calculation method based on aging confirmation credit risk characteristic combination

√Applicable □Not applicable

For details, please see Note 5.11, "Financial Instruments"

Judgment criteria for individual provision of bad debt provisions based on individual provision

√Applicable □Not applicable

For details, please see Note 5.11, "Financial Instruments"

15. Other receivables

√Applicable □Not applicable

Combination categories and determination basis for bad debt provisions based on credit risk characteristics √ Applicable □ Not applicable

For details, please see Note 5.11, "Financial Instruments"

Account aging calculation method based on aging confirmation credit risk characteristic combination

√Applicable □Not applicable

For details, please see Note 5.11, "Financial Instruments"

Judgment criteria for individual provision of bad debt provisions based on individual provision

√Applicable □Not applicable

For details, please see Note 5.11, "Financial Instruments"

16. Inventory

√Applicable □Not applicable

Inventory categories, issue pricing methods, inventory systems, amortization methods for low-value consumables and packaging √ Applicable □ Not applicable

Inventories refer to the finished products or commodities held by the company for sale in daily activities, products in progress during the production process, materials and supplies consumed in the production process or the provision of labor services, etc., mainly including raw materials, products in progress, turnover materials, inventory commodities, etc.

Inventories are valued at actual cost when acquired, and inventory costs include purchase costs, processing costs and other costs. The price is calculated based on the weighted average method at the end of the month when it is collected and issued.

The inventory system of inventories is a perpetual inventory system, which must be taken at least once a year, and the amount of inventory gains and losses shall be included in the current year's profits and losses. Low-value consumables are amortized according to the one-time amortization method when they are used; packaging materials are amortized according to the one-time amortization method when they are used.

94/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Recognition standards and accrual methods for inventory depreciation provisions

√Applicable □Not applicable

Net realizable value refers to the estimated selling price of inventory in daily activities minus the estimated costs to be incurred to completion, estimated selling expenses and related taxes. When determining the net realizable value of inventories, it is based on the conclusive evidence obtained and the purpose of holding the inventories and the impact of events after the balance sheet date are also considered.

The company's finished products, materials for sale and other inventories that are directly for sale, during the normal production and operation process, determine its net realizable value based on the estimated selling price of the inventory minus the estimated sales expenses and related taxes. For inventories held for the execution of sales contracts or service contracts, the contract price is used as the measurement basis of its net realizable value; if the quantity of inventory held is greater than the quantity ordered in the sales contract, the excess net realizable value of the inventory is measured based on the general sales price. For materials used for sale, the market price is used as the measurement basis of their net realizable value. For materials inventories that need to be processed, in the normal production and operation process, the net realizable value is determined by the estimated selling price of the finished products minus the estimated costs to be incurred upon completion, estimated sales expenses and related taxes.

Inventory depreciation provisions are generally withdrawn based on individual inventory items. For inventories with large quantities and low unit prices, inventory depreciation provisions are made based on inventory categories. On the balance sheet date, inventories are measured at the lower of cost and net realizable value. When the net realizable value is lower than the cost, the inventory depreciation reserve is withdrawn. After the provision for inventory depreciation is accrued, if the factors that previously caused the inventory value to be written down have disappeared, causing the net realizable value of the inventory to be higher than its book value, the amount of the inventory depreciation provision that was originally accrued will be reversed, and the amount reversed will be included in the current profit and loss.

The combination categories and basis for determining inventory depreciation provisions according to the combination, and the basis for determining the net realizable value of different types of inventories.

□Applicable √Not applicable

The calculation method and basis for determining the net realizable value of each warehouse age combination based on the inventory age confirmation

□Applicable √Not applicable

17. Contract assets

√Applicable □Not applicable

Recognition methods and standards for contract assets

√Applicable □Not applicable

The Company presents contract assets or contract liabilities in the balance sheet based on the relationship between performance obligations and customer payments. The Company lists the rights of the customer that have not paid the contract consideration but that have fulfilled the performance obligations under the contract and are not unconditional (that is, only dependent on the passage of time) to receive payment from the customer as contract assets in the balance sheet. Contract assets and contract liabilities under the same contract are presented on a net basis, and contract assets and contract liabilities under different contracts are not offset.

Combination categories and determination basis for bad debt provisions based on combinations of credit risk characteristics

√Applicable □Not applicable

For details, please see Note 5.11, "Financial Instruments"

Account aging calculation method based on aging confirmation credit risk characteristic combination

√Applicable □Not applicable

For details, please see Note 5.11, "Financial Instruments"

95/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Judgment criteria for single provision based on the determination of individual provision for bad debts

√Applicable □Not applicable

For details, please see Note 5.11, "Financial Instruments"

18. Non-current assets or disposal groups held for sale

√Applicable □Not applicable

If the company recovers its book value mainly through sale (including non-monetary asset exchange with commercial substance, the same below) rather than continuing to use a non-current asset or disposal group, it will be classified as held for sale. The specific criteria are to meet the following conditions at the same time: a certain non-current asset or disposal group can be sold immediately under the current conditions according to the practice of selling such assets or disposal groups in similar transactions; the company has made a resolution on the sales plan and obtained a firm purchase commitment; the sale is expected to be completed within one year. Among them, a disposal group refers to a group of assets that are disposed of as a whole in a transaction through sale or other means, as well as the liabilities directly related to these assets transferred in the transaction. If the asset group or asset group combination to which the disposal group belongs has allocated the goodwill acquired in the business merger in accordance with the "Accounting Standards for Business Enterprises No. 8 - Asset Impairment", the disposal group shall include the goodwill allocated to the disposal group.

Recognition standards and accounting treatment methods for non-current assets or disposal groups classified as held for sale

√Applicable □Not applicable

When the company initially measures or remeasures and divides the assets into non-current assets and disposal groups held for sale on the balance sheet date, if its book value is higher than the net amount of the fair value minus the selling expenses, the book value will be written down to the net amount of the fair value minus the selling expenses. The amount of the write-down is recognized as an asset impairment loss and included in the current profit and loss. At the same time, a provision for impairment of the assets held for sale is made. For the disposal group, the recognized asset impairment loss is first deducted from the book value of the goodwill in the disposal group, and then deducted proportionally from the book value of various non-current assets in the disposal group that are subject to the measurement provisions of "Accounting Standards for Business Enterprises No. 42 - Non-current Assets Held for Sale, Disposal Groups and Discontinued Operations" (hereinafter referred to as the "Held for Sale Standards"). If the net amount of the fair value of the disposal group held for sale less the selling expenses increases on the subsequent balance sheet date, the previously written-down amount shall be restored and reversed within the amount of asset impairment loss recognized for non-current assets after being classified as held-for-sale and subject to the measurement provisions of the held-for-sale standards. The reversed amount shall be included in the current profit and loss, and According to the proportion of the book value of each non-current asset in the disposal group that is subject to the measurement requirements of the held-for-sale standards, except for goodwill, the book value is increased proportionally; the book value of goodwill that has been deducted, and the asset impairment losses recognized before the non-current assets are classified as held-for-sale categories are not reversed.

No depreciation or amortization is provided for non-current assets held for sale or non-current assets in the disposal group, and interest and other expenses on liabilities in the disposal group held for sale continue to be recognized.

When a non-current asset or disposal group no longer meets the classification conditions of the held-for-sale category, the company will no longer continue to classify it as a held-for-sale category or remove the non-current assets from the held-for-sale disposal group, and measure it according to the lower of the following two: ① The book value before being classified as a held-for-sale category, adjusted for the depreciation, amortization or impairment that would have been recognized if it was not classified as a held-for-sale category; ② The recoverable amount.

Determination standards and presentation methods for discontinued operations

√Applicable □Not applicable

Discontinued operations refer to components that have been disposed of or classified as held for sale by the company and that can be separately distinguished when operating and preparing financial statements that meet one of the following conditions: ① The component represents an independent main business or a main operating area;

96/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

② This component is part of the planned disposal plan for an independent main business or a main operating area; ③ This component is a subsidiary acquired solely for resale.

For the accounting treatment method of discontinued operations, please refer to the relevant description in Note 5.18 "Non-current assets or disposal groups held for sale".

The company separately lists the profit and loss from continuing operations and the profit and loss from discontinued operations in the income statement. For discontinued operations reported in the current period, the company will re-present the information originally presented as profits and losses from continuing operations as profits and losses from discontinued operations in the comparable accounting period in the current financial statements. If the discontinued operations no longer meet the conditions for classification into the held-for-sale category, the company will re-present the information originally presented as profits and losses from discontinued operations as profits and losses from continuing operations in the comparable accounting period in the current financial statements.

19. Long-term equity investment

√Applicable □Not applicable

The Company's long-term equity investments include equity investments that control and have significant influence on the invested units, as well as equity investments in joint ventures. If the company can exert significant influence on the invested unit, it is an associate of the company.

Joint control refers to the company's shared control over an arrangement in accordance with relevant agreements, and the relevant activities of the arrangement must be decided with the unanimous consent of the participants sharing control rights. Significant influence means that the company has the power to participate in decision-making on the financial and operating policies of the investee, but it is not able to control or jointly control the formulation of these policies with other parties.

(1) Determination of investment cost

For long-term equity investments obtained through a business combination under common control, the share of the book value of the merged party's shareholders' equity/owner's equity in the ultimate controlling party's consolidated financial statements on the date of merger shall be regarded as the initial investment cost of the long-term equity investment. The difference between the initial investment cost of long-term equity investment and the cash paid, non-cash assets transferred and the book value of debts assumed shall be adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings shall be adjusted. If the issuance of equity securities is used as the merger consideration, the share of the book value of the merged party's shareholders' equity/owner's equity in the final controlling party's consolidated financial statements on the merger date shall be used as the initial investment cost of the long-term equity investment, and the total face value of the issued shares shall be used as equity capital. The difference between the initial investment cost of the long-term equity investment and the total face value of the shares issued shall be adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings shall be adjusted.

For long-term equity investments obtained through a business combination not under common control, the initial investment cost of the long-term equity investment shall be the merger cost on the acquisition date. The merger cost includes the sum of the assets paid by the purchaser, liabilities incurred or assumed, and the fair value of the equity securities issued.

Intermediary fees such as auditing, legal services, evaluation and consulting, and other related administrative expenses incurred by the merging party or purchaser during a business merger shall be included in the current profit and loss when incurred.

Equity investments other than long-term equity investments formed through business combinations are initially measured at cost. Depending on the way in which the long-term equity investment is acquired, the cost is determined based on the actual cash purchase price paid by the company, the fair value of the equity securities issued by the company, the value stipulated in the investment contract or agreement, the fair value or original book value of the assets exchanged in non-monetary asset exchange transactions, the fair value of the long-term equity investment itself, etc. Fees, taxes and other necessary expenses directly related to obtaining long-term equity investment are also included in the investment cost. For additional investment that can have a significant impact on the investee or impose common

97/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

If it controls but does not constitute control, the cost of long-term equity investment is the sum of the fair value of the original equity investment determined in accordance with the "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" plus the new investment cost.

(2) Subsequent measurement and profit and loss recognition methods

Long-term equity investments that have joint control (except for joint operators) or significant influence on the investee unit are accounted for using the equity method. In addition, the company's financial statements adopt the cost method to account for long-term equity investments that can control the invested unit. ①Long-term equity investment accounted for by cost method

When accounting using the cost method, long-term equity investment is valued at the initial investment cost, and the cost of long-term equity investment is adjusted when additional investment or withdrawal of investment is made. Except for the actual price paid when acquiring the investment or the cash dividends or profits that have been declared but not yet distributed included in the consideration, the current investment income is recognized according to the cash dividends or profits declared and distributed by the investee.

②Long-term equity investment accounted for by equity method

When accounting using the equity method, if the initial investment cost of a long-term equity investment is greater than the fair value share of the investee's identifiable net assets at the time of investment, the initial investment cost of the long-term equity investment will not be adjusted; if the initial investment cost is less than the fair value share of the investee's identifiable net assets at the time of investment, the difference will be included in the current profit and loss, and the cost of the long-term equity investment will be adjusted at the same time.

When accounting using the equity method, investment income and other comprehensive income are recognized respectively according to the share of the net profit or loss and other comprehensive income realized by the investee, and the book value of the long-term equity investment is adjusted at the same time. The book value of the long-term equity investment is calculated based on the profit or cash dividend declared by the investee to be distributed, and the book value of the long-term equity investment is reduced accordingly. For other changes in the owner's equity of the invested unit other than net profits and losses, other comprehensive income and profit distribution, the book value of the long-term equity investment is adjusted and included in the owner's equity. When confirming the share of the investee's net profits and losses, the net profit of the investee is adjusted and recognized based on the fair value of the investee's identifiable assets when the investment is obtained. If the accounting policies and accounting periods adopted by the invested unit are inconsistent with those of the Company, the financial statements of the invested unit shall be adjusted in accordance with the Company's accounting policies and accounting periods, and investment income and other comprehensive income shall be recognized accordingly. Unrealized gains and losses from internal transactions between the Company and its associates and joint ventures are offset to the portion attributable to the Company calculated in proportion to the Company's share of the profits and losses, and investment gains and losses are recognized on this basis. However, if the unrealized internal transaction losses between the company and the investee are impairment losses on the transferred assets, they should be recognized in full. If the assets invested by the company into a joint venture or associated enterprise constitute a business, and the investor obtains a long-term equity investment but does not obtain control, the fair value of the invested business shall be used as the initial investment cost of the new long-term equity investment. The difference between the initial investment cost and the book value of the invested business shall be fully included in the current profit and loss. If the assets sold by the company to a joint venture or associated enterprise constitute a business, the difference between the consideration obtained and the book value of the business shall be fully included in the current profit and loss. If the assets purchased by the company from associates and joint ventures constitute a business, accounting treatment shall be carried out in accordance with the provisions of "Accounting Standards for Business Enterprises No. 20 - Business Merger", and the gains or losses related to the transaction shall be recognized in full.

When confirming the share of the net losses incurred by the investee, the book value of the long-term equity investment and other long-term interests that essentially constitute the net investment in the investee are reduced to zero. In addition, if the company has an obligation to bear additional losses to the investee, it will recognize estimated liabilities based on the estimated obligations and include them in the current investment losses. If the invested unit realizes net profit in the subsequent period, the company will resume recognition of the income sharing amount after the income sharing amount makes up for the unrecognized loss sharing amount.

98/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

For long-term equity investments in associates and joint ventures held by the Company before the first implementation of the new accounting standards, if there is any equity investment debit balance related to the investment, the amount will be included in the current profit and loss based on the straight-line amortization of the original remaining period.

③Disposal of long-term equity investments

In the consolidated financial statements, if the parent company partially disposes of the long-term equity investment in the subsidiary without losing control, the difference between the disposal price and the net assets of the subsidiary corresponding to the disposal of the long-term equity investment is included in shareholders' equity; if the parent company partially disposes of the long-term equity investment in the subsidiary, resulting in the loss of control over the subsidiary, it shall be handled in accordance with the relevant accounting policies described in Note 5.7, "Method for Preparation of Consolidated Financial Statements".

For the disposal of long-term equity investments under other circumstances, the difference between the book value of the disposed equity and the actual price obtained shall be included in the current profit and loss.

For long-term equity investments accounted for using the equity method, if the remaining equity after disposal is still accounted for using the equity method, the portion of other comprehensive income originally included in shareholders' equity at the time of disposal will be accounted for in proportion and on the same basis as if the investee directly disposed of relevant assets or liabilities. Owner's equity recognized due to changes in other owners' equity of the investee other than net profit and loss, other comprehensive income and profit distribution shall be carried forward to the current profit and loss on a proportional basis.

For long-term equity investments accounted for using the cost method, if the remaining equity after disposal is still accounted for using the cost method, other comprehensive income recognized by using the equity method or financial instrument recognition and measurement standards before obtaining control over the investee shall be calculated using the method directly related to the investee. Accounting treatment is carried out on the same basis as the disposal of relevant assets or liabilities, and the profits and losses of the current period are carried forward in proportion; changes in other owners' equity other than net profits and losses, other comprehensive income and profit distribution in the net assets of the investee recognized due to the use of equity method accounting are carried forward to the profits and losses of the current period in proportion.

If the company loses control over the invested unit due to the disposal of part of its equity investment, when preparing individual financial statements, if the remaining equity after disposal can jointly control or exert significant influence on the invested unit, it shall be accounted for according to the equity method instead, and the remaining equity shall be deemed to have adopted equity since the time of acquisition. If the remaining equity after disposal cannot jointly control or exert significant influence on the invested unit, the accounting treatment shall be carried out in accordance with the relevant provisions of the financial instrument recognition and measurement standards, and the difference between its fair value and book value on the date of loss of control shall be included in the current profit and loss. For other comprehensive income recognized due to the use of equity method accounting or financial instrument recognition and measurement standards before the company obtains control of the invested unit, when it loses control of the invested unit, it will be accounted on the same basis as the invested unit's direct disposal of relevant assets or liabilities. Other changes in owner's equity in the net assets of the invested unit recognized due to the use of equity method accounting, except for net profit and loss, other comprehensive income and profit distribution, will be carried forward to the current profit and loss when it loses control of the invested unit. Among them, if the remaining equity after disposal is accounted for using the equity method, other comprehensive income and other owners' equity will be carried forward in proportion; if the remaining equity after disposal is accounted for in accordance with the financial instrument recognition and measurement standards, all other comprehensive income and other owners' equity will be carried forward.

If the company loses joint control or significant influence on the investee due to the disposal of part of its equity investment, the remaining equity after disposal will be accounted for in accordance with the financial instrument recognition and measurement standards, and the difference between its fair value and book value on the date of loss of joint control or significant influence will be included in the current profit and loss. Other comprehensive income recognized due to the use of the equity method for accounting in the original equity investment shall be accounted for on the same basis as the investee's direct disposal of relevant assets or liabilities when the use of the equity method is terminated.

99/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Owners' equity recognized from changes in other owners' equity other than net profit and loss, other comprehensive income and profit distribution will all be transferred to the investment income of the current period when the equity method is terminated.

20. Investment real estate

(1). If the cost measurement model is adopted

Depreciation or amortization method

Investment property is property held to earn rentals or for capital appreciation, or both. Including leased land use rights, land use rights held and prepared to be transferred after appreciation, leased buildings, etc.

Investment properties are initially measured at cost. Subsequent expenditures related to investment real estate shall be included in the cost of investment real estate if the economic benefits related to the asset are likely to flow in and its cost can be measured reliably. Other subsequent expenditures shall be included in the current profits and losses when incurred.

The Company adopts the cost model for subsequent measurement of investment real estate, and conducts depreciation or amortization in accordance with policies consistent with buildings or land use rights.

Please refer to Note V. 27 "Impairment of Long-term Assets" for details on the impairment testing method and impairment provision method for investment real estate.

When self-use real estate or inventory is converted into investment real estate or investment real estate is converted into self-use real estate, the book value before conversion shall be used as the entry value after conversion.

When the purpose of investment real estate is changed to self-use, the investment real estate will be converted into fixed assets or intangible assets from the date of change. When the purpose of self-occupied real estate is changed to earn rent or capital appreciation, the fixed assets or intangible assets will be converted into investment real estate from the date of change. When a conversion occurs, if it is converted into an investment real estate measured using the cost model, the book value before conversion will be used as the entry value after the conversion; if it is converted into an investment real estate measured using the fair value model, the fair value on the date of conversion will be used as the entry value after the conversion.

When an investment real estate is disposed of, or is permanently withdrawn from use and no economic benefits are expected to be obtained from its disposal, the investment real estate shall be derecognised. The disposal income from the sale, transfer, scrapping or damage of investment real estate shall be included in the current profit and loss after deducting its book value and relevant taxes.

21. Fixed assets

(1). Confirm conditions

√Applicable □Not applicable

Fixed assets refer to tangible assets held for the production of goods, provision of labor services, leasing or operation and management, and with a useful life of more than one accounting year. Fixed assets are recognized only when the economic benefits related to them are likely to flow to the company and their costs can be measured reliably.

(2). Depreciation method

√Applicable □Not applicable

Depreciation is calculated using the straight-line method over the useful life of a fixed asset starting from the month after it reaches its intended usable condition. The useful lives, estimated net residual values and annual depreciation rates of various types of fixed assets are as follows:

Category Depreciation method Depreciation life (years) Residual value rate (%) Annual depreciation rate (%)

100/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Houses and buildings Average age method 10-35 5.00 9.50-2.71

Machinery and equipment Average age method 5-10 5.00 19.00-9.50

Transportation equipment average age method 5-10 5.00 19.00-9.50

Electronic equipment and other average years method 3-5 5.00 31.67-19.00

22. Projects under construction

√Applicable □Not applicable

The cost of construction in progress is determined based on actual project expenditures, including various project expenditures incurred during the construction period, capitalized borrowing costs before the project reaches its intended usable state, and other related expenses. Construction in progress will be transferred to fixed assets after reaching the intended usable state. Fixed assets that have been constructed and have reached the intended usable state, but have not yet completed the final settlement, will be transferred to fixed assets at an estimated value based on the project budget, cost or actual project cost from the date they reach the intended usable state, and depreciation of the fixed assets will be accrued in accordance with the company's fixed asset depreciation policy. After the final settlement is processed, the original estimated value will be adjusted based on the actual cost, but the originally accrued depreciation amount will not be adjusted.

Please refer to Note V. 27 "Impairment of Long-term Assets" for details on the impairment testing method and impairment provision accrual method for projects under construction.

23. Borrowing costs

√Applicable □Not applicable

Borrowing costs include borrowing interest, amortization of discounts or premiums, auxiliary expenses, and exchange differences arising from foreign currency borrowings. Borrowing costs directly attributable to the acquisition, construction or production of assets that meet the capitalization conditions shall be capitalized when asset expenditures have been incurred, borrowing costs have been incurred, and the acquisition, construction or production activities necessary to bring the assets to the intended usable or salable state have begun; capitalization shall cease when the assets constructed or produced that meet the capitalization conditions have reached the intended usable or salable state. The remaining borrowing costs are recognized as expenses in the current period.

The interest expenses actually incurred on special borrowings in the current period shall be capitalized after deducting the interest income from unused borrowed funds deposited in banks or investment income from temporary investments; the capitalization amount of general borrowings shall be determined based on the weighted average of asset disbursements exceeding the part of special borrowings multiplied by the capitalization rate of the occupied general borrowings. The capitalization rate is calculated and determined based on the weighted average interest rate of general borrowings.

During the capitalization period, all exchange differences on special foreign currency borrowings are capitalized; exchange differences on general foreign currency borrowings are included in the current profits and losses.

Assets that qualify for capitalization refer to fixed assets, investment real estate, inventories and other assets that require a considerable period of acquisition, construction or production activities to reach the intended usable or salable state.

If an asset that meets the capitalization conditions is abnormally interrupted during the acquisition, construction or production process, and the interruption lasts for more than 3 months, the capitalization of borrowing costs will be suspended until the acquisition, construction or production activities of the asset are restarted.

24. Biological assets

□Applicable √Not applicable

25. Oil and gas assets

□Applicable √Not applicable

101/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

26. Intangible assets

(1). Useful life and its determination basis, estimation, amortization method or review procedure

√Applicable □Not applicable

Intangible assets refer to identifiable non-monetary assets without physical form owned or controlled by the company.

Intangible assets are initially measured at cost. Expenditures related to intangible assets are included in the cost of intangible assets if the relevant economic benefits are likely to flow into the company and their costs can be measured reliably. Expenditures on other items other than these are included in the current profits and losses when incurred.

Acquired land use rights are usually accounted for as intangible assets. For self-developed and constructed factories and other buildings, the related land use right expenditures and building construction costs are accounted for as intangible assets and fixed assets respectively. In the case of outsourced houses and buildings, the relevant price will be allocated between the land use rights and the buildings. If it is difficult to reasonably distribute them, all of them will be treated as fixed assets.

From the time when an intangible asset with a limited service life becomes available for use, its original value minus the estimated net residual value and the cumulative amount of impairment reserves that have been provided are amortized evenly in installments using the straight-line method over its estimated service life. Intangible assets with indefinite useful lives are not amortized. At the end of the period, the service life and amortization method of intangible assets with limited service life are reviewed, and any changes are treated as changes in accounting estimates. In addition, the service life of intangible assets with indefinite service life is also reviewed. If there is evidence that the intangible asset will bring economic benefits to the enterprise for a foreseeable period, its service life is estimated and amortized in accordance with the amortization policy for intangible assets with limited service life.

Please refer to Note V. 27, "Impairment of Long-term Assets" for details on the impairment testing method and impairment provision method for intangible assets.

(2). Scope of aggregation of R&D expenditures and related accounting treatment methods

√Applicable □Not applicable

The Company's internal research and development project expenditures are divided into research stage expenditures and development stage expenditures.

Expenditures in the research stage are included in the current profits and losses when incurred.

Expenditures in the development stage that meet the following conditions at the same time are recognized as intangible assets. Expenditures in the development stage that do not meet the following conditions are included in the current profit and loss:

① It is technically feasible to complete the intangible asset so that it can be used or sold;

② Have the intention to complete the intangible asset and use or sell it;

③The way intangible assets generate economic benefits includes being able to prove that there is a market for the products produced using the intangible assets or that the intangible assets themselves have a market. If the intangible assets will be used internally, their usefulness can be proven;

④ Have sufficient technical, financial and other resource support to complete the development of the intangible assets, and have the ability to use or sell the intangible assets;

⑤ The expenditures attributable to the development stage of the intangible asset can be measured reliably.

If it is impossible to distinguish between expenditures in the research stage and expenditures in the development stage, all R&D expenditures incurred will be included in the current profit and loss.

27. Impairment of long-term assets

√Applicable □Not applicable

102/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

For non-current non-financial assets such as fixed assets, projects under construction, right-of-use assets, intangible assets with limited useful lives, investment properties measured using the cost model, and long-term equity investments in subsidiaries, joint ventures, and associates, the Company determines whether there are signs of impairment on the balance sheet date. If there is any indication of impairment, the recoverable amount is estimated and an impairment test is performed. Goodwill, intangible assets with indefinite useful lives and intangible assets that have not yet reached a usable state are subject to impairment testing every year regardless of whether there are signs of impairment.

If the impairment test results show that the recoverable amount of the asset is lower than its book value, impairment provisions will be made based on the difference and included in the impairment loss. The recoverable amount is the higher of the asset's fair value less disposal costs and the present value of the asset's expected future cash flows. The fair value of an asset is determined based on the sales agreement price in a fair transaction; if there is no sales agreement but there is an active market for the asset, the fair value is determined based on the buyer's bid for the asset; if there is no sales agreement and there is an active market for the asset, the fair value of the asset is estimated based on the best information available. Disposal costs include legal fees, related taxes, transportation fees and direct costs incurred in bringing the assets to a salable condition. The present value of the estimated future cash flows of an asset is determined by selecting an appropriate discount rate to discount the estimated future cash flows generated during the continued use and final disposal of the asset. Asset impairment provisions are calculated and recognized on the basis of individual assets. If it is difficult to estimate the recoverable amount of an individual asset, the recoverable amount of the asset group to which the asset belongs is determined. An asset group is the smallest combination of assets that can independently generate cash inflows.

For goodwill that is presented separately in the financial statements, when performing impairment testing, the book value of the goodwill is allocated to the asset group or combination of asset groups that are expected to benefit from the synergy effects of the business combination. If the test results show that the recoverable amount of an asset group or combination of asset groups containing amortized goodwill is lower than its book value, the corresponding impairment loss will be recognized. The amount of impairment loss first deducts the book value of the goodwill allocated to the asset group or asset group combination, and then deducts the book value of other assets in proportion to the proportion of the book value of other assets in the asset group or asset group combination except goodwill.

Once the above-mentioned asset impairment losses are recognized, the portion whose value has been restored will not be reversed in subsequent periods.

28. Long-term deferred expenses

√Applicable □Not applicable

Long-term deferred expenses are expenses that have been incurred but should be borne by the reporting period and subsequent periods with an amortization period of more than one year. The company's long-term deferred expenses mainly include molds, decoration and renovation fees, service fees and maintenance fees. Long-term deferred expenses are amortized on a straight-line basis over the expected benefit period.

29. Contract liabilities

√Applicable □Not applicable

The Company presents contract assets or contract liabilities in the balance sheet based on the relationship between performance obligations and customer payments. Contract liabilities refer to the company's obligation to transfer goods to customers for consideration it has received or receivable from customers. If the customer has paid the contract consideration or the company has obtained the unconditional right to receive payment before the company transfers the goods to the customer, the company will list the amount received or receivable as a contract liability at the earlier of the actual payment by the customer and the amount due. Contract assets and contract liabilities under the same contract are presented on a net basis, and contract assets and contract liabilities under different contracts are not offset.

103/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

30. Employee compensation

(1).Accounting treatment method of short-term compensation

√Applicable □Not applicable

The company's employee compensation mainly includes short-term compensation, post-employment benefits, termination benefits and other long-term employee benefits.

Among them, short-term remuneration mainly includes wages, bonuses, allowances and subsidies, employee welfare fees, medical insurance premiums, maternity insurance premiums, work-related injury insurance premiums, housing provident funds, labor union funds and employee education funds, non-monetary benefits, etc. The company recognizes actual short-term employee benefits as liabilities during the accounting period when employees provide services to the company, and includes them in current profits and losses or related asset costs. Among them, non-monetary benefits are measured at fair value.

(2).Accounting treatment of post-employment benefits

√Applicable □Not applicable

Post-employment benefits mainly include basic pension insurance, unemployment insurance and annuities. Post-employment benefit plans include defined contribution plans and defined benefit plans. If a defined contribution plan is adopted, the corresponding deposit amount payable shall be included in the relevant asset cost or current profit and loss when incurred.

(3).Accounting treatment of dismissal benefits

√Applicable □Not applicable

When the company terminates the labor relationship with employees before the expiration of the employee's labor contract, or makes a proposal to provide compensation to encourage employees to voluntarily accept layoffs, when the company cannot unilaterally withdraw the dismissal benefits provided by the termination of labor relationship plan or layoff proposal, and the company confirms the costs related to the restructuring involving the payment of dismissal benefits, whichever is earlier, the employee compensation liabilities arising from the dismissal benefits are recognized and included in the current profit and loss. However, if dismissal benefits are not expected to be fully paid twelve months after the end of the annual reporting period, they will be treated as other long-term employee benefits.

Internal employee retirement plans are treated on the same principles as the above-mentioned termination benefits. The company will include the wages and social insurance premiums to be paid to early retirees from the date when the employees stop providing services to the normal retirement date, etc., when they meet the conditions for recognition of estimated liabilities, and included in the current profit and loss (dismissal benefits).

(4). Accounting treatment methods for other long-term employee benefits

√Applicable □Not applicable

Other long-term employee benefits provided by the company to employees that comply with the defined contribution plan shall be accounted for in accordance with the defined contribution plan; otherwise, they shall be accounted for in accordance with the defined benefit plan.

31. Estimated liabilities

√Applicable □Not applicable

When obligations related to contingencies meet the following conditions at the same time, they are recognized as estimated liabilities: (1) The obligation is a current obligation assumed by the company; (2) Fulfillment of the obligation is likely to result in an outflow of economic benefits; (3) The amount of the obligation can be measured reliably.

On the balance sheet date, estimated liabilities are measured based on the best estimate of the expenditure required to fulfill the relevant current obligations, taking into account factors such as risks, uncertainties and the time value of money related to contingencies.

104/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

If all or part of the expenses required to settle estimated liabilities are expected to be compensated by a third party, the compensation amount will be recognized separately as an asset when it is basically certain that it will be received, and the recognized compensation amount will not exceed the book value of the estimated liabilities.

(1) Loss-making contract

Onerous contracts are contracts in which the unavoidable costs of fulfilling contractual obligations exceed the expected economic benefits. If a contract to be executed becomes a loss-making contract, and the obligations arising from the loss-making contract meet the above recognition conditions for estimated liabilities, the excess of the expected losses from the contract over the recognized impairment losses (if any) of the underlying assets of the contract shall be recognized as estimated liabilities.

(2) Reorganization obligations

For a reorganization plan that is detailed, formal and has been announced to the outside world, if the aforementioned recognition conditions for estimated liabilities are met, the amount of estimated liabilities will be determined based on the direct expenditures related to the restructuring. Regarding the restructuring obligation to sell part of the business, the obligation related to the restructuring will only be recognized when the Company commits to sell part of the business (i.e., enters into a binding sale agreement).

32. Share-based payment

√Applicable □Not applicable

(1) Accounting treatment method for share-based payment

Share-based payment is a transaction in which equity instruments are granted or liabilities determined based on equity instruments are granted in order to obtain services from employees or other parties. Share-based payment is divided into equity-settled share-based payment and cash-settled share-based payment.

① Equity-settled share-based payment

Equity-settled share-based payments in exchange for services provided by employees are measured at the fair value of the equity instruments granted to employees on the date of grant. If the amount of the fair value becomes exercisable after completing the services during the waiting period or meeting the specified performance conditions, it will be calculated on a straight-line basis and included in the relevant costs or expenses during the waiting period based on the best estimate of the number of exercisable equity instruments. If the amount becomes exercisable immediately after the grant, the amount will be included in the relevant costs or expenses on the date of grant, and the capital reserve will be increased accordingly.

On each balance sheet date during the waiting period, the Company makes its best estimate based on the latest changes in the number of vested employees and other subsequent information, and corrects the number of equity instruments expected to be vested. The impact of the above estimates is included in the relevant costs or expenses of the current period, and the capital reserve is adjusted accordingly.

For equity-settled share-based payments in exchange for services from other parties, if the fair value of the other party's services can be reliably measured, it will be measured based on the fair value of the other party's services on the date of acquisition. If the fair value of the other party's services cannot be reliably measured, but the fair value of the equity instrument can be reliably measured, it will be measured based on the fair value of the equity instrument on the date of service acquisition, and will be included in relevant costs or expenses, and shareholders' equity will be increased accordingly.

②Cash-settled share-based payment

Cash-settled share-based payments are measured based on the fair value of the company's liabilities determined based on shares or other equity instruments. If the rights are exercisable immediately after grant, the relevant costs or expenses will be included on the date of grant, and the liabilities will be increased accordingly; if the rights must be completed after the services during the waiting period or the specified performance conditions are met before the rights can be exercised, on each balance sheet date of the waiting period, based on the best estimate of the vesting situation and the fair value of the liabilities borne by the company, the services obtained in the current period will be included in the costs or expenses, and the liabilities will be increased accordingly.

105/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

On each balance sheet date and settlement date before the settlement of relevant liabilities, the fair value of the liability is remeasured, and its changes are included in the current profit and loss.

(2) Relevant accounting treatment for modifying and terminating share-based payment plans

When the company modifies the share-based payment plan, if the modification increases the fair value of the equity instruments granted, the increase in services obtained shall be recognized accordingly based on the increase in the fair value of the equity instruments. The increase in the fair value of equity instruments refers to the difference between the fair values ​​of the equity instruments before and after the modification on the modification date. If the modification reduces the total fair value of share-based payment or adopts other methods that are unfavorable to employees, the accounting treatment for the services obtained will continue, and it will be deemed that the change has never occurred, unless the company cancels some or all of the equity instruments that have been granted.

During the waiting period, if the granted equity instruments are canceled, the company will treat the cancellation of the granted equity instruments as accelerated exercise, and the amount that should be recognized during the remaining waiting period will be immediately included in the current profit and loss, and the capital reserve will be recognized at the same time. If employees or other parties can choose to meet the non-vesting conditions but fail to do so within the waiting period, the company will treat it as the cancellation of the equity instruments granted. (3) Accounting treatment involving share-based payment transactions between the company and its shareholders or actual controllers

For share-based payment transactions involving the company and its shareholders or actual controllers, if one of the settlement enterprise and the service-receiving enterprise is within the company and the other is outside the company, accounting treatment will be carried out in the company's consolidated financial statements in accordance with the following provisions:

① If the settlement enterprise settles the transaction with its own equity instruments, the share-based payment transaction will be treated as equity-settled share-based payment; otherwise, the share-based payment transaction will be treated as cash-settled share-based payment.

If the settlement enterprise is an investor in the enterprise that receives services, it shall be recognized as a long-term equity investment in the enterprise that receives services based on the fair value of the equity instruments or the fair value of the liabilities on the date of grant, and the capital reserve (other capital reserve) or liabilities shall be recognized at the same time.

② If the service-receiving enterprise has no settlement obligation or the equity instruments granted to the employees of the enterprise are its own equity instruments, the share-based payment transaction shall be treated as equity-settled share-based payment; if the service-receiving enterprise has settlement obligations and the equity instruments granted to the employees of the enterprise are not its own equity instruments, the share-based payment transaction shall be treated as cash-settled share-based payment.

For share-based payment transactions that occur between enterprises within the company, if the service-receiving enterprise and the settlement enterprise are not the same enterprise, the recognition and measurement of the share-based payment transaction in the respective financial statements of the service-receiving enterprise and the settlement enterprise shall be handled in accordance with the above principles.

33. Preferred shares, perpetual bonds and other financial instruments

□Applicable √Not applicable

34. Income

(1). Disclose the accounting policies adopted for revenue recognition and measurement according to business type

√Applicable □Not applicable

When the contract between the company and the customer meets the following conditions at the same time, revenue is recognized when the customer obtains control of the relevant goods: the parties to the contract have approved the contract and promised to perform their respective obligations; the contract clarifies the rights and obligations of the parties to the contract related to the transferred goods or the provision of labor services; the contract has clear payment terms related to the transferred goods; the contract has commercial substance, that is, the performance of the contract will change the risk, time distribution or amount of the company's future cash flows; the consideration that the company is entitled to receive for transferring goods to the customer is likely to be recovered.

106/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

On the contract inception date, the Company identifies each individual performance obligation that exists in the contract, and allocates the transaction price to each individual performance obligation in accordance with the relative proportion of the standalone selling price of the goods promised by each individual performance obligation. When determining the transaction price, the impact of variable consideration, significant financing components in the contract, non-cash consideration, consideration payable to customers and other factors was considered.

For each individual performance obligation in the contract, if one of the following conditions is met, the company will recognize the transaction price allocated to the individual performance obligation as revenue according to the performance progress during the relevant performance period: the customer obtains and consumes the company at the same time that the company performs the contract. The economic benefits brought by the performance of the contract; the customer can control the goods under construction during the company's performance of the contract; the goods produced by the company during the performance of the contract have irreplaceable uses, and the company has the right to collect payment for the cumulative performance part that has been completed so far during the entire contract period. The progress of contract performance is determined using the input method or the output method according to the nature of the transferred goods. When the progress of contract performance cannot be reasonably determined and the costs incurred by the company are expected to be compensated, revenue will be recognized based on the amount of costs incurred until the progress of contract performance can be reasonably determined.

If one of the above conditions is not met, the company will recognize revenue at the transaction price allocated to the individual performance obligation at the point when the customer obtains control of the relevant goods. When judging whether the customer has obtained control of the goods, the company considers the following signs: the company has the current right to receive payment for the goods, that is, the customer has current payment obligations for the goods; the company has transferred the legal ownership of the goods to the customer, that is, the customer already has the legal ownership of the goods; the company has The commodity is physically transferred to the customer, which means that the customer has physically taken possession of the commodity; the enterprise has transferred the main risks and rewards of ownership of the commodity to the customer, that is, the customer has obtained the main risks and rewards of ownership of the commodity; the customer has accepted the commodity; and other signs indicate that the customer has obtained control of the commodity.

The company's business of selling goods usually includes the transfer of the performance obligations of the goods. When the company ships the goods to the customer's designated location and the customer signs for receipt on the delivery note or entrusted transportation record, the control of the goods is transferred, and the company recognizes the realization of revenue at that point.

(2) Similar businesses using different business models involve different revenue recognition methods and measurement methods

□Applicable √Not applicable

35. Contract costs

√Applicable □Not applicable

Contract costs include contract performance costs and contract acquisition costs.

If the costs incurred by the company to perform the contract do not fall within the scope of accounting standards other than "Accounting Standards for Business Enterprises No. 14 - Revenue (2017 Revision)" and meet the following conditions at the same time, they are recognized as an asset as the cost of contract performance: ① The cost is consistent with a current or expected cost Directly related to the contract obtained, including direct labor, direct materials, manufacturing overhead (or similar expenses), costs clearly borne by the customer, and other costs incurred solely because of the contract; ② This cost increases the company's future resources for fulfilling performance obligations; ③ This cost is expected to be recovered. The asset is reported in inventory or other non-current assets based on whether its amortization period at initial recognition exceeds one normal operating cycle.

The incremental costs incurred by the Company to obtain the contract are expected to be recovered and are recognized as an asset as the contract acquisition cost. However, if the amortization period of the asset does not exceed one year, it will be included in the current profit and loss when incurred.

Assets related to contract costs are amortized on the same basis as the commodity revenue recognition related to the asset and included in the current profit and loss.

107/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

36. Government subsidies

√Applicable □Not applicable

Government subsidies refer to the monetary assets and non-monetary assets that the company obtains free of charge from the government, excluding capital invested by the government as an investor and enjoying corresponding owner's rights. Government subsidies are divided into asset-related government subsidies and income-related government subsidies. The company defines the government subsidies obtained for the purchase, construction or other formation of long-term assets as asset-related government subsidies; the remaining government subsidies are defined as income-related government subsidies. If the government document does not clearly stipulate the subsidy object, the following method will be used to divide the subsidy into income-related government subsidies and asset-related government subsidies: (1) If the government document clarifies the specific project for which the subsidy is targeted, the expenditure of the asset will be formed in the budget of the specific project. The amount and the relative proportion of the expenditure included in expenses shall be divided. The division proportion shall be reviewed on each balance sheet date and changed if necessary; (2) If the purpose is only a general statement in the government document and no specific project is specified, it shall be regarded as a government subsidy related to income. If government subsidies are monetary assets, they shall be measured based on the amount received or receivable. If the government subsidy is a non-monetary asset, it shall be measured at fair value; if the fair value cannot be obtained reliably, it shall be measured at the nominal amount. Government subsidies measured according to the nominal amount are directly included in the current profit and loss.

The Company usually recognizes and measures government subsidies based on the actual amount received when they are actually received. However, if there is conclusive evidence at the end of the period that it can meet the relevant conditions stipulated in the financial support policy and is expected to receive financial support funds, it will be measured according to the amount receivable. Government subsidies measured based on the amount receivable shall meet the following conditions: (1) The amount of the subsidy receivable has been confirmed by a document issued by the competent government department, or can be reasonably calculated by oneself in accordance with the relevant provisions of the officially released fiscal fund management measures, and the amount is not expected to have significant uncertainty; (2) It is based on the fiscal support projects and fiscal fund management officially announced by the local financial department and proactively disclosed in accordance with the "Government Information Disclosure Regulations" The management method should be universal (any enterprise that meets the specified conditions can apply), rather than formulated specifically for specific enterprises; (3) The relevant subsidy approval documents have clearly promised the disbursement period, and the disbursement of the funds is guaranteed by the corresponding financial budget, so it can be reasonably guaranteed to be received within the specified period; (4) Other relevant conditions (if any) that should be met according to the specific circumstances of the company and the subsidy matter.

Government subsidies related to assets are recognized as deferred income and included in current profits and losses in installments in a reasonable and systematic manner within the useful life of the relevant assets. If government subsidies related to income are used to compensate for relevant costs, expenses or losses in the future period, they are recognized as deferred income and included in the current profit and loss during the period when the relevant costs, expenses or losses are recognized; if they are used to compensate for relevant costs, expenses or losses that have already occurred, they are directly included in the current profits and losses.

Government subsidies that include both asset-related parts and income-related parts are distinguished and accounted for separately. If it is difficult to distinguish, the whole is classified as income-related government subsidies.

Government subsidies related to the company's daily activities shall be included in other income or offset related costs and expenses according to the nature of the economic business; government subsidies unrelated to daily activities shall be included in non-operating income and expenses.

When a recognized government subsidy needs to be returned, if there is a relevant deferred income balance, the book balance of the relevant deferred income will be offset, and the excess will be included in the current profit and loss or (for asset-related government subsidies that offset the book value of the relevant assets at the time of initial recognition) the book value of the asset will be adjusted; in other cases, it will be directly included in the current profit and loss.

108/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

37. Deferred income tax assets/deferred income tax liabilities

√Applicable □Not applicable

Income tax includes current income tax and deferred income tax. Except for the current income tax and deferred income tax related to transactions and events recognized as other comprehensive income or directly included in shareholders' equity, which are included in other comprehensive income or shareholders' equity, and the deferred income tax arising from business combinations adjusts the book value of goodwill, the remaining current income tax and deferred income tax expenses or income are included in the current profit and loss.

(1) Current income tax

On the balance sheet date, current income tax liabilities (or assets) formed in the current and previous periods are measured based on the amount of income tax expected to be paid (or refunded) calculated in accordance with the provisions of tax laws. The taxable income based on which the income tax expense for the current period is calculated is calculated based on the relevant tax laws and regulations by making corresponding adjustments to the pre-tax accounting profit for the reporting period.

(2) Deferred income tax assets and deferred income tax liabilities

The company usually uses the balance sheet liability method to recognize and measure the impact of taxable temporary differences or deductible temporary differences on income tax as deferred income tax liabilities or deferred income tax assets based on the temporary differences between the book values and tax bases of assets and liabilities on the balance sheet date. The Company does not discount deferred income tax assets and deferred income tax liabilities.

Deferred income tax liabilities will not be recognized for taxable temporary differences related to the initial recognition of goodwill and the initial recognition of assets or liabilities arising from transactions that are neither business combinations nor affect accounting profits and taxable income (or deductible losses) at the time of occurrence. In addition, for taxable temporary differences related to investments in subsidiaries, associates and joint ventures, if the company can control the timing of the reversal of the temporary differences, and the temporary differences are likely not to be reversed in the foreseeable future, the relevant deferred income tax liabilities will not be recognized. Except for the above exceptions, the Company recognizes deferred income tax liabilities arising from all other taxable temporary differences.

Deductible temporary differences related to the initial recognition of assets or liabilities arising from transactions that are neither business combinations nor affect accounting profits and taxable income (or deductible losses) at the time of occurrence shall not be recognized as deferred income tax assets. In addition, for deductible temporary differences related to investments in subsidiaries, associates and joint ventures, if the temporary differences are not likely to be reversed in the foreseeable future, or it is not likely to be taxable income that can be used to offset the deductible temporary differences in the future, the relevant deferred income tax assets will not be recognized. Except for the above exceptions, the Company recognizes deferred income tax assets arising from other deductible temporary differences to the extent that it is likely to obtain taxable income that can be used to offset the deductible temporary differences.

For deductible losses and tax credits that can be carried forward to future years, the corresponding deferred income tax assets are recognized to the extent that it is probable that the future taxable income will be used to offset the deductible losses and tax credits.

On the balance sheet date, deferred income tax assets and deferred income tax liabilities are measured at the applicable tax rate during the period when the relevant assets are expected to be recovered or the relevant liabilities are settled in accordance with the provisions of tax laws.

On the balance sheet date, the book value of the deferred tax assets is reviewed. If it is likely that sufficient taxable income will not be available in the future to offset the benefits of the deferred tax assets, the book value of the deferred tax assets will be written down. The amount of the write-down is reversed when it is probable that sufficient taxable income will be obtained.

(3) Offset of income tax

109/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

When it has the legal right to settle on a net basis and intends to settle on a net basis or acquire assets and pay off liabilities at the same time, the company's current income tax assets and current income tax liabilities are presented at the net amount after offsetting.

When you have the legal right to settle current income tax assets and current income tax liabilities on a net basis, and the deferred income tax assets and deferred income tax liabilities are related to the income tax levied by the same tax collection and administration department on the same taxable entity or on different taxable entities, but in the future each During the period when significant deferred income tax assets and liabilities are reversed, when the tax payer involved intends to settle the current income tax assets and liabilities on a net basis or to acquire assets and settle liabilities at the same time, the Company's deferred income tax assets and deferred income tax liabilities will be presented at the net amount after offsetting.

38. Leasing

√Applicable □Not applicable

As a lessee, the judgment basis and accounting treatment method for simplified treatment of short-term leases and low-value asset leases

√Applicable □Not applicable

The company's leased assets mainly include buildings, machinery and equipment.

①Initial measurement

On the start date of the lease period, the Company recognizes the right to use the leased asset during the lease term as a right-of-use asset, and recognizes the present value of the unpaid lease payments as a lease liability, except for short-term leases and low-value asset leases. Right-of-use assets refer to the lessee’s right to use the leased assets during the lease term. On the commencement date of the lease term, the right-of-use asset is initially measured at cost. This cost includes: the initial measurement amount of the lease liability; the lease payment amount paid on or before the start date of the lease term, and if there is a lease incentive, the amount related to the lease incentive that has been enjoyed will be deducted; the initial direct costs incurred by the lessee; the costs expected to be incurred by the lessee to dismantle and remove the leased asset, restore the site where the leased asset is located, or restore the leased asset to the state agreed upon in the lease terms. When calculating the present value of lease payments, the company uses the interest rate implicit in the lease as the discount rate; if the interest rate implicit in the lease cannot be determined, the lessee's incremental borrowing rate is used as the discount rate.

②Subsequent measurement

The Company accrues depreciation on right-of-use assets with reference to the relevant depreciation provisions of "Accounting Standards for Business Enterprises No. 4 - Fixed Assets" (see Note V. 21 "Fixed Assets" for details). If it is reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, the Company shall accrue depreciation within the remaining useful life of the leased asset. If it is not reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, the Company will accrue depreciation during the shorter of the lease term and the remaining useful life of the leased asset.

Lease liabilities shall be initially measured based on the present value of the unpaid lease payments at the beginning of the lease term. Lease payments include the following five items: fixed payments and substantive fixed payments, if there are lease incentives, the amount related to the lease incentives is deducted; variable lease payments that depend on the index or ratio; the exercise price of the purchase option, provided that the lessee is reasonably certain that the option will be exercised; the payment required to exercise the lease termination option, provided that the lease term reflects that the lessee will exercise the lease termination option; and the amount expected to be paid based on the residual value of the guarantee provided by the lessee. The difference between the lease payment and its present value is regarded as an unrecognized financing expense. The interest expense for each period of the lease period is calculated at a fixed periodic interest rate based on the discount rate used to confirm the present value of the lease payment during each period of the lease term, and is included in the current profit and loss or included in the cost of related assets. Variable lease payments that are not included in the measurement of lease liabilities are included in the current profit and loss or included in the cost of related assets when they actually occur.

110/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

After the start date of the lease period, when the actual fixed payment amount changes, the expected amount payable of the guaranteed residual value changes, the index or ratio used to determine the lease payment amount changes, the evaluation results or actual exercise of the purchase option, lease renewal option or termination option change, the company remeasures the lease liability based on the present value of the changed lease payment amount, and adjusts the book value of the right-of-use asset accordingly. If the book value of the right-of-use asset has been reduced to zero, but the lease liability still needs to be further reduced, the company will include the remaining amount in the current profit and loss.

③ Impairment testing method and impairment provision accrual method for right-of-use assets

For details on the impairment testing method and impairment provision method for right-of-use assets, please refer to Note V. 27 "Impairment of Long-term Assets".

④Short-term leasing and low-value asset leasing

For short-term leases (leases with a lease period of no more than 12 months on the lease commencement date) and low-value asset leases, the company adopts a simplified treatment method and does not recognize right-of-use assets and lease liabilities. Instead, the lease payments are included in the relevant asset costs or current profits and losses according to the straight-line method or other systematic and reasonable methods during each period of the lease term.

Lease classification standards and accounting treatment methods as a lessor

√Applicable □Not applicable

On the lease commencement date, the Company divides leases into finance leases and operating leases based on the nature of the transaction. A finance lease is a lease that transfers substantially all the risks and rewards associated with ownership of the leased asset. Operating leases refer to leases other than finance leases.

①Operating lease

The company uses the straight-line method or other systematic and reasonable amortization methods to recognize the lease receipts from operating leases as rental income for each period during the lease term. Variable lease payments related to operating leases that are not included in lease receipts are included in the current profit and loss when they actually occur.

②Financial lease

On the commencement date of the lease period, the Company recognizes the finance lease receivable and derecognizes the finance lease assets. When the Company initially measures the financial lease receivables, it takes the net lease investment as the entry value of the financial lease receivables. The net investment in a lease is the sum of the unguaranteed residual value and the present value of the lease payments that have not yet been received at the start of the lease term, discounted at the interest rate implicit in the lease. The Company calculates and recognizes interest income in each period during the lease term based on fixed periodic interest rates.

The derecognition and impairment of finance lease receivables shall be accounted for in accordance with Note 5.11 "Financial Instruments" of this Note.

Variable lease payments obtained by the Company that are not included in the measurement of net lease investment are included in the current profit and loss when actually incurred.

39. Other important accounting policies and accounting estimates

√Applicable □Not applicable

Accounting treatments related to repurchases of company shares

The consideration and transaction costs paid in share repurchases reduce shareholders' equity, and no gain or loss is recognized when the company's shares are repurchased, transferred or canceled.

111/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

When treasury shares are transferred, the difference between the actual amount received and the book amount of the treasury shares will be included in the capital reserve. If the capital reserve is insufficient to offset, the surplus reserve and undistributed profits will be offset. When treasury shares are canceled, the share capital is reduced according to the face value of the stock and the number of canceled shares. The difference between the book balance and the face value of the canceled treasury shares is used to offset the capital reserve. If the capital reserve is insufficient for offset, the surplus reserve and undistributed profits are offset.

40. Changes in important accounting policies and accounting estimates

(1).Changes in important accounting policies

□Applicable √Not applicable

(2).Changes in important accounting estimates

√Applicable □Not applicable

Unit: Yuan Currency: RMB The content of the change in accounting estimates and the time point when the original significantly affected statement items become applicable. The amount of the impact is due to the item name.

In recent years, as the company has developed

Continuous increase in investment and new fields

Expansion and in-depth research and development, company research

The development strength of medical devices has been continuously enhanced, and the number of medical devices has increased significantly. According to the relevant provisions of "Accounting Policy No. 28 - Accounting Policy, Changes in Accounting Estimates and Correction of Errors in Newly Approved Registration (Filing) Certificates for Companies in 2022, 2023, and 2024", the number of medical devices were 57 and 60 respectively. This change in accounting estimates adopts

In the future, the applicable law will be used to conduct 128 accounting offices, and the company will conduct research and development projects

Informatization and refined management will gradually be carried out. This accounting valuation does not need to enhance the disclosed financial information. The financial report will be retrospectively adjusted from 2025 onwards. The financial report will be adjusted retrospectively from 2025, while the reliability of aggregation and accounting will be implemented. The implementation of the company's previous annual financial/

The status and operating results will not be timely, which also reduces the efficiency of R&D results.

Certainty has an impact on R&D project management and management.

The ability to control technical risks has been significantly improved with this change in accounting estimates. In order to make the accounting estimates more relevant, the specific impact depends on studying the actual business, comprehensively and objectively reflecting the actual occurrence of the company's R&D expenses and assets in the future development stage of the project and meeting the capitalization requirements. According to the "Enterprise Accounting Standards for Expenditures, it is not yet accurate. No. 28 - Accounting Policies, Estimating the specific impact."

Changes in Accounting Estimates and Correction of Errors"

and other relevant regulations, the company’s research and development expenditure

Accounting treatment related to capitalization

112/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

re-examined and evaluated, and concluded

of the company’s research and development activities

The actual situation and reference to the same industry

Capitalization of R&D expenditures by municipal companies

situation, the company decides to spend on R&D

Estimates at the time of capitalization change

so that it can be more objective and true

Reflect the company's financial status and operations

Results.

Other notes:

The company held the 2024 annual meeting of the Audit Committee of the fifth board of directors, the fourth meeting of the fifth board of directors, and the fourth meeting of the fifth board of supervisors on April 16, 2025, and reviewed and approved the "Proposal on Changes in Accounting Estimates" respectively. According to relevant laws and regulations such as the "Shanghai Stock Exchange Stock Listing Rules" and the "Articles of Association" and other relevant provisions, this change in accounting estimates does not need to be submitted to the company's shareholders' meeting for review.

(3). The first implementation of new accounting standards or standard interpretations starting in 2025 will involve adjustments to the financial statements at the beginning of the year of first implementation.

□Applicable √Not applicable

41. Others

√Applicable □Not applicable

In the process of applying accounting policies, due to the inherent uncertainty in operating activities, the Company needs to make judgments, estimates and assumptions on the book values of statement items that cannot be accurately measured. These judgments, estimates and assumptions are based on the past historical experience of the company's management and taking into account other relevant factors. These judgments, estimates and assumptions affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities at the balance sheet date. However, the actual results resulting from the uncertainty of these estimates may differ from the current estimates of the Company's management, resulting in significant adjustments to the carrying amounts of the assets or liabilities affected in the future.

The Company conducts regular reviews of the aforementioned judgments, estimates and assumptions on a going concern basis. If a change in accounting estimates only affects the current period of the change, the impact will be recognized in the current period of the change; if it affects both the current period of the change and future periods, the impact will be recognized in the current period of the change and future periods.

On the balance sheet date, the important areas where the company needs to make judgments, estimates and assumptions on the amounts of financial statement items are as follows: (1) Revenue recognition

As stated in Note V. 34, "Revenue", the Company's revenue recognition involves the following significant accounting judgments and estimates: identifying customer contracts; estimating the recoverability of the consideration to which it is entitled due to the transfer of goods to customers; identifying performance obligations in the contract; estimating the variable consideration existing in the contract and the cumulative recognized revenue that is unlikely to be significantly reversed when the relevant uncertainty is eliminated.

113/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

the amount; whether there is a significant financing component in the contract; estimate the stand-alone selling price of a single performance obligation in the contract; determine whether the performance obligation will be performed within a certain period of time or at a certain point in time.

The Company mainly relies on past experience and work to make judgments. These major judgments and changes in estimates may have an impact on the operating income, operating costs, and profits and losses of the current or subsequent periods, and may have a significant impact.

(2) Leasing

①Identification of lease

When the company identifies whether a contract is a lease or contains a lease, it needs to evaluate whether there is an identified asset and the customer controls the right to use the asset within a certain period. When evaluating, consideration needs to be given to the nature of the asset, substantial substitution rights, and whether the customer has the right to receive substantially all of the economic benefits arising from the use of the asset during the period and to be able to direct the use of the asset. ②Classification of leasing

When the Company acts as a lessor, it classifies leases into operating leases and finance leases. When classifying, management needs to make analysis and judgment on whether all risks and rewards related to the ownership of the leased assets have been substantially transferred to the lessee.

③Lease liabilities

When the Company acts as a lessee, lease liabilities are initially measured based on the present value of the unpaid lease payments at the beginning of the lease term. When measuring the present value of lease payments, the Company estimates the discount rate used and the lease term of the lease contract with renewal options or termination options. When evaluating the lease term, the Company comprehensively considers all relevant facts and circumstances related to the economic benefits brought by the Company's exercise of the option, including expected changes in facts and circumstances from the start of the lease term to the date of exercise of the option. Different judgments and estimates may affect the recognition of lease liabilities and right-of-use assets, and will affect profits and losses in subsequent periods.

(3) Classification and impairment of financial assets

The Company's significant judgments involved in determining the classification of financial assets include analysis of business models and contractual cash flow characteristics.

The Company determines the business model for managing financial assets at the level of financial asset portfolios. Factors considered include the way to evaluate and report the performance of financial assets to key management personnel, the risks that affect the performance of financial assets and their management methods, and the way in which relevant business managers are remunerated.

When the company evaluates whether the contractual cash flows of financial assets are consistent with the basic lending arrangements, the following main judgments are made: whether the time distribution or amount of the principal may change during the duration due to early repayment and other reasons; whether the interest only includes the time value of money, credit risk, other basic lending risks and consideration for costs and profits. For example, whether the amount of early repayment only reflects the unpaid principal and interest based on the unpaid principal, as well as reasonable compensation paid for early termination of the contract.

The Company uses the expected credit loss model to assess the impairment of financial instruments. Applying the expected credit loss model requires significant judgments and estimates, and all reasonable and evidence-based information, including forward-looking information, must be considered. When making such judgments and estimates, the Company infers the expected changes in the debtor's credit risk based on historical data combined with changes in economic policies, macroeconomic indicators, industry risks, external market environment, technical environment, customer conditions and other factors. The Company regularly monitors and reviews assumptions related to the calculation of expected credit losses.

(4) Provision for inventory decline

114/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

According to the inventory accounting policy, the company measures the inventory at the lower of cost and net realizable value, and makes provision for inventory depreciation for inventory that has a cost higher than net realizable value and is obsolete and slow-moving. The impairment of inventories to net realizable value is based on an assessment of the inventory's salability and its net realizable value. Identification of inventory impairment requires management to make judgments and estimates based on obtaining conclusive evidence and considering factors such as the purpose of holding inventory and the impact of events after the balance sheet date. The difference between the actual results and the original estimate will affect the book value of inventories and the provision or reversal of inventory depreciation provisions in the period when the estimate is changed.

(5) Fair value of financial instruments

For financial instruments that do not have an active trading market, the Company determines their fair value through various valuation methods. These valuation methods include discounted cash flow model analysis, etc. During valuation, the company needs to estimate future cash flow, credit risk, market volatility and correlation, and select an appropriate discount rate. These relevant assumptions are uncertain and changes will have an impact on the fair value of financial instruments. If an equity instrument investment or contract has a public quotation, the Company does not use cost as the best estimate of its fair value.

(6) Investment in other equity instruments

The Company's determination of whether other equity instrument investments are impaired depends to a large extent on management's judgment and assumptions to determine whether impairment losses need to be recognized in the income statement. In the process of making judgments and assumptions, the company needs to evaluate the extent and duration for which the fair value of the investment is lower than the cost, as well as the financial condition and short-term business prospects of the investee, including industry conditions, technological changes, credit ratings, default rates and counterparty risks.

(7) Provision for impairment of long-term assets

The Company determines whether there are signs of possible impairment of non-current assets other than financial assets on the balance sheet date. For intangible assets with indefinite useful lives, in addition to annual impairment testing, impairment testing is also conducted when there are signs of impairment. Other non-current assets other than financial assets are tested for impairment when there are signs that their carrying amounts are irrecoverable.

Impairment has occurred when the carrying value of an asset or asset group is greater than its recoverable amount, which is the higher of fair value less disposal costs and the present value of expected future cash flows.

The net amount of fair value less disposal expenses is determined by referring to the sales agreement price or observable market price of similar assets in an arm's length transaction, less the incremental costs directly attributable to the disposal of the asset.

When estimating the present value of future cash flows, significant judgments need to be made on the output, selling price, related operating costs, and the discount rate used in calculating the present value of the asset (or asset group). The Company will use all relevant information available when estimating the recoverable amount, including forecasts of output, selling price and related operating costs based on reasonable and supportable assumptions.

The Company tests whether goodwill is impaired at least annually. This requires estimating the present value of the future cash flows of the asset group or asset group combination to which goodwill is allocated. When estimating the present value of future cash flows, the company needs to estimate the cash flows generated by future asset groups or asset group combinations, and at the same time select an appropriate discount rate to determine the present value of future cash flows.

(8) Depreciation and amortization

The Company depreciates and amortizes investment real estate, fixed assets and intangible assets on a straight-line basis over their useful lives after taking into account their residual values. The Company regularly reviews useful lives to determine the amount of depreciation and amortization expenses to be included in each reporting period. Use

115/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Life is determined by the Company based on past experience with similar assets and combined with expected technological updates. If there are material changes to previous estimates, depreciation and amortization expenses will be adjusted in future periods.

(9) Deferred income tax assets

The Company recognizes deferred income tax assets for all unused tax losses to the extent that it is probable that there will be sufficient taxable profits to offset the losses. This requires the company's management to use a lot of judgment to estimate the time and amount of future taxable profits, combined with tax planning strategies, to determine the amount of deferred income tax assets that should be recognized.

(10) Income tax

In the company's normal operating activities, there are certain uncertainties in the final tax treatment and calculation of some transactions. Whether some items can be deducted before tax requires the approval of the tax authorities. If the final determination of these tax matters is different from the initially estimated amount, the difference will have an impact on current income tax and deferred income tax during the period of final determination. (11) Estimated liabilities

Based on the contract terms, existing knowledge and historical experience, the company estimates and makes corresponding provisions for product quality assurance, expected contract losses, delayed delivery liquidated damages, etc. When such contingencies have formed a current obligation, and the performance of such current obligations is likely to result in the outflow of economic benefits from the Company, the Company recognizes the contingencies as estimated liabilities based on the best estimate of the expenditure required to fulfill the relevant current obligations. The recognition and measurement of estimated liabilities rely heavily on management's judgment. In the process of making judgments, the company needs to evaluate the risks, uncertainties, time value of money and other factors related to these contingencies.

Among them, the Company will commit estimated liabilities for after-sales quality maintenance provided to customers for the sale, repair and modification of the goods sold. The company's recent maintenance experience data has been taken into account when estimating liabilities, but recent maintenance experience may not reflect future maintenance conditions. Any increase or decrease in this provision may affect profits and losses in future years.

(12) Impairment of goodwill

The Company assesses whether goodwill is impaired at least annually. This requires an estimate of the value in use of the asset group to which goodwill is assigned. When estimating value in use, the company needs to estimate future cash flows from the asset group and select an appropriate discount rate to calculate the present value of future cash flows.

6. Taxes

1. Main tax types and tax rates

Main tax types and tax rates

√Applicable □Not applicable

Type of tax Tax calculation basis Tax rate

Sales of goods calculated in accordance with tax laws and regulations

Calculate output based on taxable service income

Value-added tax, after deducting the 13.00%, 9.00%, 6.00%, and 3.00% input taxes that are allowed to be deducted in the current period, the difference is the value-added payable

tax

Urban maintenance and construction tax is calculated and paid based on the actual value-added tax paid, 7.00%, 5.00%

Education fee surcharge is calculated and paid based on the actual value-added tax paid 3.00%

Local education surcharge is calculated and paid based on the actual value-added tax paid 2.00%

116/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

25.00%, 15.00%, 21.00%, corporate income tax calculated and paid based on taxable income

16.50%, 9.00%, 22.00%

If there are taxpayers with different corporate income tax rates, a description of the disclosure

√Applicable □Not applicable

Name of tax payer Income tax rate

Zhengzhou Antu Bioengineering Co., Ltd. 15.00% Antu Experimental Instruments (Zhengzhou) Co., Ltd. 15.00% Zhengzhou Imino Biotechnology Co., Ltd. 15.00% Beijing Antu Bioengineering Co., Ltd. 15.00% Zhengzhou Biaoyuan Biotechnology Co., Ltd. 15.00% AdvanBio, Inc. 21.00% Shanghai Biaoyuan Biotechnology Co., Ltd. 25.00% Zhengzhou Antu Technology Development Co., Ltd. 25% 25.00% Autobio (Hong Kong) Co., Ltd. 16.50% Autobio Trading (Hong Kong) Co., Ltd. 16.50% Autobio Diagnostics (Hungary) Kft. 9.00% PTAUTOBIODIAGNOSTICSINDONESIA 22.00% Yunnan Autobio Technology Co., Ltd. 25.00%

Note 1: The company's subsidiary AdvanBio, Inc. is established in the United States. Its income tax is mainly federal income tax, and the federal income tax rate is 21%; Antu Biotechnology (Hong Kong) Co., Ltd. and Antu Trading (Hong Kong) Co., Ltd. are established in Hong Kong, and their income tax is mainly profits tax, with a general tax rate of 16.50%. AutobioDiagnostics (Hungary) Kft. is established in Hungary, with an income tax rate of 9%, and PTAUTOBIODIAGNOSTICSINDONESIA is established in Indonesia, with an income tax rate of 22%.

2. Tax incentives

√Applicable □Not applicable

1. Income tax

①The company was again certified as a high-tech enterprise in Henan Province on November 22, 2023, certificate number:

GR202341001511. According to the "Enterprise Income Tax Law of the People's Republic of China" and the "Implementation Regulations of the Enterprise Income Tax Law of the People's Republic of China", income tax is calculated at a tax rate of 15% in 2023, 2024 and 2025.

117/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

② Antu Experimental Instruments (Zhengzhou) Co., Ltd., a subsidiary of the company, was again certified as a high-tech enterprise in Henan Province on November 22, 2023, with certificate number: GR202341002066. According to the "Enterprise Income Tax Law of the People's Republic of China" and the "Implementation Regulations of the Enterprise Income Tax Law of the People's Republic of China", income tax is calculated at a tax rate of 15% in 2023, 2024 and 2025.

③The company's subsidiary Zhengzhou Imino Biotechnology Co., Ltd. passed the high-tech enterprise certification again on December 23, 2022, certificate number: GR202241002936. According to the "Enterprise Income Tax Law of the People's Republic of China" and the "Regulations on the Implementation of the Enterprise Income Tax Law of the People's Republic of China", income tax will be calculated at a rate of 15% in 2022, 2023 and 2024. In 2025, when the high-tech enterprise re-certification is filed, income tax will be temporarily calculated at a rate of 15%.

④The company’s subsidiary Beijing Antu Bioengineering Co., Ltd. passed the Beijing high-tech enterprise certification again on October 26, 2023, certificate number: GS202311000058. According to the "Enterprise Income Tax Law of the People's Republic of China" and the "Implementation Regulations of the Enterprise Income Tax Law of the People's Republic of China", income tax is calculated at a tax rate of 15% in 2023, 2024 and 2025.

⑤ The company’s secondary subsidiary Zhengzhou Biaoyuan Biotechnology Co., Ltd. obtained the high-tech enterprise certificate on December 23, 2022. The certificate number: GR202241003865 is valid for three years. According to the "Enterprise Income Tax Law of the People's Republic of China" and the "Regulations on the Implementation of the Enterprise Income Tax Law of the People's Republic of China", income tax will be calculated at a rate of 15% in 2022, 2023 and 2024. In 2025, when the high-tech enterprise re-certification is filed, income tax will be temporarily calculated at a rate of 15%.

(2) Value-added tax

According to the provisions of the "Notice of the Ministry of Finance and the State Administration of Taxation on Comprehensively Launching the Pilot Program of Replacing Business Tax with Value-Added Tax" (Caishui [2016] No. 36), medical services provided by medical institutions are exempt from VAT. The company's secondary subsidiary Qiqihar Antu Medical Laboratory Co., Ltd. complies with the preferential policy of value-added tax exemption according to the documents this year.

According to the provisions of the "Notice of the Ministry of Finance and the State Administration of Taxation on Value-Added Tax Policies for Software Products" (Caishui [2011] No. 100), software products that meet the conditions can enjoy the VAT refund policy upon review and approval by the competent tax authorities. The company's subsidiaries, Antu Experimental Instruments (Zhengzhou) Co., Ltd. and Shanghai Biaoyuan Biotechnology Co., Ltd., complied with the policy of immediate refund of value-added tax on software products stipulated in the documents this year.

3. Others

□Applicable √Not applicable

7. Notes on Consolidated Financial Statement Items

1. Monetary funds

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Cash on hand 247,796.14 348,166.38 Bank deposits 454,091,234.07 451,709,935.31 Other monetary funds 22,672,104.77 13,315,021.33 Total 477,011,134.98 465,373,123.02 of which: stored abroad

1,583,125.87 7,256,240.11

Total amount

Other instructions

118/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

As of June 30, 2025, other monetary funds mainly include securities account funds, ETC system deposits and foreign exchange swap guarantees

except for the transfer amount of 20,408.00 yuan transferred to the vehicle-mounted ETC system and the foreign exchange swap business guarantee of Antu Experimental Instrument (Zhengzhou) Co., Ltd.

The certificate funds are frozen at RMB 22,650,946.15. The company has no other pledged, frozen, or potential recovery risks.

2. Trading financial assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Reason and basis for designation Measured at fair value and its changes

411,123,668.33 3,609,780.75/Financial assets included in current profits and losses

Among them:

Debt instrument investment 307,568,000.00/Financial management products 100,000,000.00/Foreign exchange swap 3,555,668.33 3,609,780.75

Total 411,123,668.33 3,609,780.75 /Other instructions:

□Applicable √Not applicable

3. Derivative financial assets

□Applicable √Not applicable

4. Notes receivable

(1). Classified presentation of notes receivable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Bank acceptance notes 12,185,793.19 14,585,836.00 Commercial acceptance notes 6,862,405.54 7,585,730.14

Total 19,048,198.73 22,171,566.14

(2). The company’s pledged notes receivable at the end of the period

□Applicable √Not applicable

(3). Notes receivable that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount derecognized at the end of the period Amount not derecognized at the end of the period Bank acceptance bill 11,818,378.19 Commercial acceptance bill 265,000.00

Total 12,083,378.19

(4). Classified disclosure according to bad debt accrual method

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Ending balance Beginning balance

Category Book balance Bad debt provision Book value Book balance Bad debt provision Book value

119/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Special accrual and provision ratio ratio

Amount Amount Ratio Amount Amount Ratio (%) (%)

Example Example

(%) (%)Press

Single

item

plan

mention

bad

account

Accurate

Prepare

Among them:

press

group

combine

plan

19,810,688.2 100.0 762,489.5 3.8 19,048,198.7 22,682,667.1 100.0 511,101.0 2.2 22,171,566.1

3 0 0 5 3 8 0 4 5 4 bad

account

Accurate

Prepare

Among them:

silver

OK

12,185,793.1 12,185,793.1 14,585,836.0 14,585,836.0 Inherited 61.51 64.30

9 9 0 0 exchange

sink

ticket

Business

industry

762,489.5 511,101.0 6.3 7,624,895.04 38.49 10 6,862,405.54 8,096,831.18 35.70 7,585,730.14

0 4 1 exchange

sink

ticket

Total 19,810,688.2 762,489.5 19,048,198.7 22,682,667.1 511,101.0 22,171,566.1

// / /Total 3 0 3 8 4 4

Provision for bad debts is made individually:

□Applicable √Not applicable

Provision for bad debts by group:

√Applicable □Not applicable

Combined accrual items: commercial acceptance bills

Unit: Yuan Currency: RMB Name Ending balance

120/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Book balance Bad debt provision Provision ratio (%) 1 to 2 years 7,624,895.04 762,489.50 10.00

Total 7,624,895.04 762,489.50

Instructions on accruing bad debt provisions by portfolio

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

Basis for division of each stage and provision ratio for bad debts

None

Explanation of significant changes in the book balance of notes receivable that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

(5). Bad debt provisions

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

Category Beginning Balance Ending Balance

Provision Recovery or reversal Write-off or write-off Other changes Commercial acceptance bill 511,101.04 251,388.46 762,489.50

Total 511,101.04 251,388.46 762,489.50

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable √Not applicable

Other notes:

None

(6). Notes receivable actually written off in the current period

□Applicable √Not applicable

Among them, the important write-off of bills receivable:

□Applicable √Not applicable

Instructions for writing off notes receivable:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

5. Accounts receivable

(1). Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Aging Book balance at the end of the period Book balance at the beginning of the period Within 1 year (including 1 year) 1,069,199,107.32 1,032,256,786.90 Total within 1 year 1,069,199,107.32 1,032,256,786.90 1 to 2 years 186,395,122.06 162,110,577.22 2 to 3 years 62,204,771.89 66,211,506.86

121/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

More than 3 years 49,099,125.58 42,292,203.73

Total 1,366,898,126.85 1,302,871,074.71

(2). Classified disclosure according to bad debt accrual method

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Book balance Bad debt provision Book balance Bad debt provision Category Provision Book ratio Provision Book category Amount Example Amount Proportion Value Amount Example Amount Proportion Value

(%) (%) (%) (%)Press

Single

item

plan

44,823,019.3 3.2 44,823,019 100. 49,921,642.3 3.8 49,921,642 100.

4 8 .34 00 3 3 .33 00 bad

account

Accurate

Prepare

Among them:

Single

item

plan

mention

bad

account

44,823,019.3 3.2 44,823,019 100. 49,921,642.3 3.8 49,921,642 100.Prepared 4 8 .34 00 3 3 .33 00Prepared

of

Should

receive

account

money

press

group

combine

plan

1,322,075,10 96. 121,164,64 1,200,910,46 1,252,949,43 96. 113,954,00 1,138,995,43 9.16 9.09

7.51 72 6.28 1.23 2.38 17 2.21 0.17 bad

account

Accurate

Prepare

Among them:

122/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

press

letter

use

wind

risk

Special

levy

group

combine

1,322,075,10 96. 121,164,64 1,200,910,46 1,252,949,43 96. 113,954,00 1,138,995,43 9.16 9.09

7.51 72 6.28 1.23 2.38 17 2.21 0.17 mention

bad

account

Accurate

Prepare

of

Should

receive

money

item

Total 1,366,898,12 165,987,66 1,200,910,46 1,302,871,07 163,875,64 1,138,995,43

/ / / /

Total 6.85 5.62 1.23 4.71 4.54 0.17

Provision for bad debts is made individually:

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Proportion (%) Reason for provision 1 to 2 years 6,908,330.74 6,908,330.74 100.00 Expected not to be recovered in 2 to 3 years 14,938,377.63 14,938,377.63 100.00 Expected not to be recovered in more than 3 years 22,976,310.97 22,976,310.97 100.00 Expected to be unrecoverable

Total 44,823,019.34 44,823,019.34 100.00 /

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

Provision for bad debts by group:

√Applicable □Not applicable

Portfolio accrual items: receivables with collective accrual of bad debt provisions based on credit risk characteristics

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Ratio of provision (%) Within 1 year 1,069,199,107.32 53,459,955.40 5.00 1 to 2 years 179,486,791.32 17,948,679.14 10.00 2 to 3 years 47,266,394.26 23,633,197.13 50.00 More than 3 years 26,122,814.61 26,122,814.61 100.00

Total 1,322,075,107.51 121,164,646.28

Instructions on accruing bad debt provisions by group:

123/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

Basis for division of each stage and provision ratio for bad debts

None

Explanation of significant changes in the book balance of accounts receivable that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

(3). Bad debt provision situation

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

Category Opening balance Recovery or transfer Write-off or verification Ending balance accrual Other changes

Return sales

Bad debt provision 163,875,644.54 2,112,022.78 1.70 165,987,665.62

Total 163,875,644.54 2,112,022.78 1.70 165,987,665.62

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable √Not applicable

Other notes:

None

(4). Accounts receivable actually written off in the current period

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Write-off Amount

Accounts receivable actually written off 1.70

Among them, the important write-off of accounts receivable

□Applicable √Not applicable

Instructions for writing off accounts receivable:

□Applicable √Not applicable

(5). Accounts receivable and contract assets of the top five closing balances collected by debtors

√Applicable □Not applicable

Unit: Yuan Currency: RMB accounts receivable and

Accounts Receivable and Hehe

Accounts receivable at the end of the period Contract assets at the end of the period Contract assets at the end of the period Bad debt provision at the end of the unit name Same assets at the end of the period

Balance Balance Balance amount of total balance

Proportion (%)

First place 65,444,176.03 65,444,176.03 4.79 3,785,501.18 Second place 65,326,069.31 65,326,069.31 4.78 3,319,742.90 Third place 42,963,064.57 42,963,064.57 3.14 2,148,153.23 Fourth place 37,655,401.45 37,655,401.45 2.75 2,705,223.03 Fifth place 35,044,293.79 35,044,293.79 2.56 2,848,726.44

124/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Total 246,433,005.15 246,433,005.15 18.02 14,807,346.78Other instructions

None

Other notes:

□Applicable √Not applicable

6. Contract assets

(1).Contract assets

□Applicable √Not applicable

(2). Amount and reasons for significant changes in book value during the reporting period □Applicable √Not applicable

(3). Classified disclosure according to bad debt accrual method

□Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model □ Applicable √ Not applicable

The basis for dividing each stage and the proportion of provision for bad debts are not available

Explanation of significant changes in the book balance of contract assets that have experienced changes in loss provisions in the current period: □ Applicable √ Not applicable

(4). Bad debt provisions for contract assets in the current period □ Applicable √ Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(5).Contract assets actually written off in the current period □Applicable √Not applicable

Among them, the important write-off of contract assets

□Applicable √Not applicable

125/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Instructions for write-off of contract assets:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

7. Accounts receivable financing

(1). Classified presentation of financing receivables

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance Notes receivable 12,485,684.89 15,933,064.72

Total 12,485,684.89 15,933,064.72

(2). Financing of the company’s pledged receivables at the end of the period

□Applicable √Not applicable

(3). Financing of receivables that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date √ Applicable □ Not applicable

Unit: Yuan Currency: RMB

Item Amount derecognized at the end of the period Amount not derecognized at the end of the period Bank acceptance bill 41,970,373.95 Commercial acceptance bill

Total 41,970,373.95

(4). Classified disclosure according to bad debt accrual method

□Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

Basis for division of each stage and provision ratio for bad debts

None

Explanation of significant changes in the book balance of accounts receivable financing that have experienced changes in loss provisions in the current period: □ Applicable √ Not applicable

126/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(5). Bad debt provisions

□Applicable √Not applicable

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable √Not applicable

Other notes:

None

(6). Financing of receivables actually written off in the current period

□Applicable √Not applicable

Important financing write-offs of receivables

□Applicable √Not applicable

Write-off instructions:

□Applicable √Not applicable

(7). Increases and decreases in receivables financing and changes in fair value during the current period:

□Applicable √Not applicable

(8). Other instructions:

□Applicable √Not applicable

8. Advance payments

(1). Prepayments are presented based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Aging

Amount Proportion (%) Amount Proportion (%)

Within 1 year 48,365,614.69 93.60 41,163,861.08 93.30 1 to 2 years 2,843,274.98 5.50 1,446,210.27 3.28 2 to 3 years 167,146.04 0.32 1,378,825.65 3.13 More than 3 years 301,196.17 0.58 129,494.57 0.29

Total 51,677,231.88 100.00 44,118,391.57 100.00 Explanation of reasons why prepayments with an aging of more than 1 year and important amounts were not settled in time:

None

(2). Prepayments of the top five ending balances by prepayment objects

√Applicable □Not applicable

Unit: Yuan Currency: RMB accounts for the total closing balance of prepayments Name of the unit Closing balance

Proportion(%)

First place 5,964,360.59 11.54 Second place 5,537,196.52 10.71 Third place 3,532,566.36 6.84 Fourth place 2,127,899.16 4.12 Fifth place 1,941,755.30 3.76

127/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Total 19,103,777.93 36.97

Other notes:

None

Other instructions

√Applicable □Not applicable

As of June 30, 2025, there were no arrears among shareholders holding more than 5% (including 5%) of the company's voting rights among the prepayments.

9. Other receivables

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Interest receivable

Dividends receivable 194,694.60 194,694.60 Other receivables 26,266,477.43 79,986,096.24

Total 26,461,172.03 80,180,790.84Other instructions:

□Applicable √Not applicable

interest receivable

(1).Classification of interest receivable

□Applicable √Not applicable

(2).Important overdue interest

□Applicable √Not applicable

(3). Classified disclosure according to bad debt accrual method

□Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

(4). Provision for bad debts based on the general expected credit loss model □Applicable √Not applicable

(5). Bad debt provisions

□Applicable √Not applicable

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

128/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

□Applicable √Not applicable

Other notes:

None

(6). Interest receivable actually written off in the current period

□Applicable √Not applicable

Among them, the important write-off of interest receivable

□Applicable √Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Dividends receivable

(7). Dividends receivable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Project (or invested unit) Closing balance Opening balance Luoyang Antu Jiuhe Medical Technology Co., Ltd. 389,389.20 389,389.20 Less: bad debt provision 194,694.60 194,694.60

Total 194,694.60 194,694.60

(8). Important dividends receivable aged more than 1 year

□Applicable √Not applicable

(9). Classified disclosure according to bad debt accrual method

□Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

(10). Provision for bad debts based on the general expected credit loss model

√Applicable □Not applicable

Unit: Yuan Currency: RMB Phase 1 Phase 2 Phase 3 Bad debt provisions Next 12 months Expected credit for the entire duration Expected credit for the entire duration Total credit losses Use losses (credit losses that have not occurred (credit losses that have occurred)

129/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Use impairment) Use impairment) January 1, 2025

194,694.60 194,694.60 amount

As of January 1, 2025

Amount in this period

--Transfer to the second stage

--Transfer to the third stage

--Return to the second stage

--Return to the first stage

Provision for this period

Transferred in this period

Sales in this period

Write-off in this period

Other changes

After June 30, 2025

194,694.60 194,694.60 amount

The basis for dividing each stage and the proportion of provision for bad debts are not available

Explanation of significant changes in the book balance of dividends receivable due to changes in loss provisions in the current period: □ Applicable √ Not applicable

(11). Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(12). Dividends receivable actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of dividends receivable □ Applicable √ Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Other receivables

(13). Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB Aging Book balance at the end of the period Book balance at the beginning of the period

130/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Within 1 year (including 1 year) 26,210,216.48 82,397,240.63 Total within 1 year 26,210,216.48 82,397,240.63 1 to 2 years 1,408,131.75 1,616,570.95 2 to 3 years 198,906.40 507,607.60 More than 3 years 8,817,093.75 10,114,428.79

Total 36,634,348.38 94,635,847.97

(14). Classification by nature of money

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Security deposits and deposits 11,805,969.71 17,771,805.38 Reserve funds 2,699,896.64 1,799,933.25 Other current accounts paid in advance 11,437,175.00 7,315,289.51 Others 10,691,307.03 67,748,819.83

Total 36,634,348.38 94,635,847.97

(15). Bad debt provision accrual

√Applicable □Not applicable

Unit: Yuan Currency: RMB

The first stage The second stage The third stage

Lifetime expectations letter Lifetime forecast letter

Provision for bad debts Expected for the next 12 months Total

loss of use (no credit loss occurred (credit loss occurred)

credit loss

Use impairment) Use impairment)

As of January 1, 2025

14,649,751.73 14,649,751.73 amount

As of January 1, 2025

Amount in this period

--Transfer to the second stage

--Transfer to the third stage

--Return to the second stage

--Return to the first stage

Provision for this period

Transferred back in the current period 4,276,443.23 4,276,443.23 Write-off in the current period 5,437.55 5,437.55 Write-off in the current period

Other changes

June 30, 2025

10,367,870.95 10,562,565.55 Balance

Basis for division of each stage and provision ratio for bad debts

None

Explanation of significant changes in the book balance of other receivables that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

131/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

The amount of bad debt provision for the current period and the basis for assessing whether the credit risk of financial instruments has increased significantly:

□Applicable √Not applicable

(16). Bad debt provisions

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Amount of changes in the current period

Category Opening balance Write-off or verification Ending balance accrual Recovery or reversal Other changes

pin

Provision for bad debts 14,649,751.73 4,276,443.23 5,437.55 10,367,870.95 Total 14,649,751.73 4,276,443.23 5,437.55 10,367,870.95

Among them, the amount of bad debt provision reversed or recovered in the current period is important:

□Applicable √Not applicable

Other instructions

None

(17). Other receivables actually written off in the current period

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Write-off Amount

Other receivables actually written off 5,437.55

Important write-offs of other receivables:

□Applicable √Not applicable

Instructions for writing off other receivables:

□Applicable √Not applicable

(18). Other receivables with top five closing balances based on debtors

√Applicable □Not applicable

Unit: Yuan Currency: RMB as a share of other receivables at the end of the period

Name of bad debt provision unit Closing balance Proportion of total balance Nature of payment Aging of accounts

Ending balance

(%)

First place deposit and deposit

5,400,000.00 14.74 More than 3 years 5,400,000.00

gold

Second place: Prepaid to other destinations

2,000,000.00 5.46 Within 1 year 100,000.00

Incoming payment

Third place deposit and deposit

1,000,000.00 2.73 Within 1 year 50,000.00

gold

Fourth Place: Security Deposit and Deposit

825,000.00 2.25 More than 3 years 825,000.00

gold

Fifth place: Prepay other transactions

513,149.62 1.40 Within 1 year 25,657.48

Incoming payment

Total 9,738,149.62 26.58 / / 6,400,657.48

132/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(19). Presented in other receivables due to centralized management of funds

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

10. Inventory

(1). Inventory classification

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Inventories are accurate for price decreases Inventories are accurate for decreases in price

item

Preparation/Contract Performance Preparation/Contract Performance

Item Book balance Book value Book balance Book value cost impairment allowance Cost impairment allowance

Be prepared

original

24,446,768.5 24,311,692.5

Materials 578,662,084.35 554,215,315.81 662,618,345.13 638,306,652.57

4 6

material

week

turn

4,564,630.64 4,564,630.64 3,687,022.93 3,687,022.93 material

material

in

Products 202,746,457.50 54,841.27 202,691,616.23 190,350,003.51 264,148.56 190,085,854.95 Products

Library

Deposit 11,368,788.2

345,980,481.99 334,611,693.75 330,021,105.49 9,011,136.67 321,009,968.82Business 4

product

Total 1,131,953,654.4 35,870,398.0 1,096,083,256.4 1,186,676,477.0 33,586,977.7 1,153,089,499.2 Total 8 5 3 6 9 7

(2). Data resources confirmed as inventory

□Applicable √Not applicable

(3). Provision for inventory depreciation and provision for impairment of contract performance costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase amount in this period Decrease amount in this period

Item Beginning balance Closing balance

Provision Others Reversal or write-off Others

Raw materials 24,311,692.56 10,128,427.26 9,993,351.28 24,446,768.54 Work in progress 264,148.56 209,307.29 54,841.27 Inventory goods 9,011,136.67 4,087,409.75 1,729,758.18 11,368,788.24

Total 33,586,977.79 14,215,837.01 11,932,416.75 35,870,398.05

Reasons for the reversal or write-off of inventory depreciation provisions in the current period

□Applicable √Not applicable

Provision for inventory decline in value on a group basis

133/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

□Applicable √Not applicable

Standards for accruing inventory depreciation provisions on a group basis

□Applicable √Not applicable

(4). The capitalized amount of borrowing costs included in the closing balance of inventory and its calculation standards and basis □Applicable √Not applicable

(5). Explanation of the amortization amount of contract performance costs for the current period

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

11. Assets held for sale

□Applicable √Not applicable

12. Non-current assets due within one year

□Applicable √Not applicable

Debt investments due within one year

□Applicable √Not applicable

Other debt investments due within one year

□Applicable √Not applicable

Other instructions for non-current assets due within one year

None

13. Other current assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Prepaid maintenance cost 2,445,429.63 2,393,368.44 Interest receivable 15,776,040.09 30,556,164.25 Tax to be deducted 7,170,088.44 12,736,033.25 Financial products 2,610,487,303.50 3,573,611,779.08

Total 2,635,878,861.66 3,619,297,345.02Other instructions:

None

14. Debt investment

(1).Debt investment situation

□Applicable √Not applicable

Changes in provision for impairment of debt investments during the current period

□Applicable √Not applicable

134/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(2). Important debt investments at the end of the period

□Applicable √Not applicable

(3).Provision of impairment provisions

□Applicable √Not applicable

Basis for division of each stage and proportion of impairment provision: None

Explanation of significant changes in the book balance of debt investments that have experienced changes in loss provisions in the current period: □ Applicable √ Not applicable

The amount of impairment provision for the current period and the basis for assessing whether the credit risk of financial instruments has increased significantly: □ Applicable √ Not applicable

(4). Actual write-off debt investments in the current period □ Applicable √ Not applicable

Among them, the write-off of important debt investments □Applicable √Not applicable

Instructions for writing off debt investments:

□Applicable √Not applicable

Other notes:

None

15. Other debt investments

(1). Other debt investments

□Applicable √Not applicable

Changes in impairment provisions for other debt investments during the period □ Applicable √ Not applicable

(2). Other important debt investments at the end of the period

□Applicable √Not applicable

(3).Provision of impairment provisions

□Applicable √Not applicable

(4). Other debt investments actually written off in the current period □Applicable √Not applicable

Among them, the write-off of other important debt investments □Applicable √Not applicable

Instructions for writing off other debt investments:

□Applicable √Not applicable

135/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Other notes:

□Applicable √Not applicable

16. Long-term receivables (1). Long-term receivables □Applicable √Not applicable

(2). Classified disclosure according to bad debt accrual method □Applicable √Not applicable

Provision for bad debts on an individual basis: □ Applicable √ Not applicable

Explanation on the provision of bad debt provisions on an individual basis: □ Applicable √ Not applicable

Provision for bad debts by combination: □ Applicable √ Not applicable

Provision for bad debts based on the general expected credit loss model □ Applicable √ Not applicable

(3).Bad debt provision □Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(4). Long-term receivables actually written off in the current period □Applicable √Not applicable

Among them, the important write-off of long-term receivables □ Applicable √ Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

136/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

17. Long-term equity investment

(1). Long-term equity investment situation

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase or decrease in the current period

Impairment

Beginning of the period Declaration of issuance End of the period Preparation of impairment quasi-invested orders Recognized under the equity method Other comprehensive

Balance (book price, decrease in investments, other rights, cash release, provision, less balance (book price, end of provision period, beginning of period, additional investment, recognized investment losses, other values), change in capital, dividend or value provision, balance, balance, profit adjustment

profit

1. Joint ventures

Subtotal

2. Joint ventures

Zhengzhou Jiuhe

Medical testing

1,273,560.21 -1,273,560.21

The laboratory has

Ltd.

Zhengzhou Gongdong

Medical devices 10,382,487.97 7,500,000.00 -38,392.69 17,844,095.28 Co., Ltd.

Subtotal 11,656,048.18 7,500,000.00 -1,311,952.90 17,844,095.28

Total 11,656,048.18 7,500,000.00 -1,311,952.90 17,844,095.28

(2). Impairment testing of long-term equity investments

□Applicable √Not applicable

Other instructions

None

137/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

18. Investment in other equity instruments

(1). Investment in other equity instruments

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase or decrease in the current period Designated as accumulated at fair value Accumulated

Included in the current period Included in the current period Recognized and measured in the current period and at the beginning and end of the period Other comprehensive Other comprehensive items Decrease in investment Other comprehensive Other comprehensive Changes in dividend income are included in the balance Additional investment Other balance Interest on income Capital loss on income Interest on income Loss on income Other comprehensive gains and losses Gains and losses Original income

Because Chengdu Kerui

Technology Co., Ltd. 3,000,000.00 3,000,000.00

company

Suzhou Jinhe

Three-phase equity

Investment partnership 80,000,000.00 80,000,000.00

Enterprise (Limited

partnership)

Guangzhou Huayin

Kang Medical Collection

22,883,561.50 22,883,561.50

Group shares have

Ltd.

shenzhen plum

Nanopore

40,000,000.00 40,000,000.00

Technology is limited

company

Humanities (deep

Shenzhen) biotechnology

15,000,000.00 15,000,000.00

Technology Co., Ltd.

Division

138/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Total 160,883,561.50 160,883,561.50 / (2). Explanation of termination of recognition in this period

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

139/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

19. Other non-current financial assets

□Applicable √Not applicable

20. Investment real estate

Investment real estate measurement model

(1). Investment real estate using cost measurement model

Unit: Yuan Currency: RMB

Item Houses, buildings Total

1. Original book value

1. Balance at the beginning of the period 23,672,813.67 23,672,813.67 2. Increase in the current period 2,793,341.14 2,793,341.14 (1) Outsourcing

(2) Transfer of inventories\fixed assets\projects under construction 2,793,341.14 2,793,341.14 (3) Increase in business mergers

3. Reduction amount in this period

(1) Disposal

(2) Other transfer-out

4. Ending balance 26,466,154.81 26,466,154.81

2. Accumulated depreciation and accumulated amortization

1. Opening balance 499,669.00 499,669.00 2. Increase in the current period 432,579.01 432,579.01 (1) Provision or amortization 432,579.01 432,579.01 3. Decrease in the current period

(1) Disposal

(2) Other transfer-out

4. Closing balance 932,248.01 932,248.01

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1) Provision

3. Reduction amount in this period

(1) Disposal

(2) Other transfer-out

4. Ending balance

4. Book value

1. Book value at the end of the period 25,533,906.79 25,533,906.79 2. Book value at the beginning of the period 23,173,144.67 23,173,144.67

(2). Investment real estate for which the title certificate has not been obtained:

□Applicable √Not applicable

(3). Impairment testing of investment real estate using the cost measurement model

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

140/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

21. Fixed assets

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Fixed assets 3,533,706,214.36 2,963,741,984.32 Liquidation of fixed assets

Total 3,533,706,214.36 2,963,741,984.32Other instructions:

None

fixed assets

(1). Fixed assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Electronic equipment and its

Items Houses and buildings Machinery and equipment Transportation Total

him

1. Original book value:

1. Opening balance 1,895,213,406.39 2,849,749,524.31 25,739,609.48 69,268,873.93 4,839,971,414.11 2. Increase in this period

734,680,463.01 71,640,713.55 856,008.85 3,766,339.93 810,943,525.34Amount

(1) Purchase 47,035,282.80 856,008.85 3,766,339.93 51,657,631.58 (2) Construction in progress

734,680,463.01 24,605,430.75 759,285,893.76 Transfer in

(3) Business merger

increase

3. Less for this period

2,793,341.14 109,033,862.75 1,242,284.99 113,069,488.88 Small amount

(1) Dispose or report

109,033,862.75 1,242,284.99 110,276,147.74 Waste

(2) Other decreases 2,793,341.14 2,793,341.14 4. Closing balance 2,627,100,528.26 2,812,356,375.11 26,595,618.33 71,792,928.87 5,537,845,450.57

2. Accumulated depreciation

1. Opening balance 167,462,207.65 1,610,181,390.89 20,122,076.85 49,928,226.78 1,847,693,902.17 2. Increase in this period

31,348,669.30 176,529,692.60 1,024,946.60 4,311,354.51 213,214,663.01Amount

(1) Provision 31,348,669.30 176,529,692.60 1,024,946.60 4,311,354.51 213,214,663.01 (2) Business combination

increase

3. Reduction in this period

71,079,112.21 1,041,692.12 72,120,804.33 Amount

(1) Dispose or report

71,079,112.21 1,041,692.12 72,120,804.33 Waste

(2) Other reductions

4. Closing balance 198,810,876.95 1,715,631,971.28 21,147,023.45 53,197,889.17 1,988,787,760.85

3. Impairment provision

1. Opening balance 28,535,527.62 28,535,527.62 2. Increase in this period

141/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Amount

(1) Provision

3. Reduction in this period

13,184,052.26 Amount of 13,184,052.26

(1) Dispose or report

13,184,052.26 13,184,052.26 Waste

4. Ending balance 15,351,475.36 15,351,475.36

4. Book value

1. Closing accounts

2,428,289,651.31 1,081,372,928.47 5,448,594.88 18,595,039.70 3,533,706,214.36 Value

2. Opening accounts

1,727,751,198.74 1,211,032,605.80 5,617,532.63 19,340,647.15 2,963,741,984.32 Value

(2). Temporarily idle fixed assets

□Applicable √Not applicable

(3). Fixed assets leased through operating leases

□Applicable √Not applicable

(4). Fixed assets whose property rights certificates have not been obtained

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Book value Reasons for not completing the property rights certificate Antu Biological In Vitro Diagnostics Industrial Park (III)

435,199,172.57 is in process of mid-term)-32# Building

Antu Biological In Vitro Diagnostics Industrial Park (III)

299,481,290.44 is in process of mid-term)-33# Building

(5). Impairment testing of fixed assets

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Fixed asset liquidation

□Applicable √Not applicable

22. Projects under construction

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB Project Ending balance Beginning balance Construction in progress 435,944,003.56 987,283,594.17 Engineering materials

Total 435,944,003.56 987,283,594.17Other instructions:

None

142/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Construction in progress

(1). Projects under construction

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Item Impairment allowance Impairment allowance

Book balance Book value Book balance Book value

Be prepared

New factory project 418,306,003.21 418,306,003.21 977,798,766.24 977,798,766.24 Instruments and equipment 4,574,954.39 4,574,954.39 9,407,703.40 9,407,703.40 Decoration project 13,063,045.96 13,063,045.96 77,124.53 77,124.53

Total 435,944,003.56 435,944,003.56 987,283,594.17 987,283,594.17

(2). Changes in important projects under construction during the current period

√Applicable □Not applicable

Unit: yuan Currency: RMB labor

Cheng Qi

This article contains:

Profit period calculation cost

Interest rate investment period

Salary, interest, capital item, income and profit for the current period

It is expected that the increase in the current period will be transferred to the fixed capital in the current period. The opening balance of the capital will be reduced. The ending balance will account for interest.

Calculate the amount of rated assets Evolution of the original name Amount of capital

Number of degrees cumulative transformation source name arithmetic book

calculation rate ratio

gold

(% example gold

amount) (% amount

)

Fund raising for new construction of factories and investment areas

977,798,766.2 175,187,699.9 734,680,463.0 418,306,003.2

work and

4 8 1 1

Cheng own capital

Jinyi own instrument has

9,407,703.40 19,772,681.74 24,605,430.75 4,574,954.39

Equipment, equipment, gold decoration, self-repair 30,973.4 Yes

77,124.53 13,016,894.88 13,063,045.96

Engineering 5 Capital Engineering Jinhe 987,283,594.1 207,977,276.6 759,285,893.7 30,973.4 435,944,003.5 / / / /Total 7 0 6 5 6

143/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(3). Provision for impairment of projects under construction in the current period

□Applicable √Not applicable

(4). Impairment testing of projects under construction

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

Engineering supplies

□Applicable √Not applicable

23. Productive biological assets

(1). Productive biological assets using cost measurement model

□Applicable√Not applicable

(2). Impairment testing of productive biological assets using the cost measurement model □ Applicable √ Not applicable

(3). Productive biological assets that adopt the fair value measurement model □Applicable √Not applicable

Other instructions

□Applicable √Not applicable

24. Oil and gas assets

(1). Oil and gas assets situation

□Applicable √Not applicable

(2). Impairment testing of oil and gas assets

□Applicable √Not applicable

Other notes:

None

25. Right-of-use assets

(1). Right-of-use assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Houses, buildings Machinery and equipment Total

1. Original book value

1. Balance at the beginning of the period 50,478,285.82 2,315,931.25 52,794,217.07 2. Increase in the current period 1,167,631.82 1,167,631.82

(1) New addition in the current period 1,167,631.82 1,167,631.82 3. Decrease in the current period 1,673,069.84 1,673,069.84 (1) Lease expiry 1,673,069.84 1,673,069.84 (2) Lease change

144/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

4. Closing balance 49,972,847.80 2,315,931.25 52,288,779.05

2. Accumulated depreciation

1. Balance at the beginning of the period 20,626,928.92 1,233,151.12 21,860,080.04 2. Increase in the current period 5,067,583.36 246,340.68 5,313,924.04

(1) Provision 5,067,583.36 246,340.68 5,313,924.04 3. Decrease amount in the current period 1,673,069.84 1,673,069.84 (1) Lease expiration 1,673,069.84 1,673,069.84

(2) Lease changes

4. Closing balance 24,021,442.44 1,479,491.80 25,500,934.24

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1)Provision

3. Reduction amount in this period

(1)Disposal

4. Ending balance

4. Book value

1. Book value at the end of the period 25,951,405.36 836,439.45 26,787,844.81 2. Book value at the beginning of the period 29,851,356.90 1,082,780.13 30,934,137.03

(2). Impairment testing of right-of-use assets

□Applicable √Not applicable

Other notes:

None

26. Intangible assets

(1). Intangible assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

non-patented technology and

Item Land use rights Registration certificate Royalties Total

Patent rights

1. Original book value

Beginning of the period 92,468,767.58 29,598,039.51 40,173,632.19 202,822,192.21 365,062,631.49 Balance

This issue

6,587,187.19 4,399,200.00 10,986,387.19 increase

Amount

(1) Purchase

182,982.15 4,399,200.00 4,582,182.15

(2) within

6,404,205.04 Ministry of Research 6,404,205.04

send

(3)Enterprise

yehe

and increase

145/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

add

This issue

314,052.63 2,721,600.00 33,322,192.21 36,357,844.84 decrease

Amount

(1) place

314,052.63 2,721,600.00 33,322,192.21 36,357,844.84

(2)its

He reduced

less

Ending of the period 92,468,767.58 35,871,174.07 41,851,232.19 169,500,000.00 339,691,173.84 Balance

2. Accumulated amortization

Beginning of the period 14,490,910.35 17,772,787.23 27,790,938.35 144,860,459.09 204,915,095.02 Balance

This issue

924,687.72 1,637,823.30 2,711,223.80 8,475,000.00 13,748,734.82 increase

Amount

(1) count

924,687.72 1,637,823.30 2,711,223.80 8,475,000.00 13,748,734.82

This issue

313,035.13 2,721,600.00 9,260,459.09 12,295,094.22 decrease

Amount

(1) place

313,035.13 2,721,600.00 9,260,459.09 12,295,094.22

(2)its

He reduced

less

End of period 15,415,598.07 19,097,575.40 27,780,562.15 144,075,000.00 206,368,735.62 Balance

3. Impairment provision

Beginning of the period 24,061,733.12 24,061,733.12 Balance

This issue

increase

Amount

(1) count

mention

This issue

24,061,733.12 24,061,733.12 decrease

Amount

(1) place

24,061,733.12 24,061,733.12

146/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

End of term

balance

4. Book value

End of term

77,053,169.51 16,773,598.67 14,070,670.04 25,425,000.00 133,322,438.22 Book

value

Beginning of period

77,977,857.23 11,825,252.28 12,382,693.84 33,900,000.00 136,085,803.35 Book

value

At the end of the period, the proportion of intangible assets formed through the company's internal research and development accounted for 1.89% of the balance of intangible assets.

(2). Data resources recognized as intangible assets

□Applicable √Not applicable

(3). Land use rights for which property rights certificates have not been obtained.

□Applicable √Not applicable

(4). Impairment testing of intangible assets

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

27. Goodwill

(1). Original book value of goodwill

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Increase in the current period. Decrease in the name of the invested unit in the current period or

Opening balance Business combination Events forming goodwill in closing balance Disposal

formed

Zhengzhou Imino Biotechnology

32,250.99 32,250.99Shu Technology Co., Ltd.

Beijing Antu Bioengineering 164,616,25 164,616,2 Co., Ltd. 3.27 53.27 164,648,50 164,648,5 Total

4.26 04.26

(2). Goodwill impairment provision

□Applicable √Not applicable

(3). Information related to the asset group or asset group combination where the goodwill is located

√Applicable □Not applicable

The asset group or portfolio it belongs to

Name, operating segment and basis. Is it consistent with previous years?

The composition and basis of

Zhengzhou Imino Biotechnology Imino as a whole / is

147/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Limited company asset groups can be independent

generate cash flow.

Beijing Antu Department of Biology

Research on in vitro diagnostic reagents

Development, production and sales for

Beijing Antu Bioengineering Co., Ltd.

The main enterprise, main business / is a limited company

The task is clear, so the North

Jing'an Tu Biological Holistic Work

is an asset group.

Changes in asset group or asset group combination

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

(4). Specific method for determining recoverable amount

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable √Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Forecast Forecast period for stable period

Key parameters during the period The key to forecasting the stable period

Parameters for recoverable impairment (increase) Key parameter items Book value Parameters (increase) for the period

The amount, amount, rate, and profit are determined based on the length of time, the rate, and the profit.

Determine the profit rate, discount profit rate, etc.)

(Based on rates, etc.) The growth rate is basically 20% compared with the forecast period, which will benefit the latter part of the forecast period in previous years.

Growth rate and profit margin remain the same

0, profit rate 15.62%, discounted Beijing Antu 50,495.05 58,185.43 0.00 6

to fee

15.62%, the rate is based on the base

The discount rate is 17.39%. The relative parameter of the quasi-date is 11.71%.

Calculated total 50,495.05 58,185.43 0.00 6 / / / /

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

□Applicable √Not applicable

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

□Applicable √Not applicable

(5). Performance commitments and corresponding goodwill impairment

There is a performance commitment when goodwill is formed and the reporting period or the previous period of the reporting period is within the performance commitment period

□Applicable √Not applicable

Other notes:

148/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

□Applicable √Not applicable

28. Long-term deferred expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Beginning balance Increase in the current period Amortization amount in the current period Other decreases Ending balance Mold 14,496,827.76 1,189,907.20 2,480,183.52 13,206,551.44 Decoration and renovation costs 60,210,734.97 2,872,227.17 10,360,700.64 52,722,261.50 Service fee 302,078.62 159,292.04 57,037.26 404,333.40

Total 75,009,641.35 4,221,426.41 12,897,921.42 66,333,146.34

Other notes:

None

29. Deferred income tax assets/deferred income tax liabilities

(1). Deferred income tax assets without offset

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Items Deductible temporary differences Deferred income tax Deductible temporary differences Deferred income taxes

Different Assets Different Asset credit impairment provisions 177,312,720.66 41,101,561.14 178,141,341.24 41,364,055.49 Unrealized profits from internal transactions 1,066,075,147.77 162,224,325.64 952,879,537.14 142,988,395.52 Deductible losses 439,228,497.77 97,108,146.60 429,563,751.35 95,195,920.86 Withheld expenses 126,466,973.17 29,360,607.52 128,158,372.96 29,211,582.17 Government subsidies 67,538,431.84 10,130,764.77 75,078,067.19 11,261,710.08 Asset impairment provision 51,221,873.41 8,389,779.76 49,324,719.35 8,254,577.48 Long-term lease 18,651,299.93 3,831,120.49 19,848,244.54 4,031,346.81 Deferred instruments 72,364,895.85 10,854,734.38 63,210,856.94 9,481,628.54 Estimated liabilities 7,844,526.33 1,176,678.95 6,693,950.07 1,004,092.51 Donation expenses 2,227,275.76 556,818.94 3,211,085.22 802,771.31

Total 2,028,931,642.49 364,734,538.19 1,906,109,926.00 343,596,080.77

(2). Deferred income tax liabilities without offset

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Item Taxable temporary difference Deferred income tax Taxable temporary difference Deferred income tax

Difference Liabilities Difference Liabilities Accelerated depreciation of fixed assets 1,580,918,295.19 248,517,236.33 1,701,102,266.64 271,964,830.35 Assets from mergers of enterprises not under common control

6,369,237.73 955,385.66 7,624,494.40 1,143,674.16Product evaluation value added

Deferred instruments 128,526,853.17 19,279,027.97 93,892,721.80 14,083,908.27 Long-term lease 17,659,033.07 3,689,099.54 20,810,760.46 4,394,429.42 Others 3,555,668.27 533,350.24 3,609,780.73 541,467.11Total 1,737,029,087.42 272,974,099.74 1,827,040,024.03 292,128,309.31

149/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(3). Deferred income tax assets or liabilities presented on a net basis after offsetting

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Deferred income tax assets Deferred items after offset Deferred income items after offset Deferred income tax assets

Assets and liabilities are offset by each other. Taxable assets or liabilities are offset by taxable assets or liabilities.

Amount Debt balance Debt balance Deferred income tax assets 8,666,316.23 356,068,221.96 7,938,759.55 335,657,321.22 Deferred income tax liabilities 8,666,316.23 264,307,783.51 7,938,759.55 284,189,549.76

(4). Details of deferred income tax assets not recognized

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Deductible temporary differences 37,882,227.90 Deductible losses 1,538,363.12 58,251,744.93

Total 1,538,363.12 96,133,972.83

(5). Deductible losses that have not been recognized as deferred income tax assets will expire in the following years

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Year Ending amount Beginning amount Remarks

2025 138,604.69 14,398,355.12 /

2026 364,336.96 22,345,033.29 /

2027 183,189.41 7,124,743.63 /

2028 159,500.96 7,014,550.43 /

2029 186,353.06 7,369,062.46 /

2030 506,378.04 /

Total 1,538,363.12 58,251,744.93 /

Other notes:

□Applicable √Not applicable

30. Other non-current assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Item Impairment allowance Impairment allowance

Book balance Book value Book balance Book value

Be prepared

To be carried forward

542,871,410.50 542,871,410.50 307,698,146.54 307,698,146.54 Device cost

prepaid equity

134,019,959.14 134,019,959.14 112,500,000.00 112,500,000.00 Deposit

asset forecast

23,487,650.74 23,487,650.74 23,025,065.88 23,025,065.88Payment

Total 700,379,020.38 700,379,020.38 443,223,212.42 443,223,212.42

150/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Other notes:

None

31. Assets with restricted ownership or use rights

√Applicable □Not applicable

Unit: Yuan Currency: RMB End of Period Beginning of Period

Book Balance Book Value Subject to Subject Book Balance Book Value Subject to Subject

limited limited limited items

type of situation type of type of situation type of situation swap

Guarantee the goods

Certificates and coins frozen

22,671,354.15 22,671,354.15 Gold 13,314,774.21 13,314,774.21 Financial balance

and gold

ETC ETC circle circle

Save it, save it, freeze it, freeze it

130,000,000.00 130,000,000.00 410,000,000.00 410,000,000.00

Moving statement statement qualification property pledge

Not yet fixed, done, done, done, done

734,680,463.01 734,680,463.01 1,054,303,826.56 1,054,303,826.56

Asset property rights

Certificate investment is not properly handled

21,929,946.80 21,929,946.80

Real estate title certificate / / / /

887,351,817.16 887,351,817.16 1,499,548,547.57 1,499,548,547.57

plan

Other notes:

None

32. Short-term borrowings

(1). Classification of short-term loans

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Credit borrowings 113,655,535.55 232,237,174.19

151/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Interest payable 44,166.67 140,803.06

Total 113,699,702.22 232,377,977.25 Description of short-term loan classification:

Note:

Credit borrowings include: a loan of 69.7 million yuan from Zhengzhou Bank, with a term from May 29, 2025 to November 25, 2025; a loan of 3 million yuan from China Construction Bank, with a term from July 5, 2024 to July 1, 2025; the discounted undue reclassification amount of digital accounts receivable certificates is 38,652,420.56 RMB 2,303,114.99 of bank acceptance bills have been discounted but not yet due and reclassified.

(2). Overdue short-term borrowings that have not been repaid

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

33. Trading financial liabilities

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

34. Derivative financial liabilities

□Applicable √Not applicable

35. Notes payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Category Ending balance Beginning balance

commercial acceptance bill

Bank acceptance bill 735,761,334.77 354,500,000.00 Letter of credit 200,000,000.00 115,000,000.00

Total 935,761,334.77 469,500,000.00

The total amount of bills payable that has expired but not been paid at the end of this period is RMB 0.00. The reason for not paying when due is none

36. Accounts payable

(1). Presentation of accounts payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Within 1 year 595,316,262.22 588,738,174.93 1 to 2 years 39,007,734.54 65,638,582.01 2 to 3 years 2,874,235.51 4,382,898.26 More than 3 years 6,828,761.03 7,019,849.97 Total 644,026,993.30 665,779,505.17

152/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(2). Important accounts payable that are aged more than 1 year or are overdue

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

37. Advance payments

(1). Presentation of accounts received in advance

□Applicable √Not applicable

(2). Important advances from customers aged more than 1 year

□Applicable √Not applicable

(3). Amount and reasons for significant changes in book value during the reporting period □Applicable √Not applicable

Other notes:

□Applicable √Not applicable

38. Contract liabilities

(1).Contract liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Contract payment in advance 78,045,015.07 87,139,442.46

Total 78,045,015.07 87,139,442.46

(2).Important contract liabilities with an aging of more than 1 year

□Applicable √Not applicable

(3). Amount and reasons for significant changes in book value during the reporting period □Applicable √Not applicable

Other notes:

□Applicable √Not applicable

39. Payable to employees

(1). Presentation of employee benefits payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Short-term compensation 210,125,828.38 559,528,834.86 663,881,157.80 105,773,505.44

2. Post-employment benefits-set withdrawals

1,800.00 61,479,375.93 61,417,498.03 63,677.90Plan

3. Dismissal benefits 1,404,565.23 1,404,565.23

4. Other benefits that expire within one year

profit

153/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Total 210,127,628.38 622,412,776.02 726,703,221.06 105,837,183.34

(2). Presentation of short-term compensation

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Salaries, bonuses, allowances and

209,071,180.20 466,530,702.85 570,188,738.75 105,413,144.30 Subsidy

2. Employee welfare fees 13,589,010.63 13,589,010.63

3. Social insurance premiums 801.50 33,414,519.95 33,393,722.41 21,599.04 Including: medical insurance premiums 764.00 29,272,399.74 29,251,632.20 21,531.54 work-related injury insurance premiums 1,385,666.45 1,385,666.45

Maternity insurance premium 37.50 2,756,453.76 2,756,423.76 67.50

4. Housing provident fund 38,084,382.88 38,056,052.88 28,330.00

5. Trade union funds and employee education

1,053,846.68 7,910,218.55 8,653,633.13 310,432.10 Funding

6. Short-term paid absences

7. Short-term profit sharing plan

Total 210,125,828.38 559,528,834.86 663,881,157.80 105,773,505.44

(3). Display of defined contribution plan

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Basic pension insurance 1,800.00 59,047,847.35 58,989,550.15 60,097.20

2. Unemployment insurance premium 2,431,528.58 2,427,947.88 3,580.70

3. Enterprise annuity payment

Total 1,800.00 61,479,375.93 61,417,498.03 63,677.90

Other notes:

√Applicable □Not applicable

As of June 30, 2025, there is no amount in arrears in the employee compensation payable; there is no amount of non-monetary benefits. due to cancellation

The compensation given by labor relations is 1,404,565.23 yuan.

40. Taxes payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Value-added tax 36,215,700.51 25,063,410.08Corporate income tax 77,687,502.91 102,376,068.83Personal income tax 839,685.35 967,951.09Urban maintenance and construction tax 2,742,979.22 1,682,711.36 Education surcharge 1,185,182.14 735,007.92 Local education surcharge 790,121.44 490,005.32 Land use tax 367,058.24 367,058.26 Property tax 4,694,261.05 3,848,953.29 Stamp duty 855,433.94 845,624.61

154/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Others 26,792.16 61.86

Total 125,404,716.96 136,376,852.62

Other notes:

None

41. Other payables

(1).Project list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

interest payable

Dividends payable

Other payables 434,410,458.04 463,823,633.39 Total 434,410,458.04 463,823,633.39

(2).Interest payable

□Applicable √Not applicable

(3). Dividends payable

□Applicable √Not applicable

(4).Other payables

Present other payables according to nature of payment

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Security deposits and deposits 268,195,579.21 287,139,534.43 Other current accounts payable 49,865,308.47 60,019,362.68 Loans 4,176,869.90 7,835,887.21 Others 3,780,938.65 2,676,613.84 Payment fees for business income rights 108,391,761.81 106,152,235.23

Total 434,410,458.04 463,823,633.39

Important other payables aged more than 1 year or overdue

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Reason for outstanding or carry-forward Company 1 23,030,000.00 Business in progress, unsettled

Total 23,030,000.00/

Other notes:

□Applicable √Not applicable

42. Liabilities held for sale

□Applicable √Not applicable 4

155/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

43. Non-current liabilities due within 1 year

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Long-term borrowings due within 1 year 285,000,000.00 Lease liabilities due within 1 year 7,498,220.30 8,344,219.75 Estimated liabilities due within 1 year 2,719,697.05 2,440,579.00 Interest payable 198,550.00

Total 10,217,917.35 295,983,348.75

Other notes:

None

44. Other current liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Deferred maintenance premium income 68,000,560.00 78,975,392.32 Output tax to be transferred 4,715,593.28 5,376,214.63 Notes receivable that have not been terminated 9,180,263.20 8,706,056.00 Supply chain bills that have not been terminated 2,381,300.00 5,381,300.00

Total 84,277,716.48 98,438,962.95

Changes in short-term bonds payable:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

45. Long-term loans

(1). Classification of long-term loans

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

46. Bonds payable

(1). Bonds payable

□Applicable √Not applicable

(2). Details of bonds payable: (excluding preference shares, perpetual bonds and other financial instruments classified as financial liabilities) □ Applicable √ Not applicable

(3). Description of convertible corporate bonds

□Applicable √Not applicable

Accounting treatment and judgment basis for equity transfer

156/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

□Applicable √Not applicable

(4). Description of other financial instruments classified as financial liabilities

Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period

□Applicable √Not applicable

Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

□Applicable √Not applicable

Explanation of the basis for classifying other financial instruments as financial liabilities

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

47. Lease liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Lease payments 28,063,161.48 31,754,851.22 Less: Unrecognized financing costs 2,254,629.28 2,779,134.08 Less: Lease liabilities due within one year 7,498,220.30 8,344,219.75

Total 18,310,311.90 20,631,497.39

Other notes:

None

48. Long-term accounts payable

Item list

□Applicable √Not applicable

long-term payables

□Applicable √Not applicable

Special payables

□Applicable √Not applicable

49. Long-term employee benefits payable

□Applicable √Not applicable

50. Estimated liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Ending balance Beginning balance Reason for formation

Provision for product quality assurance Product quality assurance 5,124,829.29 4,253,371.08 gold

157/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Total 5,124,829.29 4,253,371.08 / Other explanations, including important assumptions and estimation instructions related to important estimated liabilities:

None

51. Deferred income

Deferred income

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Beginning balance Increase in the current period Decrease in the current period Ending balance Reasons for formation Government subsidies 75,078,067.19 3,825,000.00 11,364,635.35 67,538,431.84 Government financial appropriations

Total 75,078,067.19 3,825,000.00 11,364,635.35 67,538,431.84 /

Other notes:

□Applicable √Not applicable

52. Other non-current liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance Prepaid instrument income 207,488,679.84 139,570,254.65

Total 207,488,679.84 139,570,254.65Other instructions:

None

53. Share capital

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase or decrease in this change (+, one)

public area

Balance at the beginning of the period Issuance Balance at the end of the period Bonus shares Financial transfer Others Subtotal

new shares

shares

Total shares

581,011,346.00 -9,586,578.00 -9,586,578.00 571,424,768.00

number

Other notes:

On February 20, 2025, the company submitted an application for cancellation of repurchased shares to the Shanghai Stock Exchange, applying to cancel the 9,586,578 company shares repurchased by the company. China Securities Depository and Clearing Co., Ltd. canceled this part of the repurchased shares on February 21, 2025, and the company's total share capital was reduced from 581,011,346 shares to 571,424,768 shares.

54. Other equity instruments

(1). Basic information on preferred stocks, perpetual bonds and other financial instruments outstanding at the end of the period

□Applicable √Not applicable

(2). Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

□Applicable √Not applicable

158/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Changes in other equity instruments during the current period, explanations of the reasons for the changes, and the basis for relevant accounting treatments:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

55. Capital reserve

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance Capital premium (share capital

3,816,687,410.15 460,904,332.28 3,355,783,077.87 premium)

Other capital reserves 2,344,391.63 2,344,391.63

Total 3,819,031,801.78 460,904,332.28 3,358,127,469.50 Other explanations, including changes in increases and decreases in the current period and explanations of reasons for changes:

On February 20, 2025, the company submitted an application for cancellation of repurchased shares to the Shanghai Stock Exchange, applying to cancel the 9,586,578 company shares repurchased by the company. China Securities Depository and Clearing Co., Ltd. canceled this part of the repurchased shares on February 21, 2025. The company's total share capital was reduced from 581,011,346 shares to 571,424,768 shares. Due to the cancellation of treasury shares, the corresponding capital reserve decreased by 460,904,332.28 yuan.

56. Treasury stocks

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in this period Decrease in this period Ending balance is used to write off and decrease

The registered capital of the company is

461,029,295.83 9,461,614.45 470,490,910.28

The company's shares acquired

portion

Total 461,029,295.83 9,461,614.45 470,490,910.28

Other explanations, including changes in increases and decreases in the current period and explanations of reasons for changes:

On January 29, 2024, the company held the 14th meeting of the fourth board of directors, and reviewed and approved the "About Concentrated Bidding Transactions"

"Proposal on the Plan to Repurchase the Company's Shares by Easy Way", the company held the first extraordinary shareholders meeting of 2024 on February 20, 2024.

The "Proposal on the Plan to Repurchase the Company's Shares through Centralized Bidding Transactions" was reviewed and approved. As of February 19, 2025, the company

After completing this repurchase, a total of 9,586,578 shares of the company have been repurchased through centralized bidding transactions. The company will repurchase in February 2025

On March 21, the Shanghai Branch of China Securities Depository and Clearing Co., Ltd. canceled the 9,586,578 shares repurchased this time.

All the repurchased shares will be used for cancellation and reduction of registered capital. After the cancellation is completed, the balance of treasury shares will be zero.

57. Other comprehensive income

√Applicable □Not applicable

Unit: Yuan Currency: RMB Amount incurred in the current period

minus: before minus: before

At the beginning of the period, everything included in the period was included in the period. Less: everything was attributed after tax. Items at the end of the period

Balance Before tax Other comprehensive income taxes and fees Belonging to the parent Belonging to the minority The balance occurred Consolidated income Consolidated income Used by the company Several shareholders

Transfer in the current period Transfer in the current period

159/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Into Profit and Loss Into Retention

income

1. No

Can be re-divided

Class loss

beneficial

He comprehensive

income

2. General

Reclassify

Profit and loss

1,137,045.96 -8,422.01 -8,422.01 1,128,623.95 others

Comprehensive collection

benefit

Among them:

foreign currency wealth

Financial statements 1,137,045.96 -8,422.01 -8,422.01 1,128,623.95 Translation difference

Um

Other comprehensive

Total income 1,137,045.96 -8,422.01 -8,422.01 1,128,623.95 total

Other explanations, including adjustments to the initial recognition amount of the effective portion of cash flow hedging gains and losses converted into hedged items: None

58. Special reserves

□Applicable √Not applicable

59. Surplus reserve

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance Statutory surplus reserve 293,162,011.78 293,162,011.78

Total 293,162,011.78 293,162,011.78 Description of surplus reserve, including changes in increases and decreases in the current period and explanation of reasons for changes:

According to the provisions of the Company Law and Articles of Association, the Company shall allocate 10% of its net profit to the statutory surplus reserve fund. If the accumulated statutory surplus reserve is more than 50% of the company's registered capital, no further withdrawals can be made.

After withdrawing the statutory surplus reserve fund, the company may withdraw the discretionary surplus reserve fund. Upon approval, the discretionary surplus reserve fund can be used to make up for losses in previous years or to increase share capital.

60. Undistributed profits

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Current period Last year Undistributed profits at the end of the previous period before adjustment 4,383,217,408.35 3,797,565,663.25 Total undistributed profits at the beginning of the adjustment period (Adjustment +,

Reduce -)

160/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Adjusted opening undistributed profit 4,383,217,408.35 3,797,565,663.25 plus: net profit attributable to owners of the parent company for the period

571,001,185.83 1,194,451,909.72 profit

Less: Withdrawal from statutory surplus reserve

Withdraw discretionary surplus reserve

Withdraw general risk reserve

Common stock dividends payable 719,995,207.68 608,800,164.62 Common stock dividends converted into share capital

Undistributed profits at the end of the period 4,234,223,386.50 4,383,217,408.35 Adjustment details of undistributed profits at the beginning of the period:

1. Due to the retrospective adjustment of the "Accounting Standards for Business Enterprises" and its related new regulations, the undistributed profit at the beginning of the period was affected by RMB 0.00.

2. Due to changes in accounting policies, the undistributed profit at the beginning of the period is affected by RMB 0.00.

3. Due to the correction of major accounting errors, the undistributed profit at the beginning of the period was affected by RMB 0.00.

4. The change in the scope of consolidation due to the same control affects the undistributed profit at the beginning of the period by RMB 0.00.

5. The total impact of other adjustments on the undistributed profit at the beginning of the period is 0.00 yuan.

6. Operating income and operating costs

(1). Operating income and operating costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Amount for the current period Amount for the previous period

Project

revenue cost revenue cost

Main business 2,016,184,064.67 702,723,293.18 2,164,877,257.55 733,205,611.50 Other businesses 44,123,115.28 30,111,088.67 42,226,657.08 35,070,944.97 Total 2,060,307,179.95 732,834,381.85 2,207,103,914.63 768,276,556.47

(2). Decomposition information of operating income and operating costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Total

Contract classification

Operating income Operating costs

Product type

Reagents 1,784,777,304.61 563,308,984.56 Instruments 226,416,200.28 134,785,178.70 Maintenance income 20,196,761.68 19,422,471.68 Others 28,916,913.38 15,317,746.91Classified by business area

Domestic 1,903,615,043.16 653,495,430.33 Foreign 156,692,136.79 79,338,951.52

Total 2,060,307,179.95 732,834,381.85

Other instructions

□Applicable √Not applicable

(3).Description of performance obligations

□Applicable √Not applicable

161/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(4). Description of apportionment to remaining performance obligations

□Applicable √Not applicable

(5).Major contract changes or major transaction price adjustments

□Applicable √Not applicable

Other notes:

None

62. Taxes and surcharges

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Urban maintenance and construction tax 9,943,960.02 7,434,738.38 Education surcharge 4,300,632.84 3,250,744.11 Local education surcharge 2,867,088.53 2,167,162.76 Property tax 8,323,506.00 6,621,694.89 Land use tax 734,117.12 736,237.56 Vehicle and vessel use tax 20,037.11 25,068.01 Stamp tax 1,487,168.99 1,563,176.10 Environmental protection tax 113.60 91.13

Total 27,676,624.21 21,798,912.94

Other notes:

None

63. Sales expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Salaries and surcharges 212,905,623.30 197,096,006.70 Travel expenses 53,859,520.49 47,357,379.95 Payment fees for business income rights 20,510,170.02 26,860,702.06 Exhibition publicity and promotion fees 19,543,953.68 26,456,021.83 Depreciation, amortization and leasing expenses 19,721,034.10 17,721,364.10 Business entertainment expenses 18,039,302.61 14,501,423.55 Maintenance expenses 14,558,788.74 10,464,546.02 Transportation and insurance expenses 3,326,917.38 3,368,884.70 Others 26,574,024.54 20,873,857.72

Total 389,039,334.86 364,700,186.63

Other notes:

None

64. Management expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

162/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Item Amount for the current period Amount for the previous period

Salaries and surcharges 50,656,829.18 46,138,705.53 Depreciation and amortization expenses 22,819,332.50 18,317,535.58 Office expenses 11,454,001.68 11,106,376.08 Material consumption 7,770,334.91 5,070,126.97 Business entertainment expenses 3,965,375.31 4,308,312.34 Rental expenses 2,079,131.54 1,700,393.83 Travel expenses 1,066,184.89 1,192,853.35 Others 2,477,233.92 3,592,217.05

Total 102,288,423.93 91,426,520.73

Other notes:

None

65. Research and development expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Wages and surcharges 150,467,461.69 177,938,840.13 Direct investment 63,437,574.62 96,042,277.92 Depreciation, amortization and lease fees 20,587,339.67 26,745,703.26 Inspection and certification fees 10,300,127.83 22,895,247.43Office expenses 4,717,286.76 8,536,223.59Others 836,058.79 1,074,515.22

Total 250,345,849.36 333,232,807.55

Other notes:

The change in accounting estimates for the capitalization time point of the company's R&D expenditures will be implemented starting from January 1, 2025. The capitalization of R&D expenditures in this period

Please see Note 8, “R&D Expenditures” for the information.

66. Financial expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Interest expenses 9,517,542.81 11,625,874.44Interest income -2,480,460.15 -9,302,802.12 Exchange gains and losses -3,459,710.88 1,222,282.39 Handling fees and other expenses 691,284.46 266,584.87

Total 4,268,656.24 3,811,939.58

Other notes:

None

67. Other income

√Applicable □Not applicable

Unit: Yuan Currency: RMB Classification by nature Amount incurred in the current period Amount incurred in the previous period

163/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Government subsidies 27,269,667.32 42,559,876.04 Refund of withheld tax handling fees 755,731.29 541,332.74

Total 28,025,398.61 43,101,208.78

Other notes:

None

68. Investment income

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Amount incurred in the current period Amount incurred in the previous period Income from long-term equity investments accounted for by equity method -1,311,952.90 -2,846,306.48 Investment income generated from disposal of long-term equity investments 1,787,612.00

Investment income from other equity instrument investments 894,348.00

Financial management income 65,880,431.95 40,941,038.35

Total 67,250,439.05 38,094,731.87

Other notes:

None

69. Net exposure hedging income

□Applicable √Not applicable

70. Income from changes in fair value

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Sources of income from changes in fair value Amount incurred in the current period Amount incurred in the previous period

Trading financial assets -54,112.42 7,035,162.86 Including: fair price of derivative financial instruments

-54,112.42

Gains from changes in value

Income from financial products 7,035,162.86

Total -54,112.42 7,035,162.86Other instructions:

None

71. Credit impairment losses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Bad debt losses on notes receivable -251,388.46 984,786.87 Bad debt losses on accounts receivable -2,112,022.78 -18,165,946.98 Bad debt losses on other receivables 4,276,443.23 1,515,261.23

Total 1,913,032.00 -15,665,898.88Other instructions:

None

164/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

72. Asset impairment losses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

1. Inventory depreciation losses and contract performance costs

-14,215,837.01 1,446,156.85 Impairment loss

2. Impairment losses on fixed assets -3,823,927.25

3. Impairment losses on intangible assets -4,945,714.20

Total -14,215,837.01 -7,323,484.60Other instructions:

None

73. Income from asset disposal

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Income from fixed asset disposal 38,609.84 1,334.78

Total 38,609.84 1,334.78

Other notes:

□Applicable √Not applicable

74. Non-operating income

√Applicable □Not applicable

Unit: Yuan Currency: RMB Included in non-recurring profit and loss items for the current period Amount incurred in the current period Amount incurred in the previous period

amount of

Gains on disposal of non-current assets

99,175.10

total

Including: fixed asset disposal

99,175.10

gain

Government subsidy 385,000.00

Unable to pay 1,279,689.99 986,333.47 1,279,689.99 Compensation 8,453,917.81 1,501,028.33 8,453,917.81 Others 145,424.90 52,175.58 145,424.90

Total 9,879,032.70 3,023,712.48 9,879,032.70

Other notes:

□Applicable √Not applicable

75. Non-operating expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB Included in non-recurring profit and loss items for the current period Amount incurred in the current period Amount incurred in the previous period

amount of

Loss on disposal of non-current assets

1,565,864.87 1,838,408.15 1,565,864.87 Total loss

Including: Disposal of fixed assets 1,565,864.87 1,838,408.15 1,565,864.87

165/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

loss

External donations 2,245,000.00 2,030,000.00 2,245,000.00 fines, liquidated damages, and delay

982,158.20 1,027,468.46 982,158.20 Najin

Others 3,052,014.03 42,325.15 3,052,014.03

Total 7,845,037.10 4,938,201.76 7,845,037.10

Other notes:

None

76. Income tax expenses

(1). Income tax expense schedule

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Current income tax expense 101,101,063.65 66,748,963.48 Deferred income tax expense -40,292,618.23 -6,540,646.30

Total 60,808,445.42 60,208,317.18

(2).Accounting profit and income tax expense adjustment process

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount incurred in this period

Total profit 638,845,435.17 Income tax expenses calculated according to statutory/applicable tax rates 95,826,815.28 The impact of different tax rates applicable to subsidiaries 2,116,229.91 The impact of adjusting income tax in previous periods 4,833,093.61 The impact of non-taxable income 292,533.53 The impact of non-deductible costs, expenses and losses -6,730,898.36 Deductible losses using deferred income tax assets not recognized in the previous period

Impact of 271,386.61

No deductible temporary differences have been recognized for deferred income tax assets in the current period

1,535,520.46 The impact of exclusive or deductible losses

Additional deductible expenses stipulated in the tax law -37,336,235.60 Tax rate adjustment resulted in the balance of deferred income tax assets/liabilities at the beginning of the year

changes

Income tax expenses 60,808,445.42

Other notes:

□Applicable √Not applicable

77. Other comprehensive income

√Applicable □Not applicable

See Note 7, 57 for details.

166/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

78. Cash flow statement items

(1). Cash related to operating activities

Other cash received related to operating activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Government subsidies 7,550,191.37 81,274,062.95Interest income 1,790,114.73 9,152,043.00Deposit 18,600,817.76 20,123,619.09Other amounts 85,412,028.10 17,902,588.71

Total 113,353,151.96 128,452,313.75

Description of other cash received related to operating activities:

None

Other cash paid related to operating activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Cash expenses for administrative expenses and R&D expenses 62,689,680.66 102,098,609.95 Cash expenses for sales expenses 139,959,938.56 129,069,197.71 Cash expenses for financial expenses 1,604,332.04 328,571.43Deposit 29,793,721.54 54,403,085.93 Other cash expenses 12,336,932.04 12,886,829.89

Total 246,384,604.84 298,786,294.91

Description of other cash paid related to operating activities:

None

(2).Cash related to investing activities

Cash received in connection with significant investing activities

□Applicable √Not applicable

Cash payments related to significant investment activities

□Applicable √Not applicable

Other cash received related to investing activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Bank financial management principal 2,702,721,422.79 737,995,000.00 Bank financial management income 64,347,563.05 3,344,132.96 Interest income from borrowings and capital occupation

Total 2,767,068,985.84 741,339,132.96

Description of other cash received related to investing activities:

None

167/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Other cash paid related to investing activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Bank financial management principal 2,131,839,077.53 941,208,432.91 Prepaid equity deposit

Recovered from disposal of subsidiaries and other business units

net cash

Total 2,131,839,077.53 941,208,432.91

Description of other cash paid related to investment activities:

None

(3).Cash related to financing activities

Other cash received related to financing activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Letters of credit and financing bills 907,000,000.00 300,000,000.00 Bill discount receipts 12,397,210.85

Total 919,397,210.85 300,000,000.00

Description of other cash received related to financing activities:

None

Other cash payments related to financing activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Letters of credit and financing bills 468,000,000.00 244,000,000.00 Funding loans 226,966.99 1,536,266.43 Equity acquisition funds 25,949,869.28 321,035,722.40 Lease liabilities 7,478,978.63 5,297,297.32

Total 501,655,814.90 571,869,286.15

Description of other cash payments related to financing activities:

None

Changes in various liabilities arising from financing activities

□Applicable √Not applicable

(4).Explanation on presenting cash flow in net amount

□Applicable √Not applicable

(5). Major activities and financial activities that do not involve current cash receipts and expenditures but affect the company's financial status or may affect the company's cash flow in the future.

business impact

□Applicable √Not applicable

168/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

79. Supplementary information for cash flow statement

(1). Supplementary information for cash flow statement

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Supplementary information Amount for the current period Amount for the previous period

1. Reconcile net profit to cash flow from operating activities:

Net profit 578,036,989.75 626,977,239.08 Plus: asset impairment provision 14,215,837.01 7,323,484.60 Credit impairment loss -1,913,032.00 15,665,898.88 Fixed asset depreciation, oil and gas asset depletion, production

215,464,941.83 210,215,115.15 Depreciation of biological assets

Amortization of right-of-use assets 5,313,924.04 7,679,576.18 Amortization of intangible assets 13,748,734.82 15,455,911.85 Amortization of long-term prepaid expenses 12,897,921.42 16,153,799.00 Disposal of fixed assets, intangible assets and other long-term

-38,609.84 -1,334.78 Loss of assets (income is listed with "-")

Loss from scrapping of fixed assets (income should be filled in with "-"

1,562,991.87 1,739,233.05 columns)

Loss from changes in fair value (income is filled in with "-"

54,112.42 -7,035,162.86 columns)

Financial expenses (income is listed with "-") 9,517,542.81 11,625,874.44 Investment losses (income is listed with "-") -67,250,439.05 -38,094,731.87 Decrease in deferred income tax assets (increase is marked with "-"

-20,410,900.74 -27,516,794.87 (Fill in the numbers)

Increase in deferred income tax liabilities (decrease indicated by “-”

No. 19,881,766.25 -20,972,481.88)

Decrease in inventory (increases are indicated by "-") 57,006,242.84 -106,553,491.91 Decrease in operating receivables (increases are indicated by "-"

-215,522,717.17 -77,268,206.12)

Increase in operating payable items (decrease marked with “-”

-204,841,745.56 -201,201,676.56 (Fill in the numbers)

Others -7,539,635.35 61,298,594.95 Net cash flow generated from operating activities 410,183,925.35 495,490,846.33 2. Major investing and financing activities that do not involve cash receipts and payments:

debt to capital

Convertible corporate bonds due within one year

Financing leased fixed assets

3. Net changes in cash and cash equivalents:

Closing balance of cash 454,339,780.83 349,101,510.49 Less: Opening balance of cash 452,058,348.81 1,485,369,305.45 Add: Closing balance of cash equivalents

Less: Opening balance of cash equivalents

Net increase in cash and cash equivalents 2,281,432.02 -1,136,267,794.96

(2). Net cash paid in the current period to acquire subsidiaries

□Applicable √Not applicable

169/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(3). Net cash received from disposal of subsidiaries in the current period

□Applicable √Not applicable

(4). Composition of cash and cash equivalents

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

1. Cash 454,339,780.83 452,058,348.81 Of which: Cash on hand 247,796.14 348,166.38 Bank deposits that can be used for payment at any time 454,091,234.07 451,709,935.31 Other currencies that can be used for payment at any time

750.62 247.12Funds

Deposit central bank available for payments

payment

Deposit funds from other banks

Funds placed with other banks

2. Cash equivalents

Including: Bond investments due within three months

3. Balance of cash and cash equivalents at the end of the period 454,339,780.83 452,058,348.81 Among them: used by the parent company or subsidiaries within the group

22,671,354.15 13,314,774.21 Restricted cash and cash equivalents

(5). Situations where the scope of use is limited but still presented as cash and cash equivalents

□Applicable √Not applicable

(6). Monetary funds that are not cash and cash equivalents

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance Reason Other monetary funds 22,671,354.15 13,314,774.21 Frozen funds

Total 22,671,354.15 13,314,774.21 /

Other notes:

□Applicable √Not applicable

80. Notes on items in the statement of changes in owners’ equity

Explain the names of "other" items that were adjusted to the closing balance of the previous year and the amount of adjustment, etc.:

□Applicable √Not applicable

81. Foreign currency monetary items

(1). Foreign currency monetary items

√Applicable □Not applicable

Unit: yuan Conversion into RMB items at the end of the period Foreign currency balance at the end of the period Conversion exchange rate

Balance monetary funds

Including: USD 7,400,292.52 7.1586 52,975,734.03

170/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Euro 99,496.31 8.4024 836,007.80 Japanese yen 17,229.00 0.0496 854.56 Singapore dollar 4.50 5.6179 25.28 Canadian dollar 340.00 5.2358 1,780.17 Indonesian rupiah 170,645,720.85 0.0004 75,425.41 Accounts receivable

Including: USD 9,293,922.53 7.1586 66,531,473.82 Accounts payable

Including: Euro 67.97 8.4024 571.11 Japanese yen 3,045,008.00 0.0496 151,032.40 Other accounts payable

Including: USD 289,221.25 7.1586 2,070,419.24 Russian Rubles 816,212.67 0.0913 74,520.22 Ringgit 95,360.00 1.6947 161,601.82 Other receivables

Of which: USD 1,200.00 7.1586 8,590.32 EUR 4,005.27 8.4024 33,653.88

Other notes:

None

(2). Description of overseas operating entities, including for important overseas operating entities, their main overseas operating place, accounting standard currency and basis for selection should be disclosed. If the accounting standard currency changes, the reasons should also be disclosed.

□Applicable √Not applicable

82. Leasing

(1). As a lessee

√Applicable □Not applicable

Variable lease payments not included in the measurement of lease liabilities

□Applicable √Not applicable

Simplified treatment of short-term leases or lease payments for low-value assets

√Applicable □Not applicable

The expense amount of simplified short-term lease and low-value asset lease included in the current profit and loss in this period is RMB 6,956,320.57.

Sale and leaseback transactions and basis for judgment

□Applicable √Not applicable

Total cash outflow related to leasing 11,166,696.49 (Unit: Yuan Currency: RMB)

(2). As a lessor

Operating lease as lessor

√Applicable □Not applicable

Unit: Yuan Currency: RMB Including: Variable items not included in lease receipts Lease income

Income related to lease payments Operating leased fixed assets 851,045.88

171/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Total 851,045.88

Finance lease as lessor

□Applicable √Not applicable

Reconciliation of undiscounted lease receipts and net lease investment

□Applicable √Not applicable

Undiscounted lease receipts over the next five years

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Annual undiscounted lease payments

Project

Ending amount Beginning amount

First year 1,552,829.28 1,668,317.84 Second year 802,340.00 360,020.00 Third year 746,483.00 304,163.00 Fourth year 487,345.00 45,025.00 Fifth year 442,320.00

Total undiscounted lease payments after five years 95,950.00

(3). Recognize financial lease sales profits and losses as a manufacturer or distributor

□Applicable √Not applicable

Other instructions

None

83. Data resources

□Applicable √Not applicable

84. Others

□Applicable √Not applicable

8. R&D expenditures

1. List according to nature of expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Salaries and surcharges 212,864,600.97 177,938,840.13 Direct investment 82,402,762.65 96,042,277.92 Depreciation, amortization and lease fees 27,297,831.03 26,745,703.26 Inspection and certification fees 19,512,931.99 22,895,247.43Office expenses 7,068,046.47 8,536,223.59Others 857,214.11 1,074,515.22

Total 350,003,387.23 333,232,807.55 Including: Expenditure R&D expenditure 250,345,849.36 333,232,807.55

Capitalized R&D expenditure 99,657,537.87

Other notes:

172/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

None

2. Development expenditures on R&D projects that meet capitalization conditions

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Increased amount in the current period Decreased amount in the current period Beginning of the period Ending of the period Items recognized as intangible assets Transferred to the balance of the current period Internal development expenses Other balances

Product Profit and Loss Software Research

52,061,931.08 2,758,812.64 49,303,118.44 projects

Reagent research

30,304,318.55 3,645,392.40 26,658,926.15 development projects

Instrument research

17,291,288.24 17,291,288.24 projects

Total 99,657,537.87 6,404,205.04 93,253,332.83

Significant Capitalized R&D Projects

□Applicable √Not applicable

Impairment provision for development expenditures

□Applicable √Not applicable

Other instructions

None

3. Important outsourced research projects

□Applicable √Not applicable

9. Changes in consolidation scope

1. Merger of enterprises not under common control

□Applicable √Not applicable

2. Merger of enterprises under common control

□Applicable √Not applicable

173/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

3. Reverse purchase

□Applicable √Not applicable

4. Disposal of subsidiaries

Are there any transactions or events that result in the loss of control of subsidiaries during this period?

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Is there any situation where investments in subsidiaries are disposed of step by step through multiple transactions and control is lost in the current period?

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

5. Changes in the scope of consolidation due to other reasons

Explain the changes in the scope of consolidation caused by other reasons (such as the establishment of new subsidiaries, liquidation of subsidiaries, etc.) and their related circumstances:

√Applicable □Not applicable

Shareholding ratio Companies that are no longer subsidiaries in this period Registration place Nature of business

(%) Reason

Zhengzhou Antumobi Molecular Diagnostics

Zhengzhou, Henan Manufacturing 65 Cancellation

Technology Co., Ltd.

6. Others

□Applicable √Not applicable

10. Interests in other entities

1. Interests in subsidiaries

(1).Construction of enterprise groups

√Applicable □Not applicable

Unit: Yuan Currency: RMB Industry Shareholding Ratio

Registration services (%) Obtain subsidiary name Main place of business Registration place

Capital sex mode is direct

Quality is the same

give birth to

Antu Experimental Instrument Zhengzhou Economic and Technological Development Zone Zhengzhou Economic and Technological Development Zone Control

produce

Qi (Zhengzhou) has Jingkai 15th Street 199 5,000 Jingkai 15th Street 199 100.00 Xiaqi

system

Co., Ltd. No. Ye Hezhi

And the same

Henan Pilot Free Trade Zone Zhengzhou Henan Pilot Free Trade Zone Zhengzhou

Zhengzhou Antuco Control

Area (Economic Development) Jingbei 1st Road Area (Economic Development) Jingbei 1st Road Business

Technology Development Co., Ltd. 5,000 100.00 Enterprise

No. 87 Yard Production R&D Center No. 87 Yard Production R&D Center Trade

Company Yehe Production Building Production Building

Merged with Zhengzhou Imino Zhengzhou Economic and Technological Development Zone 500 Zhengzhou Economic and Technological Development Zone Health 100.00 Not the same

174/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Biotechnology has Factory No. 1, 133 Sixth Street. Factory No. 1, 133 Sixth Street, Production Control Co., Ltd., a manufacturing company, a merger of companies.

technology

Shanghai Biaoyuansheng

Wenshuidong, Hongkou District, Shanghai Wenshuidong, Hongkou District, Shanghai Tech Investment Technology Co., Ltd. 1,000 87.00

Room 108, Building 2, No. 918 Road. Room 108, Building 2, No. 918 Road. Service to set up a company.

service

unusual

Beiwu Town, Shunyi District, Beijing Beiwu Town, Shunyi District, Beijing

Beijing Antusheng First Control

No. 17, Yard No. 13, Mintai Road No. 17, Yard No. 13, Mintai Road

Physical Engineering Co., Ltd. 5,700 100.00 Under the system

Building, Building 18 (Technology Innovation Building, Building 18 (Technology Innovation Building)

Company Enterprise New Functional Area) New Functional Area) Made

merge

Taihang South, Shijiazhuang High-tech Zone Taihang South, Shijiazhuang High-tech Zone

Hebei Antujiu

No. 509 Guojietang Medical Street No. 509 Guojietang Medical Investment and medical technology 1,000 51.00

Medical Equipment Industrial Park, Tower A-2, 5. Medical Equipment Industrial Park, Tower A-2, 5. Trade and establish a limited company.

Floor 501 on the west side Floor 501 on the west side

technology

Shanghai Antusheng China (Shanghai) Free Trade Trial China (Shanghai) Free Trade Trial

Technology Investment Material Technology Co., Ltd. No. 1011, Harley Road, inspection area 10,000 No. 1011, Harley Road, inspection area 100.00

Service Company Establishment Room 302, 303 Room 302, 303

service

Henan Pilot Free Trade Zone Zhengzhou Henan Pilot Free Trade Zone Zhengzhou Technology

Zhengzhou Sikunsheng

The area (economic development) is the sixth largest in terms of economic development. The area (economic development) is the sixth largest in terms of economic development. Technology Investment Engineering Co., Ltd. 1,000 100.00

No. 3, Factory Building 1, No. 133 Street No. 3, Factory Building 1, No. 133 Street Service Setting up a company

Floor 6 Floor 6 Floor Service

give birth to

8717 Research Dr., 2 million 8717 Research Dr., material investment AdvanBio, Inc. 100.00

Irvine,CA92618 USD Irvine,CA92618 Research and development

UNIT 2508A 25/F UNIT 2508A 25/F

BANK OF AMERICA BANK OF AMERICA

Antu Biotech (Hong Kong) TOWER 12 3 million TOWER 12 investment investment

100.00

Hong Kong) Co., Ltd. HARCOURT RD USD HARCOURT RD Capital Establishment CENTRAL HONG CENTRAL HONG

KONG KONG

Shenzhen Antusheng Xixiang Street, Baoan District, Shenzhen City Xixiang Street, Baoan District, Shenzhen City

Business Investment Engineering Co., Ltd. Haicheng Road 5, Azabu Community 200 Haicheng Road 5, Azabu Community 100.00

Trade Establish a Company No. 2602, Qiancheng Commercial Center No. 2602, Qiancheng Commercial Center

Dianchi Road, Kunming City, Yunnan Province Dianchi Road, Kunming City, Yunnan Province Not the same as Antui, Yunnan Six kilometers of Dianchi Kangcheng Group One Group six kilometers of Dianchi Kangcheng One Control

Business

Nuo Technology Co., Ltd. No. 6, 1st floor shop, Tuan 2 Building, 3,400 No. 6, 1st floor shop, Tuan 2 Building, 51.00

trade

Company No. 7, Attachment No. 3, Attachment 3B Company No. 7, Attachment No. 3, Attachment 3B Enterprise

No. Merge

Explanation on the difference between the proportion of shareholding in subsidiaries and the proportion of voting rights:

None

Basis for holding half or less of the voting rights but still controlling the invested unit, and holding more than half of the voting rights but not controlling the invested unit:

None

175/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

For important structured entities included in the scope of consolidation, the basis for control: None

Basis for determining whether a company is an agent or a principal: None

Other notes:

None

(2).Important non-wholly owned subsidiaries

□Applicable √Not applicable

(3).Main financial information of important non-wholly-owned subsidiaries □Applicable √Not applicable

(4). Significant restrictions on the use of enterprise group assets and settlement of enterprise group debts: □ Applicable √ Not applicable

(5). Financial support or other support provided to structured entities included in the scope of consolidated financial statements: □ Applicable √ Not applicable

Other notes:

□Applicable √Not applicable

2. Transactions in which the ownership share of the subsidiary changes and the subsidiary is still controlled □Applicable √Not applicable

3. Interests in joint ventures or associates √Applicable □Not applicable

(1). Important joint ventures or associates

□Applicable √Not applicable

(2). Main financial information of important joint ventures □ Applicable √ Not applicable

(3). Main financial information of important associates □Applicable √Not applicable

(4). Summary financial information of unimportant joint ventures and associates √Applicable □Not applicable

Unit: Yuan Currency: RMB

Ending balance/Amount incurred in the current period Opening balance/Amount incurred in the previous period Joint ventures:

Total book value of investments

The total of the following items calculated based on shareholding ratio

176/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

--Net profit

--Other comprehensive income

--Total comprehensive income

Associates:

Total book value of investments 19,500,000.00 9,000,000.00 Total of the following items calculated based on shareholding ratio

--Net profit -1,311,952.90 -2,846,306.48 --Other comprehensive income

--Total comprehensive income

Other instructions

None

(5). Explanation of significant restrictions on the ability of joint ventures or associates to transfer funds to the company □Applicable √Not applicable

(6). Excess losses incurred by joint ventures or associates

□Applicable √Not applicable

(7). Unconfirmed commitments related to investments in joint ventures

□Applicable √Not applicable

(8). Contingent liabilities related to investments in joint ventures or associates □ Applicable √ Not applicable

4. Important joint operations

□Applicable √Not applicable

5. Interests in structured entities that are not included in the scope of consolidated financial statements. Relevant instructions for structured entities that are not included in the scope of consolidated financial statements: □ Applicable √ Not applicable

6. Others

□Applicable √Not applicable

11. Government subsidies

1. Government subsidies recognized according to the amount receivable at the end of the reporting period

□Applicable √Not applicable

Reasons for failure to receive the estimated amount of government subsidy at the estimated time □ Applicable √ Not applicable

2. Liability items involving government subsidies

√Applicable □Not applicable

Unit: Yuan Currency: RMB

177/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Current period

and assets financial report New additions to the business in this period were transferred to it in this period

Beginning balance Ending balance/Income statement items Grant amount Extra income Other income Other changes

Related

Amount

Deferred revenue and assets

75,078,067.19 3,825,000.00 11,364,635.35 67,538,431.84

Total related benefits 75,078,067.19 3,825,000.00 11,364,635.35 67,538,431.84 /

3. Government subsidies included in current profits and losses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Type Amount for the current period Amount for the previous period

Related to assets 11,364,635.35 14,602,105.05 Related to income 15,905,031.97 27,957,770.99 Non-operating income 385,000.00

Total 27,269,667.32 42,944,876.04Other instructions:

None

12. Risks related to financial instruments

1. Risks of financial instruments

√Applicable □Not applicable

The company's main financial instruments include: financial assets and liabilities, receivables, and payables measured at fair value and whose changes are included in current profits and losses. The main risks arising from the above financial instruments are as follows:

(1) Credit risk

Credit risk mainly arises from bank deposits and receivables.

The company's bank deposits are mainly deposited in state-owned banks and other large and medium-sized listed banks. The company does not expect that there will be significant credit risk in bank deposits.

For accounts receivable, the Company sets relevant policies to control credit risk exposure. The Company evaluates the debtor's credit qualifications and sets corresponding credit terms based on the debtor's financial status, external ratings, the possibility of obtaining guarantees from third parties, credit records and other factors such as current market conditions.

Debtors' payment records are regularly monitored. For non-performing debtors whose payment period exceeds the due date by 60 days, the company will use written reminders, shorten the credit period or impose interest penalties to ensure that the company's overall credit risk is within a controllable range.

(2) Liquidity risk

Liquidity risk refers to the risk of a shortage of funds when an enterprise fulfills its obligations to settle by delivering cash or other financial assets. The Company's policy is to ensure that sufficient cash is available to repay debt obligations as they fall due. Liquidity risk is centrally controlled by the Company's financial department. The Finance Department ensures that the company has sufficient funds to repay its debt under all reasonable forecasts by monitoring cash balances, readily realizable securities, and rolling forecasts of cash flows over the next 12 months.

(3) Market risk

178/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Market risk of financial instruments refers to the risk of fluctuations in the fair value or future cash flows of financial instruments due to market price changes, mainly interest rate risk.

Interest rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market interest rates. Interest rate risk can arise from both recognized interest-bearing financial instruments and unrecognized financial instruments (such as certain loan commitments).

The Company pays close attention to the impact of interest rate changes on the Company's interest rate risk. The Company currently does not adopt an interest rate hedging policy. However, management is responsible for monitoring interest rate risk and will consider hedging significant interest rate risk if necessary.

2. Hedging

(1). The company carries out hedging business for risk management

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

(2). The company carries out qualified hedging business and applies hedging accounting □ Applicable √ Not applicable

Other instructions

□Applicable √Not applicable

(3). The company carries out hedging business for risk management and expects to achieve risk management objectives but does not apply hedging accounting □ Applicable √ Not applicable

Other instructions

□Applicable √Not applicable

3. Transfer of financial assets

(1). Classification of transfer methods

□Applicable √Not applicable

(2). Financial assets derecognized due to transfer

□Applicable √Not applicable

(3). Transferred financial assets that continue to be involved

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

13. Disclosure of fair value

1. Closing fair value of assets and liabilities measured at fair value √Applicable □Not applicable

Unit: Yuan Currency: RMB Item Fair value at the end of the period

179/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Level 1 fair price Level 2 fair price Total fair price at Level 3

value measurement value measurement value measurement

1. Continuous fair value measurement

(1) Trading financial assets 411,123,668.33 411,123,668.33 1. Measured at fair value and changes

411,123,668.33 411,123,668.33 Financial assets included in current profits and losses

(1) Debt instrument investment 307,568,000.00 307,568,000.00 (2) Financial management products 100,000,000.00 100,000,000.00 (3) Derivative financial assets 3,555,668.33 3,555,668.33

2. Designated to be measured at fair value

and its changes are included in the current profit and loss

financial assets

(1) Debt instrument investment

(2) Equity instrument investment

(2) Other debt investments

(3) Investment in other equity instruments 160,883,561.50 160,883,561.50

(4) Investment real estate

1. Land use rights for lease

2. Buildings for rent

3. Hold and prepare to transfer after appreciation

land use rights

(5) Biological assets

1. Consumable biological assets

2. Productive biological assets

(6) Accounts receivable financing 12,485,684.89 12,485,684.89 1. Notes receivable 12,485,684.89 12,485,684.89 Assets continuously measured at fair value

411,123,668.33 173,369,246.39 584,492,914.72 Total output

(6) Trading financial liabilities

1. Measured at fair value and changes

Financial liabilities included in current profits and losses

Including: trading bonds issued

Derivative financial liabilities

Others

2. Designated as measured at fair value

and the changes are included in the current profit and loss

financial liabilities

Negative assets measured at fair value on an ongoing basis

Total debt

2. Non-continuous fair value measurement

quantity

(1) Assets held for sale

Measured at fair value on a non-continuous basis

Total assets

Measured at fair value on a non-continuous basis

total liabilities

2. Basis for determining the market price of continuous and non-continuous first-level fair value measurement items □Applicable √Not applicable

180/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

3. Continuous and non-continuous second-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters √ Applicable □ Not applicable

(1) Debt instrument investment: The fair value of government bond reverse repurchase investment is measured based on the annualized rate of return determined when the investment transaction is completed;

(2) Financial management products: The fair value of investment in financial products with floating returns is measured based on the market value provided by the sponsoring bank;

(3) Derivative financial assets: The fair value of foreign exchange swaps is measured based on the valuation amount of the sponsoring bank;

4. Continuous and non-continuous third-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters √ Applicable □ Not applicable

(1) The receivables financing are all bank acceptance bills with a higher credit rating of the acceptor, and the fair value is basically equal to the amortized cost.

(2) Other equity instrument investments include the purchase or capital increase of Chengdu Kerui Technology Co., Ltd., Shenzhen Meili Nanopore Technology Co., Ltd., Suzhou Jinhe Phase III Equity Investment Partnership (Limited Partnership), Guangzhou Huayinkang Medical Group Co., Ltd., and Renke (Shenzhen) Biotechnology Co., Ltd. Since the equity of the invested company is not quoted in the active market, it is not feasible to use the income method or the market method to value the equity.

5. For ongoing third-level fair value measurement items, the reconciliation information and unobservable parameters between the opening and closing book values are sensitive

sexual analysis

□Applicable √Not applicable

6. For ongoing fair value measurement items, if there is a conversion between levels during the current period, the reasons for the conversion and the policy for determining the time of conversion.

policy

□Applicable √Not applicable

7. Valuation technology changes that occurred during the period and reasons for the changes

□Applicable √Not applicable

8. Fair value of financial assets and financial liabilities not measured at fair value

□Applicable √Not applicable

9. Others

□Applicable √Not applicable

14. Related parties and related transactions

1. Information about the parent company of this enterprise

√Applicable □Not applicable

Unit: 10,000 yuan Currency: RMB Parent company’s contribution to the company

The parent company’s shareholding ratio in the company’s parent company name, place of registration, nature of business, registered capital

Proportion of voting rights (%) (%)

Henan Free Trade

Zhengzhou Antusi Experimental Zone Zheng Industrial Investment, Medical

Industrial Group Co., Ltd. Prefecture Area (Economic Research and Experimental 1,250.00 57.65 57.65 Co., Ltd. opened) through the North Experimental Development

Road No. 126

Description of the parent company of this enterprise

None

181/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

The ultimate controller of this enterprise is Miao Yongjun

Other notes:

None

2. Information about the company’s subsidiaries

Please refer to the notes for details of the company’s subsidiaries.

√Applicable □Not applicable

For details, please refer to Note 10.1, "Equity in Subsidiaries" of this Note.

3. Information about the company’s joint ventures and associated enterprises

Please refer to the notes for details of important joint ventures or associates of this company.

□Applicable √Not applicable

The information of other joint ventures or associates that have related party transactions with the company in the current period, or have balances from related party transactions with the company in previous periods, is as follows:

√Applicable □Not applicable

Name of the joint venture or associated enterprise Relationship with the enterprise Zhengzhou Jiuhe Medical Testing Laboratory Co., Ltd. Zhengzhou Gongdong Medical Equipment Co., Ltd., a joint-stock company in which the company's subsidiaries hold 45.00% of the shares Zhengzhou Gongdong Medical Instruments Co., Ltd., a joint-stock company in which Antu Biotech holds 30.00% of the shares

Other instructions

□Applicable √Not applicable

4. Other related parties

√Applicable □Not applicable

Names of other related parties Relationship between other related parties and the company Zhengzhou Dior Medical Technology Co., Ltd. Company supervisor Han Mingming serves as director Henan Zhengfeng Agriculture and Animal Husbandry Technology Development Co., Ltd. Holding subsidiary of the major shareholder

Zhengzhou Jiuhe Medical Testing Laboratory Co., Ltd. Renke (Shenzhen) Biotechnology Co., Ltd., a joint-stock company in which the company's subsidiaries hold 45.00% of the shares. Zhengzhou Gongdong Medical Equipment Co., Ltd., a company where the company's director Zhang Ruifeng serves as a director. Antu Biological's joint-stock company (30% shareholding) Shenzhen Meili Nanopore Technology Co., Ltd. Zhengzhou Demai Pharmaceutical Development Co., Ltd., a company in which the company's director Zhang Ruifeng serves as a director. A subsidiary of the controlling shareholder of Antu Bio.

Zhengzhou Demai Pharmaceutical Co., Ltd. A subsidiary of the controlling shareholder of Antu Biotechnology

Hiken Biotechnology (Suzhou) Co., Ltd., a minority shareholder of 35% of MobidiagOy's subsidiary MobidiagOy, which was canceled during the reporting period, has a significant impact on it.

Hiken Medical Technology (Suzhou) Co., Ltd. has a significant impact on it

Other instructions

None

5. Related transactions

(1). Related transactions related to the purchase and sale of goods, provision and receipt of services

Procurement of goods/service acceptance form

√Applicable □Not applicable

Unit: Yuan Currency: RMB Approved transaction amount Whether it exceeds the transaction related parties Content of related transactions Amount incurred in the current period Amount incurred in the previous period (if applicable) Amount (if applicable)

182/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Zhengzhou Jiuhe Medical

equipment, materials, inspection

Scientific testing laboratory 361,484.57 195,061.88

Testing fee

Ltd.

Henan Zhengfeng Agriculture and Animal Husbandry

Science and Technology Development Co., Ltd. Food 278,445.00 494,894.20 Company

Zhengzhou Antu Industrial

Group Co., Ltd. Materials 26,902.65 Company

Hiken Biotechnology

Reagents, instruments, materials

(Suzhou) Co., Ltd. 4,933,023.94 3,331,575.93

material

company

Hiken Medical Technology

(Suzhou) Co., Ltd. Materials 13,274.34 5,309.73 Company

Shenzhen Melina

MiKong Technology Co., Ltd. Materials 53,097.35

company

Zhengzhou Demai Pharmaceutical

Materials 1,505.76

Development Co., Ltd.

Human Science (Shenzhen)

Biotechnology Co., Ltd. Outsourcing R&D 3,000,000.00 Company

List of goods sold/services provided

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Related parties Contents of related transactions Amount incurred in the current period Amount incurred in the previous period Zhengzhou Jiuhe Medical Laboratory Laboratory

Reagents and materials 497,586.70 727,320.69 Co., Ltd.

Zhengzhou Antu Industrial Group Co., Ltd. has technical service fees and comprehensive services

2,351,022.68 383,259.24 Co., Ltd. fee

Hangzhou Antu Jiuhe Medical Technology has reagents, instruments, materials, maintenance

2,639,401.65 Co., Ltd. Premium, etc.

Hiken Biotechnology (Suzhou) provides reagents, instruments, and comprehensive services

7,823,883.01 6,904,284.40 Co., Ltd. fee

Hiken Medical Technology (Suzhou) has

Instruments and materials 38,961.06 211,882.53 Co., Ltd.

Zhengzhou Demai Pharmaceutical Co., Ltd. Equipment 59,721.32 Zhengzhou Demai Pharmaceutical Development Co., Ltd.

Reagents 54,234.52 195,706.56 Division

Description of related transactions for purchasing and selling goods, providing and receiving services

√Applicable □Not applicable

Note: Hangzhou Antu Jiuhe Medical Technology Co., Ltd. was once a secondary subsidiary of Antu Bio (Antu Technology holds 75.00% of the shares). Antu Technology withdrew its equity on April 3, 2023. From January to March 2024, it was still a related party of Antu Bio, and its sales revenue during this period was 2.6394 million yuan.

(2). Related entrusted management/contracting and entrusted management/outsourcing situation

The company's entrusted management/contracting status table:

183/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

□Applicable √Not applicable

Description of related trusteeship/contracting □Applicable √Not applicable

The company’s entrusted management/outsourcing status table: □ Applicable √ Not applicable

Description of related management/outsourcing situation □Applicable √Not applicable

(3). Related leasing situation

As a lessor, our company:

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Name of the lessee Type of leased assets Lease income recognized in the current period Lease income recognized in the previous period Zhengzhou Dior Medical Technology

House 17,339.45 Ltd.

Zhengzhou Jiuhe Medical Laboratory

House 401,462.52 227,172.51 Laboratory Co., Ltd.

Zhengzhou Antu Industrial Group

House 125,793.19 Co., Ltd.

Zhengzhou Demai Pharmaceutical Development

House 127,598.61 Ltd.

As a lessee, our company:

□Applicable √Not applicable

Description of related leasing situation

□Applicable √Not applicable

(4). Related guarantees

The company acts as a guarantor

□Applicable √Not applicable

The company as the guaranteed party

□Applicable √Not applicable

Description of related guarantees

□Applicable √Not applicable

(5). Related party fund lending □Applicable √Not applicable

(6). Related party asset transfer and debt restructuring □Applicable √Not applicable

(7). Remuneration of key management personnel √ Applicable □ Not applicable

184/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Unit: 10,000 yuan Currency: RMB

Item Amount for the current period Amount for the previous period Remuneration of key management personnel 201.51 338.35

(8). Other related transactions

□Applicable √Not applicable

6. Unsettled items such as receivables and payables to related parties

(1). Items receivable

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Project name Related parties

Book balance Provision for bad debts Book balance Provision for bad debts

Zhengzhou Jiuhe Medical

Accounts receivable Testing laboratory has 813,746.56 59,664.52 439,632.05 38,514.80 Co., Ltd.

Zhengzhou Demai Pharmaceutical

Accounts receivable 682.44 34.12 Ltd.

Zhengzhou Antu Industrial

Accounts receivable Group Co., Ltd. 1,726.20 86.31

company

Zhengzhou Jiuhe Medical

Other receivables Testing laboratories have 27,295.72 1,364.79

Ltd.

Hiken Biotechnology

Other receivables (Suzhou) Co., Ltd. 170,000.00 11,500.00 640,000.00 38,000.00Company

Zhengzhou Antu Industrial

Other receivables Group Co., Ltd. 19,690.00 984.50

company

Hiken Biotechnology

Prepaid accounts (Suzhou) Co., Ltd. 5,537,196.52 5,685,394.38

company

Zhengzhou Jiuhe Medical

Prepayments for testing laboratories: 11,813.23 85,006.54

Ltd.

Other receivables MobidiagOy 57,507,200.00 2,875,360.00

(2). Items payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Project name Related parties Book balance at the end of the period Book balance at the beginning of the period Contract liabilities MobidiagOy 11,811.69 11,860.86

Hiken Biotechnology (Suzhou)

Contract liabilities 1,037,735.85 1,037,735.85 Co., Ltd.

Hiken Medical Technology (Suzhou)

Contract liabilities 6,303.84 6,303.84

Ltd.

Contract liabilities Zhengzhou Demai Pharmaceutical Development has 14,703.55

185/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Ltd.

Hiken Biotechnology (Suzhou) Accounts Payable 224,886.78 51,582.81 Co., Ltd.

Hiken Medical Technology (Suzhou) Accounts Payable 21,061.97 6,061.97 Co., Ltd.

Zhengzhou Demai Pharmaceutical Development has accounts payable 123.00 Co., Ltd.

Zhengzhou Jiuhe Medical Laboratory Accounts Payable 6,064.28 Laboratory Co., Ltd.

Zhengzhou Jiuhe Medical Laboratory Other payables 166,676.32 102,915.30 Laboratory Co., Ltd.

Zhengzhou Demai Pharmaceutical Development Co., Ltd. has other payables 82,209.00 98,139.00

Other payables of Zhengzhou Antu Industrial Group 329,836.00 272,272.00

Co., Ltd.

(3). Other items

□Applicable √Not applicable

7. Related party commitments

□Applicable √Not applicable

8. Others

□Applicable √Not applicable

15. Share-based payment

1. Various equity instruments

(1).Details

□Applicable √Not applicable

(2). Stock options or other equity instruments outstanding at the end of the period □ Applicable √ Not applicable

2. Equity-settled share-based payment

□Applicable √Not applicable

3. Share-based payment settled in cash

□Applicable √Not applicable

4. Share-based payment expenses for this period

□Applicable √Not applicable

5. Modification and termination of share-based payment

□Applicable √Not applicable

186/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

6. Others

□Applicable √Not applicable

16. Commitments and contingencies

17. Important commitments

□Applicable √Not applicable

2. Contingencies

(1). Important contingencies existing on the balance sheet date □Applicable √Not applicable

(2). If the company has no important contingencies that need to be disclosed, it should also be explained: □Applicable √Not applicable

3. Others

□Applicable √Not applicable

17. Events after the balance sheet date

18. Important non-adjustment matters □Applicable √Not applicable

19. Profit distribution

□Applicable √Not applicable

3. Sales returns

□Applicable √Not applicable

4. Description of other post-balance sheet events □Applicable √Not applicable

5. Other important matters

6. Correction of accounting errors in the previous period (1). Retrospective restatement method

□Applicable √Not applicable

(2). Prospective application of law

□Applicable √Not applicable

2. Important debt restructuring

□Applicable √Not applicable

187/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

3. Asset replacement

(1). Non-monetary asset exchange

□Applicable √Not applicable

(2). Other asset replacements

□Applicable √Not applicable

4. Annuity plan

□Applicable √Not applicable

5. Termination of operations

□Applicable √Not applicable

6. Branch information

(1). Basis for determination of reporting segments and accounting policies

□Applicable √Not applicable

(2). Financial information of reportable segments

□Applicable √Not applicable

(3). If the company has no reportable segments, or cannot disclose the total assets and total liabilities of each reportable segment, the reasons should be stated □Applicable √Not applicable

(4). Other instructions

□Applicable √Not applicable

7. Other important transactions and matters that have an impact on investors’ decision-making

□Applicable √Not applicable

8. Others

□Applicable √Not applicable

19. Notes on main items of the parent company’s financial statements

1. Accounts receivable

(1). Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Aging Book balance at the end of the period Book balance at the beginning of the period Within 1 year (including 1 year) 556,346,576.53 581,087,553.41 Total within 1 year 556,346,576.53 581,087,553.41 1 to 2 years 2,330,624.96 1,638,928.77 2 to 3 years 1,331,140.62 204,857.57 More than 3 years 488.16 Total 560,008,342.11 582,931,827.91

188/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(2). Classified disclosure according to bad debt accrual method

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Book balance Bad debt provision Book balance Bad debt provision calculation

Withdrawal category book book

Ratio Ratio Ratio Ratio Amount Amount Value Amount Amount Value (%) Example (%) Example (% (%

) ) press

Single

item

plan

mention

bad

account

Accurate

Prepare

Among them:

press

group

combine

plan

560,008,342. 100.0 28,715,961. 5.1 531,292,380. 582,931,827. 100.0 29,321,187. 5.0 553,610,640.

11 0 63 3 48 91 0 49 3 42 bad

account

Accurate

Prepare

Among them:

189/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

press

letter

use

wind

risk

Special

levy

group

combine

560,008,342. 100.0 28,715,961. 5.1 531,292,380. 582,931,827. 100.0 29,321,187. 5.0 553,610,640.

11 0 63 3 48 91 0 49 3 42 mentions

bad

account

Accurate

Prepare

of

Should

receive

money

item

Total 560,008,342. 28,715,961. 531,292,380. 582,931,827. 29,321,187. 553,610,640.

/ / / /Total 11 63 48 91 49 42

Provision for bad debts is made individually:

□Applicable √Not applicable

Provision for bad debts by group:

√Applicable □Not applicable

Portfolio accrual items: receivables with collective accrual of bad debt provisions based on credit risk characteristics

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Proportion of provision (%) Within 1 year 556,346,576.53 27,817,328.83 5.00 1 to 2 years 2,330,624.96 233,062.50 10.00 2 to 3 years 1,331,140.62 665,570.31 50.00

Total 560,008,342.11 28,715,961.63

Instructions on accruing bad debt provisions by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

Basis for division of each stage and provision ratio for bad debts

None

Explanation of significant changes in the book balance of accounts receivable that have experienced changes in loss provisions in the current period: □ Applicable √ Not applicable

190/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

(3). Bad debt provision situation

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

Category Opening balance Recovery or transfer Write-off or verification Ending balance accrual Other changes

Return sales

Provision for bad debts 29,321,187.49 605,225.86 28,715,961.63

Total 29,321,187.49 605,225.86 28,715,961.63

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable √Not applicable

Other instructions

None

(4). Accounts receivable actually written off in the current period

□Applicable √Not applicable

Among them, the important write-off of accounts receivable

□Applicable √Not applicable

Instructions for writing off accounts receivable:

□Applicable √Not applicable

(5). Accounts receivable and contract assets of the top five closing balances collected by debtors

√Applicable □Not applicable

Unit: Yuan Currency: RMB accounts receivable and

Accounts Receivable and Hehe

Accounts receivable at the end of the period Contract assets at the end of the period Contract assets at the end of the period Bad debt provision at the end of the unit name Same assets at the end of the period

Balance Balance Balance amount of total balance

Proportion (%)

First place 45,914,852.38 45,914,852.38 8.20 2,295,742.62 Second place 42,312,511.35 42,312,511.35 7.56 2,115,625.57 Third place 25,869,086.51 25,869,086.51 4.62 1,293,454.33 Fourth place 23,634,213.00 23,634,213.00 4.22 1,181,710.65 Fifth place 22,567,809.65 22,567,809.65 4.03 1,128,390.48

Total 160,298,472.89 160,298,472.89 28.63 8,014,923.65

Other instructions

None

Other notes:

□Applicable √Not applicable

2. Other receivables

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Closing balance Opening balance

191/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

interest receivable

Dividends receivable

Other receivables 622,063,037.81 683,774,895.23

Total 622,063,037.81 683,774,895.23

Other notes:

□Applicable √Not applicable

interest receivable

(1).Classification of interest receivable

□Applicable √Not applicable

(2).Important overdue interest

□Applicable √Not applicable

(3). Classified disclosure according to bad debt accrual method □Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Explanation on the provision of bad debt provisions on an individual basis: □ Applicable √ Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

(4). Provision for bad debts based on the general expected credit loss model □Applicable √Not applicable

(5). Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(6). Interest receivable actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of interest receivable □ Applicable √ Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

192/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

□Applicable √Not applicable

Dividends receivable

(7). Dividends receivable

□Applicable √Not applicable

(8). Important dividends receivable aged more than 1 year □ Applicable √ Not applicable

(9). Classified disclosure according to bad debt accrual method □Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Explanation on the provision of bad debt provisions on an individual basis: □ Applicable √ Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

(10). Provision for bad debts based on the general expected credit loss model □Applicable √Not applicable

(11). Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(12). Dividends receivable actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of dividends receivable □ Applicable √ Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Other receivables

(13). Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB

193/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 303,201,560.71 442,539,836.25 Total within 1 year 303,201,560.71 442,539,836.25 1 to 2 years 277,570,287.60 220,290,467.63 2 to 3 years 168,416,592.60 130,201,259.85 More than 3 years 172,401,811.77 121,065,437.19

Total 921,590,252.68 914,097,000.92

(14). Classification by nature of money

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Security deposits and deposits 4,859,080.28 9,709,463.15 Reserve funds 2,340,656.52 1,505,685.40 Other current accounts paid in advance 12,413,890.03 28,744,529.78 Loans 895,248,343.91 823,335,707.67 Others 6,728,281.94 50,801,614.92

Total 921,590,252.68 914,097,000.92

(15). Bad debt provision accrual

√Applicable □Not applicable

Unit: Yuan Currency: RMB

The first stage The second stage The third stage

Lifetime expectations letter Lifetime forecast letter

Estimated total for the next 12 months

Provision for bad debts

loss of use (no credit loss occurred (credit loss occurred)

period credit loss

Use impairment) Use impairment)

As of January 1, 2025

230,322,105.69 230,322,105.69 amount

As of January 1, 2025

Amount in this period

--Transfer to the second stage

--Transfer to the third stage

--Return to the second stage

--Return to the first stage

Provision in this period 69,205,109.18 69,205,109.18 Transferred in this period

Sales in this period

Write-off in this period

Other changes

After June 30, 2025

299,527,214.87 299,527,214.87 amount

Basis for division of each stage and provision ratio for bad debts

None

Explanation of significant changes in the book balance of other receivables that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

194/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

The amount of bad debt provision for the current period and the basis for assessing whether the credit risk of financial instruments has increased significantly: □ Applicable √ Not applicable

(16). Bad debt provisions

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

Category Opening balance Recovery or write-off or verification Ending balance accrual Other changes

reversal pin

Bad debt provision 230,322,105.69 69,205,109.18 299,527,214.87

Total 230,322,105.69 69,205,109.18 299,527,214.87

Among them, the amount of bad debt provision reversed or recovered in the current period is important:

□Applicable √Not applicable

Other instructions

None

(17). Other receivables actually written off in the current period

□Applicable √Not applicable

Important write-offs of other receivables:

□Applicable √Not applicable

Instructions for writing off other receivables:

□Applicable √Not applicable

(18). Other receivables with top five closing balances based on debtors

√Applicable □Not applicable

Unit: Yuan Currency: RMB in other receivable periods

Name of bad debt provision unit Closing balance Total closing balance Nature of payment Aging

Ending balance ratio (%)

Within 1 year/1-2

borrow/advance it

First place 418,308,528.96 45.39 years/2-3 years/3 223,009,566.44 other current funds

years and above

Within 1 year/1-2

borrow/advance it

Second place 210,714,498.03 22.86 years/2-3 years/3 52,840,172.29 Other current funds

years and above

Borrowing/prepayment within 1 year/1-2 third place 205,859,963.08 22.34 14,148,199.46 other current accounts year

Borrowing/prepayment within 1 year/1-2 fourth place 52,954,990.51 5.75 3,722,808.09 other current accounts/2-3 years

Within 1 year/1-2 fifth place 7,467,056.36 0.81 Loan 393,875.37 years

Total 895,305,036.94 / / 294,114,621.65

195/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report (19). Due to centralized management of funds, it is presented in other receivables □ Applicable √ Not applicable

Other notes:

□Applicable √Not applicable

196/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

3. Long-term equity investment

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Item Impairment allowance Impairment allowance

Book balance Book value Book balance Book value

Be prepared

Investment in subsidiaries 533,803,187.44 533,803,187.44 596,018,578.84 596,018,578.84 Investment in associates and joint ventures

17,844,095.28 17,844,095.28 10,382,487.97 10,382,487.97 Industrial investment

Total 551,647,282.72 551,647,282.72 606,401,066.81 606,401,066.81

(1).Investment in subsidiaries

√Applicable □Not applicable

Unit: Yuan Currency: RMB minus Increase or decrease in the current period Impairment Value calculation

Quasi-quasi-subtraction

Beginning balance (account provision) Ending balance (account provision) Invested unit Less Less

(face value) additional investment in the period, other (face value) period investment value

Beginner's end of year capital is accurate

spare spare

Er Antu Experimental Instrument

Equipment (Zhengzhou) Co., Ltd. 53,161,335.15 53,161,335.15 Company

Zhengzhou Antuco

Technology Development Co., Ltd. 51,461,641.06 51,461,641.06 Company

Zhengzhou Imeno

Biotechnology Co., Ltd. 4,990,983.05 4,990,983.05

Shanghai Biaoyuansheng

Biotechnology Co., Ltd. 8,700,000.00 8,700,000.00 Company

Hebei Antujiu

He Medical Technology 23,460,000.00 23,460,000.00 Co., Ltd.

Beijing Antusheng

Physical Engineering Co., Ltd. 337,500,000.00 337,500,000.00 Company

Zhengzhou Antumo

than molecular diagnostics

62,731,581.00 62,731,581.00

Technology Co., Ltd.

Division

Shanghai Antusheng

Material Technology Co., Ltd. 11,200,000.00 11,200,000.00 Company

Zhengzhou Sikunsheng

10,000,000.00 10,000,000.00Physical Engineering Co., Ltd.

197/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

company

AdvanBio, Inc. 13,335,360.00 13,335,360.00

Shenzhen Antusheng

Physical Engineering Co., Ltd. 2,000,000.00 2,000,000.00 Company

Antuy, Yunnan

Nuo Technology Co., Ltd. 17,340,000.00 17,340,000.00 Company

Antu Bio (incense

137,678.58 516,189.60 653,868.18 Hong Kong) Co., Ltd.

Total 596,018,578.84 516,189.60 62,731,581.00 533,803,187.44

(2). Investment in associates and joint ventures

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase or decrease in the current period

announce

reduce warning reduce it

value

His plan

Accurate release at the beginning of the investment period

Less Comprehensive other provisions under the equity method Closing balance (account balance (book value) Current provision

Additional investment less Confirmed investment option minus its face value) single value) futures gold

Investment gains and losses income value he

The initial share capital and the final capital gain will change accurately.

Yu Li Yu Tiao move preparation

Amount or Amount

profit

Run

1. Joint ventures

small

plan

2. Joint ventures

Zheng

state

arch

East

doctor

Treatment 10,382,487.9 7,500,000.0 -38,392.6 17,844,095.2 devices 7 0 9 8 devices

Yes

limited

Public

Division

Small 10,382,487.9 7,500,000.0 -38,392.6 17,844,095.2 Total 7 0 9 8

10,382,487.9 7,500,000.0 -38,392.6 17,844,095.2 combined

7 0 9 8

198/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report Plan

(3). Impairment testing of long-term equity investments □ Applicable √ Not applicable

Other notes:

□Applicable √Not applicable

199/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

4. Operating income and operating costs

(1). Operating income and operating costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Amount for the current period Amount for the previous period

Project

Revenue Cost Revenue Cost Main business 1,604,079,457.26 714,990,194.75 1,683,229,051.20 686,979,691.20 Other businesses 66,209,381.43 54,497,625.86 58,237,566.48 56,288,148.05

Total 1,670,288,838.69 769,487,820.61 1,741,466,617.68 743,267,839.25

(2). Decomposition information of operating income and operating costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Total

Contract classification

Operating income Operating costs

Product type

Reagents 1,432,821,966.30 515,158,951.17 Instruments 171,254,336.97 199,828,564.62 Maintenance income 21,562,712.90 20,736,055.97 Others 44,649,822.52 33,764,248.85Classified by business area

Domestic 1,528,157,421.68 672,436,159.53 Foreign 142,131,417.01 97,051,661.08

Total 1,670,288,838.69 769,487,820.61

Other instructions

□Applicable √Not applicable

(3). Description of performance obligations

□Applicable √Not applicable

(4). Description of allocation to remaining performance obligations

□Applicable √Not applicable

(5). Major contract changes or major transaction price adjustments

□Applicable √Not applicable

Other notes:

None

5. Investment income

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

Long-term equity investment income calculated using the cost method 113,213,752.00 2,009,400.00 Long-term equity investment income calculated using the equity method -38,392.69

200/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Investment income from the disposal of long-term equity investments -58,093,703.05 Investment income from other equity instrument investments 894,348.00 Financial management income 60,053,046.90 38,811,080.40

Total 116,029,051.16 40,820,480.40Other instructions:

None

6. Others

□Applicable √Not applicable

20. Supplementary information

1. Detailed statement of non-recurring profits and losses for the current period

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount Description of gains and losses from disposal of non-current assets, including provision for asset impairment

-1,524,382.03 prepared write-off portion

Government subsidies included in the current profit and loss, but related to the company's normal operations

Closely related to the business, in compliance with national policies and regulations, and in accordance with the determined

The government enjoys the standard of 16,065,626.53 and has a continuous impact on the company’s profits and losses.

Except for subsidies

Except for effective hedging related to the company’s normal business operations

Outside of financial affairs, non-financial enterprises hold financial assets and financial liabilities

4,402,691.44 gains and losses from changes in fair value and disposal of financial assets and funds

Profit and loss arising from financial liabilities

Occupation of funds collected from non-financial enterprises included in current profits and losses

fee

Gains and losses from entrusting others to invest or manage assets - Gains and losses from external entrusted loans - Various losses arising from force majeure factors, such as natural disasters

-Loss of assets

Reversal of impairment provision for accounts receivable subject to separate impairment test 5,098,622.99 The enterprise obtains investments from subsidiaries, associates and joint ventures

The cost is less than the income generated by the investee's identifiable - fair value of net assets that should be enjoyed when acquiring the investment.

Subsidiaries resulting from business mergers under common control from the beginning of the period to the merger

-Net profit and loss for the current period on the day

Gains and losses from non-monetary asset exchanges - Gains and losses from debt restructuring - One-time losses incurred by the enterprise due to the discontinuation of relevant operating activities

-Expenses, such as expenses for placement of employees, etc.

Adjustments to current profits and losses due to tax, accounting and other laws and regulations

• One-time impact

Shares recognized in one go due to cancellation or modification of equity incentive plan

-Pay the fee

For cash-settled share-based payments, after the vesting date,

-Profits and losses arising from changes in fair value of employee compensation payable

Investment real estate that adopts the fair value model for subsequent measurement -

201/202

Zhengzhou Antu Bioengineering Co., Ltd. 2025 Semi-annual Report

Gains and losses arising from changes in fair value of assets

Gains from transactions whose transaction prices are obviously unfair - Losses arising from contingencies unrelated to the company's normal business operations

-Benefit

Trusteeship fee income from entrusted operations - Other non-operating income and expenses other than the above items 3,596,987.28 Other profit and loss items that meet the definition of non-recurring gains and losses 755,731.29 Less: Income tax impact 4,950,868.82 Impact on minority shareholders' equity (after tax) -1,240,130.31

Total 24,684,539.00

If the company determines items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as non-recurring gains and losses and is significant in amount, and if it defines the non-recurring gain or loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as recurring gains and losses, the reasons should be explained. □Applicable √Not applicable

Other instructions

□Applicable √Not applicable

2. Return on net assets and earnings per share

√Applicable □Not applicable

Weighted average net assets Earnings per share Profit for the reporting period

Yield (%) Basic earnings per share Diluted earnings per share Net attributable to the company’s ordinary shareholders

6.51 1.02 1.02Profit

After deducting non-recurring gains and losses, attributable to

6.23 0.97 0.97 Net profit of the company’s ordinary shareholders

3. Differences in accounting data under domestic and foreign accounting standards

□Applicable √Not applicable

4. Others

□Applicable √Not applicable

Chairman: Miao Yongjun

Board approval submission date: August 21, 2025

Revision information

□Applicable √Not applicable

202/202